

(19) United States

(12) Patent Application Publication Khvorova et al.

(54) FUNCTIONAL AND HYPERFUNCTIONAL SIRNA DIRECTED AGAINST BCL-2

(75) Inventors: **Anastasia Khvorova**, Boulder, CO (US); Angela Reynolds, Conifer, CO (US); Devin Leake, Denver, CO (US); William Marshall, Boulder, CO (US); Stephen Scaringe, Lafayette, CO (US)

> Correspondence Address: KALOW & SPRINGUT LLP **488 MADISON AVENUE** 19TH FLOOR **NEW YORK, NY 10022 (US)**

(73) Assignee: **DHARMACON INC.**, Lafayette, CO

(21) Appl. No.: 11/975,661

(22) Filed: Oct. 19, 2007

(10) Pub. No.: US 2008/0108803 A1

May 8, 2008 (43) **Pub. Date:**

Related U.S. Application Data


- (60) Division of application No. 11/083,784, filed on Mar. 18, 2005, which is a continuation of application No. 10/714,333, filed on Nov. 14, 2003.
- (60) Provisional application No. 60/426,137, filed on Nov. 14, 2002. Provisional application No. 60/502,050, filed on Sep. 10, 2003.

Publication Classification

(51) Int. Cl. C07H 21/02 (2006.01)

(57)**ABSTRACT**

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.







Figure 2


Figure 3A


■ HEK293 ■ DU145 □ Hela siRNA functionality is independent from the cell line

ε


DBI Expresion (% of Control)









% Silencing of Control




% Silencing of Controls




% Silencing of Controls



% Silencing of Controls



% Silencing of Controls



Expression (% Control)




Figure 6A
Differential internal stability







Figure 6B











Figure 10A

Human Secreted Alkaline Phosphatase









Figure 10C

Homo sapiens polo-like kinase (PLK)



SMART Pool Control Mn004 Mn001 **SMART siRNAs ヤ#** £ # ٦# Figure 10D **١**# 1314 094 Random siRNAs 8448 1212 1203 9611 8811 100 80 9 40 0 Exp (% Cntrl)








Figure 12





Figure 13 Sequences of top Bcl2

304 308 GGAGAUAGUGAUGAAGUAC (SEQ. ID NO. 309) 305) 307) GGGAGAUAGUGAUGAAGUA (SEQ. ID NO. 301 siRNA 10 GAAGACUCUGCUCAGUUUG (SEQ. ID NO. 310) GCAUGCGGCCUCUGUUUGA (SEQ. ID NO. 306) GAAGUACAUCCAUUAUAAG (SEQ. ID NO. UGCGGCCUCUGUUUGAUUU (SEQ. ID NO. GAGAUAGUGAUGAAGUACA (SEQ. ID NO. AGAUAGUGAUGAAGUACAU (SEQ. ID NO. GUACGACAACCGGGAGAUA (SEQ. ID NO. UGAAGACUCUGCUCAGUUU (SEQ. ID NO. siRNA 9 siRNA 6 siRNA 8 siRNA 2 siRNA 4 siRNA 5 siRNA 7 siRNA 3 siRNA 1

Figure 14



Reporter gene individual siRNAs walk





Figure 15

Figure 16 A











Figure 17 A



% Expression




% Expression



Pools of siRNAs located 20 bp apart 100 80 09 40 20 120

% Expression



igure 19




Figure 20

Figure 21A








Figure 21B













Figure 24

Figure 25



FUNCTIONAL AND HYPERFUNCTIONAL SIRNA DIRECTED AGAINST BCL-2

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of the filing dates of U.S. patent application Ser. No. 11/083,784, filed Mar. 18, 2005 entitled, "Functional and Hyperfunctional siRNA Directed Against Bcl-2," U.S. patent application Ser. No. 10/714,333, filed Nov. 14, 2003 entitled, "Functional and Hyperfunctional siRNA," U.S. Provisional Application Ser. No. 60/426,137, filed Nov. 14, 2002, entitled "Combinatorial Pooling Approach for siRNA Induced Gene Silencing and Methods for Selecting siRNA," and U.S. Provisional Application Ser. No. 60/502,050, filed Sep. 10, 2003, entitled "Methods for Selecting siRNA," the entire disclosures of which are hereby incorporated by reference into the present disclosure.

SEQUENCE LISTING

[0002] The sequence listing for this application has been submitted in accordance with 37 CFR § 1.52(e) and 37 CFR § 1.821 on CD-ROM in lieu of paper on a disk containing the sequence listing file entitled "DHARMA_0100-US28_CRF.txt" created Oct. 17, 2007, 80 kb. Applicants hereby incorporate by reference the sequence listing provided on CD-ROM in lieu of paper into the instant specification.

FIELD OF INVENTION

[0003] The present invention relates to RNA interference ("RNAi").

BACKGROUND OF THE INVENTION

[0004] Relatively recently, researchers observed that double stranded RNA ("dsRNA") could be used to inhibit protein expression. This ability to silence a gene has broad potential for treating human diseases, and many researchers and commercial entities are currently investing considerable resources in developing therapies based on this technology.

[0005] Double stranded RNA induced gene silencing can occur on at least three different levels: (i) transcription inactivation, which refers to RNA guided DNA or histone methylation; (ii) siRNA induced mRNA degradation; and (iii) mRNA induced transcriptional attenuation.

[0006] It is generally considered that the major mechanism of RNA induced silencing (RNA interference, or RNAi) in mammalian cells is mRNA degradation. Initial attempts to use RNAi in mammalian cells focused on the use of long strands of dsRNA. However, these attempts to induce RNAi met with limited success, due in part to the induction of the interferon response, which results in a general, as opposed to a target-specific, inhibition of protein synthesis. Thus, long dsRNA is not a viable option for RNAi in mammalian systems

[0007] More recently it has been shown that when short (18-30 bp) RNA duplexes are introduced into mammalian cells in culture, sequence-specific inhibition of target mRNA can be realized without inducing an interferon response. Certain of these short dsRNAs, referred to as small inhibitory RNAs ("siRNAs"), can act catalytically at sub-molar concentrations to cleave greater than 95% of the target mRNA in the

cell. A description of the mechanisms for siRNA activity, as well as some of its applications are described in Provost et al., Ribonuclease Activity and RNA Binding of Recombinant Human Dicer, E.M.B.O. J., 2002 Nov. 1; 21(21): 5864-5874; Tabara et al., The ds RNA Binding Protein RDE-4 Interacts with RDE-1, DCR-1 and a DexH-box Helicase to Direct RNAi in C. elegans, Cell 2002, June 28; 109(7):861-71; Ketting et al., Dicer Functions in RNA Interference and in Synthesis of Small RNA Involved in Developmental Timing in C. elegans; Martinez et al., Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi, Cell 2002, Sep. 6; 110(5):563; Hutvagner & Zamore, A microRNA in a multiple-turnover RNAi enzyme complex, Science 2002, 297:2056.

[0008] From a mechanistic perspective, introduction of long double stranded RNA into plants and invertebrate cells is broken down into siRNA by a Type III endonuclease known as Dicer. Sharp, RNA interference—2001, Genes Dev. 2001, 15:485. Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3' overhangs. Bernstein, Caudy, Hammond, & Hannon, Role for a bidentate ribonulclease in the initiation step of RNA interference, Nature 2001, 409:363. The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition. Nykanen, Haley, & Zamore, ATP requirements and small interfering RNA structure in the RNA interference pathway, Cell 2001, 107:309. Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleaves the target to induce silencing. Elbashir, Lendeckel, & Tuschl, RNA interference is mediated by 21- and 22-nucleotide RNAs, Genes Dev 2001, 15:188, FIG. 1.

[0009] The interference effect can be long lasting and may be detectable after many cell divisions. Moreover, RNAi exhibits sequence specificity. Kisielow, M. et al. (2002) *Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA*, J. of Biochemistry 363: 1-5. Thus, the RNAi machinery can specifically knock down one type of transcript, while not affecting closely related mRNA. These properties make siRNA a potentially valuable tool for inhibiting gene expression and studying gene function and drug target validation. Moreover, siRNAs are potentially useful as therapeutic agents against: (1) diseases that are caused by over-expression or misexpression of genes; and (2) diseases brought about by expression of genes that contain mutations.

[0010] Successful siRNA-dependent gene silencing depends on a number of factors. One of the most contentious issues in RNAi is the question of the necessity of siRNA design, i.e., considering the sequence of the siRNA used. Early work in C. elegans and plants circumvented the issue of design by introducing long dsRNA (see, for instance, Fire, A. et al. (1998) *Nature* 391:806-811). In this primitive organism, long dsRNA molecules are cleaved into siRNA by Dicer, thus generating a diverse population of duplexes that can potentially cover the entire transcript. While some fraction of these molecules are non-functional (i.e. induce little or no silencing) one or more have the potential to be highly functional, thereby silencing the gene of interest and alleviating the need for siRNA design. Unfortunately, due to the interferon response, this same approach is unavailable for mammalian systems. While this effect can be circumvented by bypassing

the Dicer cleavage step and directly introducing siRNA, this tactic carries with it the risk that the chosen siRNA sequence may be non-functional or semi-functional.

[0011] A number of researches have expressed the view that siRNA design is not a crucial element of RNAi. On the other hand, others in the field have begun to explore the possibility that RNAi can be made more efficient by paying attention to the design of the siRNA. Unfortunately, none of the reported methods have provided a satisfactory scheme for reliably selecting siRNA with acceptable levels of functionality. Accordingly, there is a need to develop rational criteria by which to select siRNA with an acceptable level of functionality, and to identify siRNA that have this improved level of functionality, as well as to identify siRNAs that are hyperfunctional.

SUMMARY OF THE INVENTION

[0012] The present invention is directed to increasing the efficiency of RNAi, particularly in mammalian systems. Accordingly, the present invention provides kits, siRNAs and methods for increasing siRNA efficacy.

[0013] According to one embodiment, the present invention provides a kit for gene silencing, wherein said kit is comprised of a pool of at least two siRNA duplexes, each of which is comprised of a sequence that is complementary to a portion of the sequence of one or more target messenger RNA

[0014] According to a second embodiment, the present invention provides a method for optimizing RNA interference by using one or more siRNAs that are optimized according to a formula (or algorithm) selected from:

wherein in Formulas I-VII:

[0015] $Tm_{20^{\circ} C} = 1$ if the Tm is greater than 20° C.;

[0016] $A_{19}=1$ if A is the base at position 19 on the sense strand, otherwise its value is 0;

[0017] AU_{15-19} =0-5 depending on the number of A or U bases on the sense strand at

[**0018**] positions 15-19;

[0019] $G_{13}=1$ if G is the base at position 13 on the sense strand, otherwise its value is 0;

[0020] $C_{19}=1$ if C is the base at position 19 of the sense strand, otherwise its value is 0;

[0021] GC=the number of G and C bases in the entire sense strand;

[0022] $A_3=1$ if A is the base at position 3 on the sense strand, otherwise its value is 0;

[0023] $A_{11}=1$ if A is the base at position 11 on the sense strand, otherwise its value is 0;

[0024] $A_{14}=1$ if A is the base at position 14 on the sense strand, otherwise its value is 0;

[0025] $U_{10}=1$ if U is the base at position 10 on the sense strand, otherwise its value is 0;

[0026] $U_5=1$ if U is the base at position 5 on the sense strand, otherwise its value is 0; or

```
\begin{array}{lll} \text{Relative} & \text{functionality} & \text{of} & \text{siRNA} = (-14)^*G_{13} - \\ 13^*A_1 - 12^*U_7 - 11^*U_2 - 10^*A_{11} - 10^*U_4 - 10^*C_3 - \\ 10^*C_5 - 10^*C_6 - 9^*A_{10} - 9^*U_9 - 9^*C_{18} - 8^*G_{10} - \\ 7^*U_1 - 7^*U_{16} - 7^*C_{17} - 7^*C_{19} + 7^*U_{11} + 8^*A_2 + \\ 8^*A_4 + 8^*A_5 + 8^*C_4 + 9^*G_8 + 10^*A_7 + 10^*U_{18} + \\ 11^*A_{19} + 11^*C_9 + 15^*G_1 + 18^*A_3 + 19^*U_{10} - Tm - \\ 3^*(GC_{\text{total}}) - 6^*(GC_{15-19}) - 30^*X_i^* \ and \end{array} \qquad \qquad \text{Formula VIII} Relative functionality of siRNA= (14.1)^*A_3 + \\ (14.9)^*A_6 + (17.6)^*A_{13}^* + (24.7)^*A_{19} + (14.2)^*U_{10} + \\ (10.5)^*C_9 + (23.9)^*G_1 + (16.3)^*G_2 + (-12.3)^*A_{11} + (-19.3)^*U_1 + (-11.3)^*U_2 + (-11)^*U_3 + (-15.2)^*U_{15} + \\ (-11.3)^*U_16 + (-11.8)^*C_3 + (-17.4)^*C_6 + (-10.5)^*C_7 + (-13.7)^*G_{13} + (-25.9)^*G_{19} - Tm - \\ 3^*(GC_{\text{total}}) - 6^*(GC_{15-19}) - 30^*X \qquad \qquad \text{Formula IX} \end{array}
```

wherein

[0027] $A_1=1$ if A is the base at position 1 of the sense strand, otherwise its value is 0;

[0028] $A_2=1$ if A is the base at position 2 of the sense strand, otherwise its value is 0;

[0029] A₃=1 if A is the base at position 3 of the sense strand, otherwise its value is 0;

[0030] A₄=1 if A is the base at position 4 of the sense strand, otherwise its value is 0;

[0031] A₅=1 if A is the base at position 5 of the sense strand, otherwise its value is 0;

[0032] $A_6=1$ if A is the base at position 6 of the sense strand, otherwise its value is 0;

[0033] A₇=1 if A is the base at position 7 of the sense strand, otherwise its value is 0;

[0034] A₁₀=1 if A is the base at position 10 of the sense strand, otherwise its value is 0;

[0035] A₁₁=1 if A is the base at position 11 of the sense strand, otherwise its value is 0;

[0036] A₁₃=1 if A is the base at position 13 of the sense strand, otherwise its value is 0;

[0037] A₁₉=1 if A is the base at position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0;

[0038] $C_3=1$ if C is the base at position 3 of the sense strand, otherwise its value is 0;

[0039] C₄=1 if C is the base at position 4 of the sense strand, otherwise its value is 0;

[0040] C₅=1 if C is the base at position 5 of the sense strand, otherwise its value is 0;

- [0041] $C_6=1$ if C is the base at position 6 of the sense strand, otherwise its value is 0;
- [0042] $C_7=1$ if C is the base at position 7 of the sense strand, otherwise its value is 0;
- [0043] C_9 =1 if C is the base at position 9 of the sense strand, otherwise its value is 0;
- [0044] $C_{17}=1$ if C is the base at position 17 of the sense strand, otherwise its value is 0;
- [0045] $C_{18}=1$ if C is the base at position 18 of the sense strand, otherwise its value is 0;
- [0046] C₁₉=1 if C is the base at position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0;
- [0047] G_1 =1 if G is the base at position 1 on the sense strand, otherwise its value is 0;
- [0048] $G_2=1$ if G is the base at position 2 of the sense strand, otherwise its value is 0;
- [0049] $G_8=1$ if G is the base at position 8 on the sense strand, otherwise its value is 0;
- [0050] G₁₀=1 if G is the base at position 10 on the sense strand, otherwise its value is 0;
- [0051] G₁₃=1 if G is the base at position 13 on the sense strand, otherwise its value is 0;
- [0052] $G_{19}=1$ if G is the base at position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0;
- [0053] U₁=1 if U is the base at position 1 on the sense strand, otherwise its value is 0;
- [0054] $U_2=1$ if U is the base at position 2 on the sense strand, otherwise its value is 0;
- [0055] U₃=1 if U is the base at position 3 on the sense strand, otherwise its value is 0;
- [0056] U₄=1 if U is the base at position 4 on the sense strand, otherwise its value is 0;
- [0057] U₇=1 if U is the base at position 7 on the sense strand, otherwise its value is 0;
- [0058] $U_9=1$ if U is the base at position 9 on the sense strand, otherwise its value is 0;
- [0059] U₁₀=1 if U is the base at position 10 on the sense strand, otherwise its value is 0;
- [0060] U₁₅=1 if U is the base at position 15 on the sense strand, otherwise its value is 0;
- [0061] U₁₆=1 if U is the base at position 16 on the sense strand, otherwise its value is 0;
- [0062] U₁₇=1 if U is the base at position 17 on the sense strand, otherwise its value is 0;
- [0063] U₁₈=1 if U is the base at position 18 on the sense strand, otherwise its value is 0;
- [0064] GC₁₅₋₁₉=the number of G and C bases within positions 15-19 of the sense strand or within positions 15-18 if the sense strand is only 18 base pairs in length;

- [0065] GC_{total} =the number of G and C bases in the sense strand;
- [0066] $T_m=100$ if the targeting site contains an inverted repeat longer than 4 base pairs, otherwise its value is 0; and
- [0067] X=the number of times that the same nucleotide repeats four or more times in a row.
- [0068] According to a third embodiment, the present invention is directed to a kit comprised of at least one siRNA that contains a sequence that is optimized according to one of the formulas above. Preferably the kit contains at least two optimized siRNA, each of which comprises a duplex, wherein one strand of each duplex comprises at least eighteen contiguous bases that are complementary to a region of a target messenger RNA. For mammalian systems, the siRNA preferably comprises between 18 and 30 nucleotide base pairs.
- [0069] The ability to use the above algorithms, which are not sequence or species specific, allows for the cost-effective selection of optimized siRNAs for specific target sequences. Accordingly, there will be both greater efficiency and reliability in the use of siRNA technologies.
- [0070] According to a fourth embodiment, the present invention provides a method for developing an siRNA algorithm for selecting functional and hyperfunctional siRNAs for a given sequence. The method comprises:
- [0071] (a) selecting a set of siRNAs;
- [0072] (b) measuring the gene silencing ability of each siRNA from said set;
- [0073] (c) determining the relative functionality of each siRNA;
- [0074] (d) determining the amount of improved functionality by the presence or absence of at least one variable selected from the group consisting of the total GC content, melting temperature of the siRNA, GC content at positions 15-19, the presence or absence of a particular nucleotide at a particular position and the number of times that the same nucleotide repeats within a given sequence; and
- [0075] (e) developing an algorithm using the information of step (d).
- [0076] According to this embodiment, preferably the set of siRNAs comprises at least 90 siRNAs from at least one gene, more preferably at least 180 siRNAs from at least two different genes, and most preferably at least 270 and 360 siRNAs from at least three and four different genes, respectively. Additionally, in step (d) the determination is made with preferably at least two, more preferably at least three, even more preferably at least four, and most preferably all of the variables. The resulting algorithm is not target sequence specific.
- [0077] In a fifth embodiment, the present invention provides rationally designed siRNAs identified using the formulas above.
- [0078] In a sixth embodiment, the present invention is directed to hyperfunctional siRNA.
- [0079] For a better understanding of the present invention together with other and further advantages and embodiments, reference is made to the following description taken in conjunction with the examples, the scope of which is set forth in the appended claims.

BRIEF DESCRIPTION OF THE FIGURES

[0080] FIG. 1 shows a model for siRNA-RISC interactions. RISC has the ability to interact with either end of the siRNA or miRNA molecule. Following binding, the duplex is unwound, and the relevant target is identified, cleaved, and released.

[0081] FIG. 2 is a representation of the functionality of two hundred and seventy siRNA duplexes that were generated to target human cyclophilin, human diazepam-binding inhibitor (DB), and firefly luciferase.

[0082] FIG. 3A is a representation of the silencing effect of 30 siRNAs in three different cells lines, HEK293, DU145, and Hela. FIG. 3B shows the frequency of different functional groups (>95% silencing (black), >80% silencing (gray), >50% silencing (dark gray), and <50% silencing (white)) based on GC content. In cases where a given bar is absent from a particular GC percentage, no siRNA were identified for that particular group. FIG. 3C shows the frequency of different functional groups based on melting temperature (Tm). Again, each group has four different divisions: >95% (black), >80% (gray), >50% (dark gray), and <50% (white) silencing.

[0083] FIGS. 4A-4E are representations of a statistical analysis that revealed correlations between silencing and five sequence-related properties of siRNA: (4A) an A at position 19 of the sense strand, (4B) an A at position 3 of the sense strand, (4C) a U at position 10 of the sense strand, (4D) a base other than G at position 13 of the sense strand, and (4E) a base other than C at position 19 of the sense strand. All variables were correlated with siRNA silencing of firefly luciferase and human cyclophilin. SiRNAs satisfying the criterion are grouped on the left (Selected) while those that do not, are grouped on the right (Eliminated). Y-axis is "% Silencing of Control." Each position on the X-axis represents a unique siRNA.

[0084] FIGS. 5 A and 5B are representations of firefly luciferase and cyclophilin siRNA panels sorted according to functionality and predicted values using Formula VIII. The siRNA found within the circle represent those that have Formula VIII values (SMARTscoresTM) above zero. SiRNA outside the indicated area have calculated Formula VIII values that are below zero. Y-axis is "Expression (% Control)." Each position on the X-axis represents a unique siRNA.

[0085] FIG. 6A is a representation of the average internal stability profile (AISP) derived from 270 siRNAs taken from three separate genes (cyclophilin B, DBI and firefly luciferase). Graphs represent AISP values of highly functional, functional, and non-functional siRNA. FIG. 6B is a comparison between the AISP of naturally derived GFP siRNA (filled squares) and the AISP of siRNA from cyclophilin B, DBI, and luciferase having >90% silencing properties (no fill) for the antisense strand. "DG" is the symbol for ΔG , free energy.

[0086] FIG. 7 is a histogram showing the differences in duplex functionality upon introduction of basepair mismatches. The X-axis shows the mismatch introduced into the siRNA and the position it is introduced (e.g., 8C->A reveals that position 8 (which normally has a C) has been changed to an A). The Y-axis is "% Silencing (Normalized to Control)."

[0087] FIG. 8 is histogram that shows the effects of 5' sense and antisense strand modification with 2'-O-methylation on functionality.

[0088] FIG. 9 shows a graph of SMARTscoresTM versus RNAi silencing values for more than 360 siRNA directed against 30 different genes. SiRNA to the right of the vertical bar represent those siRNA that have desirable SMARTscoresTM.

[0089] FIGS. 10A-E compare the RNAi of five different genes (SEAP, DBI, PLK, Firefly Luciferase, and Renila Luciferase) by varying numbers of randomly selected siRNA and four rationally designed (SMART-selected) siRNA chosen using the algorithm described in Formula VIII. In addition, RNAi induced by a pool of the four SMART-selected siRNA is reported at two different concentrations (100 and 400 nM). 10F is a comparison between a pool of randomly selected EGFR siRNA (Pool 1) and a pool of SMART selected EGFR siRNA (Pool 2). Pool 1, S1-S4 and Pool 2 S1-S4 represent the individual members that made up each respective pool. Note that numbers for random siRNAs represent the position of the 5' end of the sense strand of the duplex. The Y-axis represents the % expression of the control(s). The X-axis is the percent expression of the control.

[0090] FIG. 11 shows the Western blot results from cells treated with siRNA directed against twelve different genes involved in the clathrin-dependent endocytosis pathway (CHC, DynII, CALM, CLCa, CLCb, Eps15, Eps15R, Rab5a, Rab5b, Rab5c, β 2 subunit of AP-2 and EEA.1). SiRNA were selected using Formula VIII. "Pool" represents a mixture of duplexes 1-4. Total concentration of each siRNA in the pool is 25 nM. Total concentration= $4\times25=100$ nM.

[0091] FIG. 12 is a representation of the gene silencing capabilities of rationally-selected siRNA directed against ten different genes (human and mouse cyclophilin, C-myc, human lamin A/C, QB (ubiquinol-cytochrome c reductase core protein I), MEK1 and MEK2, ATE1 (arginyl-tRNA protein transferase), GAPDH, and Eg5). The Y-axis is the percent expression of the control. Numbers 1, 2, 3 and 4 represent individual rationally selected siRNA. "Pool" represents a mixture of the four individual siRNA.

[0092] FIG. 13 is the sequence of the top ten Bcl2 siRNAs as determined by Formula VIII. Sequences are listed 5' to 3'.

[0093] FIG. 14 is the knockdown by the top ten Bcl2 siR-NAs at 100 nM concentrations. The Y-axis represents the amount of expression relative to the non-specific (ns) and transfection mixture control.

[0094] FIG. 15 represents a functional walk where siRNA beginning on every other base pair of a region of the luciferase gene are tested for the ability to silence the luciferase gene. The Y-axis represents the percent expression relative to a control. The X-axis represents the position of each individual siRNA. Reading from left to right across the X-axis, the position designations are 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.

[0095] FIGS. 16A and 16B are histograms demonstrating the inhibition of target gene expression by pools of 2 (16A) and 3 (16B) siRNA duplexes taken from the walk described in FIG. 15. The Y-axis in each represents the percent expression relative to control. The X-axis in each represents the position of the first siRNA in paired pools, or trios of siRNAs. For instance, the first paired pool contains siRNAs 1 and 3. The second paired pool contains siRNAs 3 and 5. Pool 3 (of paired

pools) contains siRNAs 5 and 7, and so on. For each of **16**A and **16**B, the X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.

[0096] FIGS. 17A and 17B are histograms demonstrating the inhibition of target gene expression by pools of 4 (17A) and 5 (17B) siRNA duplexes. The Y-axis in each represents the percent expression relative to control. The X-axis in each represents the position of the first siRNA in each pool. For each of 17A and 17B, the X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.

[0097] FIGS. 18A and 18B are histograms demonstrating the inhibition of target gene expression by siRNAs that are ten (18A) and twenty (18B) base pairs apart. The Y-axis represents the percent expression relative to a control. The X-axis represents the position of the first siRNA in each pool. For each of 18A and 18B, the X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.

[0098] FIG. 19 shows that pools of siRNAs (dark gray bar) work as well (or better) than the best siRNA in the pool (light gray bar). The Y-axis represents the percent expression relative to a control. The X-axis represents the position of the first siRNA in each pool. The X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.

[0099] FIG. 20 shows that the combination of several semifunctional siRNAs (dark gray) result in a significant improvement of gene expression inhibition over individual (semifunctional; light gray) siRNA. The Y-axis represents the percent expression relative to a control.

[0100] FIG. 21 shows both pools (Library, Lib) and individual siRNAs in inhibition of gene expression of Beta-Galactosidase, Renilla Luciferase and SEAP (alkaline phosphatase). Numbers on the X-axis indicate the position of the 5'-most nucleotide of the sense strand of the duplex. The Y-axis represents the percent expression of each gene relative to a control. Libraries contain siRNAs that begin at the following nucleotides: Seap: Lib 1: 206, 766, 812, 923, Lib 2: 1117, 1280, 1300, 1487, Lib 3: 206, 766, 812, 923, 1117, 1280, 1300, 1487, Lib 4: 206, 812, 1117, 1300, Lib 5: 766, 923, 1280, 1487, Lib 6: 206, 1487; Bgal: Lib 1: 979, 1339, 2029, 2590, Lib 2: 1087, 1783, 2399, 3257, Lib 3: 979, 1783, 2590, 3257, Lib 4: 979, 1087, 1339, 1783, 2029, 2399, 2590, 3257, Lib 5: 979, 1087, 1339, 1783, Lib 6: 2029, 2399, 2590, 3257; Renilla: Lib 1: 174, 300, 432, 568, Lib 2: 592, 633, 729, 867, Lib 3: 174, 300, 432, 568, 592, 633, 729, 867, Lib 4: 174, 432, 592, 729, Lib 5: 300, 568, 633, 867, Lib 6: 592, 568.

[0101] FIG. 22 shows the results of an EGFR and TfnR internalization assay when single gene knockdowns are performed. The Y-axis represents percent internalization relative to control.

[0102] FIG. 23 shows the results of an EGFR and TfnR internalization assay when multiple genes are knocked down (e.g. Rab5a, b, c). The Y-axis represents the percent internalization relative to control.

[0103] FIG. 24 shows the simultaneous knockdown of four different genes. SiRNAs directed against G6PD, GAPDH, PLK, and UBQ were simultaneously introduced into cells. Twenty-four hours later, cultures were harvested and assayed for mRNA target levels for each of the four genes. A comparison is made between cells transfected with individual siRNAs vs. a pool of siRNAs directed against all four genes.

[0104] FIG. 25 shows the functionality of ten siRNAs at 0.3 nM concentrations.

DETAILED DESCRIPTION

Definitions

[0105] Unless stated otherwise, the following terms and phrases have the meanings provided below:

siRNA

[0106] The term "siRNA" refers to small inhibitory RNA duplexes that induce the RNA interference (RNAi) pathway. These molecules can vary in length (generally between 18-30 basepairs) and contain varying degrees of complementarity to their target mRNA in the antisense strand. Some, but not all, siRNA have unpaired overhanging bases on the 5' or 3' end of the sense strand and/or the antisense strand. The term "siRNA" includes duplexes of two separate strands, as well as single strands that can form hairpin structures comprising a duplex region.

[0107] SiRNA may be divided into five (5) groups (nonfunctional, semi-functional, functional, highly functional, and hyper-functional) based on the level or degree of silencing that they induce in cultured cell lines. As used herein, these definitions are based on a set of conditions where the siRNA is transfected into said cell line at a concentration of 100 nM and the level of silencing is tested at a time of roughly 24 hours after transfection, and not exceeding 72 hours after transfection. In this context, "non-functional siRNA" are defined as those siRNA that induce less than 50% (<50%) target silencing. "Semi-functional siRNA" induce 50-79% target silencing. "Functional siRNA" are molecules that induce 80-95% gene silencing. "Highly-functional siRNA" are molecules that induce greater than 95% gene silencing. "Hyperfunctional siRNA" are a special class of molecules. For purposes of this document, hyperfunctional siRNA are defined as those molecules that: (1) induce greater than 95% silencing of a specific target when they are transfected at subnanomolar concentrations (i.e., less than one nanomolar); and/or (2) induce functional (or better) levels of silencing for greater than 96 hours. These relative functionalities (though not intended to be absolutes) may be used to compare siRNAs to a particular target for applications such as functional genomics, target identification and therapeutics.

miRNA

[0108] The term "miRNA" refers to microRNA. Gene Silencing

[0109] The phrase "gene silencing" refers to a process by which the expression of a specific gene product is lessened or attenuated. Gene silencing can take place by a variety of pathways. Unless specified otherwise, as used herein, gene silencing refers to decreases in gene product expression that results from RNA interference (RNAi), a defined, though partially characterized pathway whereby small inhibitory

RNA (siRNA) act in concert with host proteins (e.g. the RNA induced silencing complex, RISC) to degrade messenger RNA (mRNA) in a sequence-dependent fashion. The level of gene silencing can be measured by a variety of means, including, but not limited to, measurement of transcript levels by Northern Blot Analysis, B-DNA techniques, transcriptionsensitive reporter constructs, expression profiling (e.g. DNA chips), and related technologies. Alternatively, the level of silencing can be measured by assessing the level of the protein encoded by a specific gene. This can be accomplished by performing a number of studies including Western Analysis, measuring the levels of expression of a reporter protein that has e.g. fluorescent properties (e.g. GFP) or enzymatic activity (e.g. alkaline phosphatases), or several other procedures.

Transfection

[0110] The term "transfection" refers to a process by which agents are introduced into a cell. The list of agents that can be transfected is large and includes, but is not limited to, siRNA, sense and/or anti-sense sequences, DNA encoding one or more genes and organized into an expression plasmid, proteins, protein fragments, and more. There are multiple methods for transfecting agents into a cell including, but not limited to, electroporation, calcium phosphate-based transfections, DEAE-dextran-based transfections, lipid-based transfections, molecular conjugate-based transfections (e.g. polylysine-DNA conjugates), microinjection and others.

Target

[0111] The term "target" is used in a variety of different forms throughout this document and is defined by the context in which it is used. "Target mRNA" refers to a messenger RNA to which a given siRNA can be directed against. "Target sequence" and "target site" refer to a sequence within the mRNA to which the sense strand of an siRNA shows varying degrees of homology and the antisense strand exhibits varying degrees of complementarity. The term "siRNA target" can refer to the gene, mRNA, or protein against which an siRNA is directed. Similarly "target silencing" can refer to the state of a gene, or the corresponding mRNA or protein.

Off-Target Silencing and Off-Target Interference

[0112] The phrases "off-target silencing" and "off-target interference" are defined as degradation of mRNA other than the intended target mRNA due to overlapping and/or partial homology with secondary mRNA messages.

SMARTscoreTM

[0113] The term "SMARTscoreTM" refers to a number determined by applying any of the Formulas I-Formula IX to a given siRNA sequence. The term "SMART-selected" or "rationally selected" or "rational selection" refers to siRNA that have been selected on the basis of their SMARTscoresTM.

Complementary

[0114] The term "complementary" refers to the ability of polynucleotides to form base pairs with one another. Base pairs are typically formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide strands. Complementary polynucleotide strands can base pair in the Watson-Crick manner (e.g., A to T, A to U, C to G), or in any other manner that allows for the formation of duplexes. As persons skilled in the art are aware, when using RNA as opposed to DNA, uracil rather than thymine is the base that is considered

to be complementary to adenosine. However, when a U is denoted in the context of the present invention, the ability to substitute a T is implied, unless otherwise stated.

[0115] Perfect complementarity or 100% complementarity refers to the situation in which each nucleotide unit of one polynucleotide strand can hydrogen bond with a nucleotide unit of a second polynucleotide strand. Less than perfect complementarity refers to the situation in which some, but not all, nucleotide units of two strands can hydrogen bond with each other. For example, for two 20-mers, if only two base pairs on each strand can hydrogen bond with each other, the polynucleotide strands exhibit 10% complementarity. In the same example, if 18 base pairs on each strand can hydrogen bond with each other, the polynucleotide strands exhibit 90% complementarity.

Deoxynucleotide

[0116] The term "deoxynucleotide" refers to a nucleotide or polynucleotide lacking a hydroxyl group (OH group) at the 2' and/or 3' position of a sugar moiety. Instead, it has a hydrogen bonded to the 2' and/or 3' carbon. Within an RNA molecule that comprises one or more deoxynucleotides, "deoxynucleotide" refers to the lack of an OH group at the 2' position of the sugar moiety, having instead a hydrogen bonded directly to the 2' carbon.

Deoxyribonucleotide

[0117] The terms "deoxyribonucleotide" and "DNA" refer to a nucleotide or polynucleotide comprising at least one sugar moiety that has an H, rather than an OH, at its 2' and/or 3' position.

Substantially Similar

[0118] The phrase "substantially similar" refers to a similarity of at least 90% with respect to the identity of the bases of the sequence.

Duplex Region

[0119] The phrase "duplex region" refers to the region in two complementary or substantially complementary polynucleotides that form base pairs with one another, either by Watson-Crick base pairing or any other manner that allows for a stabilized duplex between polynucleotide strands that are complementary or substantially complementary. For example, a polynucleotide strand having 21 nucleotide units can base pair with another polynucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the "duplex region" has 19 base pairs. The remaining bases may, for example, exist as 5' and 3' overhangs. Further, within the duplex region, 100% complementarity is not required; substantial complementarity is allowable within a duplex region. For example, a mismatch in a duplex region consisting of 19 base pairs results in 94.7% complementarity, rendering the duplex region substantially complementary.

Nucleotide

[0120] The term "nucleotide" refers to a ribonucleotide or a deoxyribonucleotide or modified form thereof, as well as an analog thereof. Nucleotides include species that comprise purines, e.g., adenine, hypoxanthine, guanine, and their derivatives and analogs, as well as pyrimidines, e.g., cytosine, uracil, thymine, and their derivatives and analogs.

[0121] Nucleotide analogs include nucleotides having modifications in the chemical structure of the base, sugar and/or phosphate, including, but not limited to, 5-position pyrimidine modifications, 8-position purine modifications, modifications at cytosine exocyclic amines, and substitution of 5-bromo-uracil; and 2'-position sugar modifications, including but not limited to, sugar-modified ribonucleotides in which the 2'-OH is replaced by a group such as an H, OR, R, halo, SH, SR, NH₂, NHR, NR₂, or CN, wherein R is an alkyl moiety. Nucleotide analogs are also meant to include nucleotides with bases such as inosine, queuosine, xanthine, sugars such as 2'-methyl ribose, non-natural phosphodiester linkages such as methylphosphonates, phosphorothioates and peptides.

[0122] Modified bases refer to nucleotide bases such as, for example, adenine, guanine, cytosine, thymine, uracil, xanthine, inosine, and queuosine that have been modified by the replacement or addition of one or more atoms or groups. Some examples of types of modifications that can comprise nucleotides that are modified with respect to the base moieties include but are not limited to, alkylated, halogenated, thiolated, aminated, amidated, or acetylated bases, individually or in combination. More specific examples include, for example, 5-propynyluridine, 5-propynylcytidine, 6-methyladenine, 6-methylguanine, N,N-dimethyladenine, 2-propyladenine, 2-propylguanine, 2-aminoadenine, 1-methylinosine, 3-methyluridine, 5-methyluridine, 5-methyluridine and other nucleotides having a modification at the 5 position, 5-(2-amino)propyl uridine, 5-halocytidine, 5-halouridine, 4-acetylcytidine, 1-methyladenosine, 2-methyladenosine, 3-methylcytidine, 6-methyluridine, 2-methylguanosine, 7-methylguanosine, 2,2-dimethylguanosine, 5-methylaminoethyluridine, 5-methyloxyuridine, deazanucleotides such as 7-deaza-adenosine, 6-azouridine, 6-azothymidine, 5-methyl-2-thiouridine, other thio bases such as 2-thiouridine and 4-thiouridine and 2-thiocytidine, dihydrouridine, pseudouridine, queuosine, archaeosine, naphthyl and substituted naphthyl groups, any O- and N-alkylated purines and pyrimidines such as N6-methyladenosine, 5-methylcarbonylmethyluridine, uridine 5-oxyacetic acid, pyridine-4one, pyridine-2-one, phenyl and modified phenyl groups such as aminophenol or 2,4,6-trimethoxy benzene, modified cytosines that act as G-clamp nucleotides, 8-substituted adenines and guanines, 5-substituted uracils and thymines, azapyrimidines, carboxyhydroxyalkyl nucleotides, carboxyalkylaminoalkyl nucleotides, and alkylcarbonylalkylated nucleotides. Modified nucleotides also include those nucleotides that are modified with respect to the sugar moiety, as well as nucleotides having sugars or analogs thereof that are not ribosyl. For example, the sugar moieties may be, or be based on, mannoses, arabinoses, glucopyranoses, galactopyranoses, 4'-thioribose, and other sugars, heterocycles, or carbocycles.

[0123] The term nucleotide is also meant to include what are known in the art as universal bases. By way of example, universal bases include but are not limited to 3-nitropyrrole, 5-nitroindole, or nebularine. The term "nucleotide" is also meant to include the N3' to P5' phosphoramidate, resulting from the substitution of a ribosyl 3' oxygen with an amine group.

[0124] Further, the term nucleotide also includes those species that have a detectable label, such as for example a radioactive or fluorescent moiety, or mass label attached to the nucleotide.

Polynucleotide

[0125] The term "polynucleotide" refers to polymers of nucleotides, and includes but is not limited to DNA, RNA, DNA/RNA hybrids including polynucleotide chains of regularly and/or irregularly alternating deoxyribosyl moieties and ribosyl moieties (i.e., wherein alternate nucleotide units have an —OH, then and —H, then an —OH, then an —H, and so on at the 2' position of a sugar moiety), and modifications of these kinds of polynucleotides, wherein the attachment of various entities or moieties to the nucleotide units at any position are included.

Polyribonucleotide

[0126] The term "polyribonucleotide" refers to a polynucleotide comprising two or more modified or unmodified ribonucleotides and/or their analogs. The term "polyribonucleotide" is used interchangeably with the term "oligoribonucleotide."

Ribonucleotide and Ribonucleic Acid

[0127] The term "ribonucleotide" and the phrase "ribonucleic acid" (RNA), refer to a modified or unmodified nucleotide or polynucleotide comprising at least one ribonucleotide unit. A ribonucleotide unit comprises an hydroxyl group attached to the 2' position of a ribosyl moiety that has a nitrogenous base attached in N-glycosidic linkage at the 1' position of a ribosyl moiety, and a moiety that either allows for linkage to another nucleotide or precludes linkage.

DETAILED DESCRIPTION OF THE INVENTION

[0128] The present invention is directed to improving the efficiency of gene silencing by siRNA. Through the inclusion of multiple siRNA sequences that are targeted to a particular gene and/or selecting an siRNA sequence based on certain defined criteria, improved efficiency may be achieved.

[0129] The present invention will now be described in connection with preferred embodiments. These embodiments are presented in order to aid in an understanding of the present invention and are not intended, and should not be construed, to limit the invention in any way. All alternatives, modifications and equivalents that may become apparent to those of ordinary skill upon reading this disclosure are included within the spirit and scope of the present invention.

[0130] Furthermore, this disclosure is not a primer on RNA interference. Basic concepts known to persons skilled in the art have not been set forth in detail.

Optimizing siRNA

[0131] According to one embodiment, the present invention provides a method for improving the effectiveness of gene silencing for use to silence a particular gene through the selection of an optimal siRNA. An siRNA selected according to this method may be used individually, or in conjunction with the first embodiment, i.e., with one or more other siR-NAs, each of which may or may not be selected by this criteria in order to maximize their efficiency.

[0132] The degree to which it is possible to select an siRNA for a given mRNA that maximizes these criteria will depend on the sequence of the mRNA itself. However, the selection criteria will be independent of the target sequence. According to this method, an siRNA is selected for a given gene by using a rational design. That said, rational design can be described in a variety of ways. Rational design is, in simplest terms, the application of a proven set of criteria that enhance the probability of identifying a functional or hyperfunctional siRNA. In one method, rationally designed siRNA can be identified by maximizing one or more of the following criteria:

[0133] 1. A low GC content, preferably between about 30-52%.

[0134] 2. At least 2, preferably at least 3 A or U bases at positions 15-19 of the siRNA on the sense strand.

[0135] 3. An A base at position 19 of the sense strand.

[0136] 4. An A base at position 3 of the sense strand.

[0137] 5. A U base at position 10 of the sense strand.

[0138] 6. An A base at position 14 of the sense strand.

[0139] 7. A base other than C at position 19 of the sense strand.

[0140] 8. A base other than G at position 13 of the sense strand.

[0141] 9. A Tm, which refers to the character of the internal repeat that results in inter- or intramolecular structures for one strand of the duplex, that is preferably not stable at greater than 50° C., more preferably not stable at greater than 37° C., even more preferably not stable at greater than 30° C. and most preferably not stable at greater than 20° C.

[0142] 10. A base other than U at position 5 of the sense strand.

[0143] 11. A base other than A at position 11 of the sense strand.

[0144] Criteria 5, 6, 10 and 11 are minor criteria, but are nonetheless desirable. Accordingly, preferably an siRNA will satisfy as many of the aforementioned criteria as possible, more preferably at least 1-4 and 7-9, and most preferably all of the criteria

[0145] With respect to the criteria, GC content, as well as a high number of AU in positions 15-19, may be important for easement of the unwinding of double stranded siRNA duplex. Duplex unwinding has been shown to be crucial for siRNA functionality in vivo.

[0146] With respect to criterion 9, the internal structure is measured in terms of the melting temperature of the single strand of siRNA, which is the temperature at which 50% of the molecules will become denatured. With respect to criteria 2-8 and 10-11, the positions refer to sequence positions on the sense strand, which is the strand that is identical to the mRNA.

[0147] In one preferred embodiment, at least criteria 1 and 8 are satisfied. In another preferred embodiment, at least criteria 7 and 8 are satisfied. In still another preferred embodiment, at least criteria 1, 8 and 9 are satisfied.

[0148] It should be noted that all of the aforementioned criteria regarding sequence position specifics are with respect to the 5' end of the sense strand. Reference is made to the sense strand, because most databases contain information that describes the information of the mRNA. Because accord-

ing to the present invention a chain can be from 18 to 30 bases in length, and the aforementioned criteria assumes a chain 19 base pairs in length, it is important to keep the aforementioned criteria applicable to the correct bases.

[0149] When there are only 18 bases, the base pair that is not present is the base pair that is located at the 3' of the sense strand. When there are twenty to thirty bases present, then additional bases are added at the 5' end of the sense chain and occupy positions -1 to -11. Accordingly, with respect to SEQ. ID NO. 0001. NNANANNNUCNAANNNNA and SEQ. ID NO. 0028. GUCNNANANNNUCNAANNNNA, both would have A at position 3, A at position 5, U at position 10, C at position 11, A and position 13, A and position 14 and A at position 19. However, SEQ. ID NO. 0028 would also have C at position -1, U at position -2 and G at position -3.

[0150] For a 19 base pair siRNA, an optimal sequence of one of the strands may be represented below, where N is any base, A, C, G, or U:

SEQ. ID NO. 0001. NNANANNNUCNAANNNA SEQ. ID NO. 0002. NNANANNNUGNAANNNNA SEO. ID NO. 0003. NNANANNNUUNAANNNA SEO. ID NO. 0004. NNANANNNUCNCANNNNA SEQ. ID NO. 0005. NNANANNNUGNCANNNNA SEQ. ID NO. 0006. NNANANNNUUNCANNNA SEQ. ID NO. 0007. NNANANNNUCNUANNNA SEQ. ID NO. 0008.. NNANANNNUGNUANNNA SEO. ID NO. 0009. NNANANNNUUNUANNNA SEO. ID NO. 0010. NNANCNNNNUCNAANNNNA SEO. ID NO. 0011. NNANCNNNNUGNAANNNNA SEO. ID NO. 0012. NNANCNNNNUUNAANNNA SEQ. ID NO. 0013. NNANCNNNNUCNCANNNNA SEQ. ID NO. 0014. NNANCNNNNUGNCANNNNA SEO. ID NO. 0015. NNANCNNNNUUNCANNNNA SEO. ID NO. 0016. NNANCNNNNUCNUANNNA SEQ. ID NO. 0017. NNANCNNNNUGNUANNNNA SEO. ID NO. 0018. NNANCNNNNUUNUANNNNA SEQ. ID NO. 0019. NNANGNNNNUCNAANNNNA SEO. ID NO. 0020. NNANGNNNNUGNAANNNNA SEQ. ID NO. 0021. NNANGNNNNUUNAANNNNA SEQ. ID NO. 0022. NNANGNNNNUCNCANNNNA SEQ. ID NO. 0023. NNANGNNNNUGNCANNNNA SEO. ID NO. 0024. NNANGNNNNUUNCANNNNA NNANGNNNNUCNUANNNNA SEO. ID NO. 0025. SEO. ID NO. 0026. NNANGNNNNUGNUANNNA SEQ. ID NO. 0027. NNANGNNNNUUNUANNNA

[0151] In one embodiment, the sequence used as an siRNA is selected by choosing the siRNA that score highest according to one of the following seven algorithms that are represented by Formulas I-VII:

In Formulas I-VII:

wherein $A_{19}=1$ if A is the base at position 19 on the sense strand, otherwise its value is 0,

[0152] AU_{15-19} =0-5 depending on the number of A or U bases on the sense strand at

[0153] positions 15-19;

[0154] $G_{13}=1$ if G is the base at position 13 on the sense strand, otherwise its value is 0;

[0155] $C_{19}=1$ if C is the base at position 19 of the sense strand, otherwise its value is 0;

[0156] GC=the number of G and C bases in the entire sense strand;

[0157] $Tm_{20^{\circ} C.} = 1$ if the Tm is greater than $20^{\circ} C.$;

[0158] $A_3=1$ if A is the base at position 3 on the sense strand, otherwise its value is 0;

[0159] $U_{10}=1$ if U is the base at position 10 on the sense strand, otherwise its value is 0;

[0160] $A_{14}=1$ if A is the base at position 14 on the sense strand, otherwise its value is 0;

[0161] U_5 =1 if U is the base at position 5 on the sense strand, otherwise its value is 0; and

[0162] $A_{11}=1$ if A is the base at position 11 of the sense strand, otherwise its value is 0.

[0163] Formulas I-VII provide relative information regarding functionality. When the values for two sequences are compared for a given formula, the relative functionality is ascertained; a higher positive number indicates a greater functionality. For example, in many applications a value of 5 or greater is beneficial.

[0164] Additionally, in many applications, more than one of these formulas would provide useful information as to the relative functionality of potential siRNA sequences. However, it is beneficial to have more than one type of formula, because not every formula will be able to help to differentiate among potential siRNA sequences. For example, in particularly high GC mRNAs, formulas that take that parameter into account would not be useful and application of formulas that lack GC elements (e.g., formulas V and VI) might provide greater insights into duplex functionality. Similarly, formula

II might by used in situations where hairpin structures are not observed in duplexes, and formula IV might be applicable for sequences that have higher AU content. Thus, one may consider a particular sequence in light of more than one or even all of these algorithms to obtain the best differentiation among sequences. In some instances, application of a given algorithm may identify an unusually large number of potential siRNA sequences, and in those cases, it may be appropriate to re-analyze that sequence with a second algorithm that is, for instance, more stringent. Alternatively, it is conceivable that analysis of a sequence with a given formula yields no acceptable siRNA sequences (i.e. low SMARTscoresTM). In this instance, it may be appropriate to re-analyze that sequences with a second algorithm that is, for instance, less stringent. In still other instances, analysis of a single sequence with two separate formulas may give rise to conflicting results (i.e. one formula generates a set of siRNA with high SMARTscoresTM while the other formula identifies a set of siRNA with low SMARTscoresTM). In these instances, it may be necessary to determine which weighted factor(s) (e.g. GC content) are contributing to the discrepancy and assessing the sequence to decide whether these factors should or should not be included. Alternatively, the sequence could be analyzed by a third, fourth, or fifth algorithm to identify a set of rationally designed siRNA.

[0165] The above-referenced criteria are particularly advantageous when used in combination with pooling techniques as depicted in Table I:

TABLE I

		Functional Probability									
		Oligos		Pools							
Criteria	>95%	>80%	<70%	>95%	>80%	<70%					
Current New (GC)	33.0 50.0 28.0	50.0 88.5 58.9	23.0 8.0 36.0	79.5 93.8 72.8	97.3 99.98 97.1	0.3 0.005 1.6					

The term "current" refers to Tuschl's conventional siRNA parameters (Elbashir, S. M. et al. (2002) "Analysis of gene function in somatic mammalian cells using small interfering RNAs" Methods 26: 199-213). "New" refers to the design parameters described in Formulas I-VII. "GC" refers to criteria that select siRNA solely on the basis of GC content.

[0166] As Table I indicates, when more functional siRNA duplexes are chosen, siRNAs that produce <70% silencing drops from 23% to 8% and the number of siRNA duplexes that produce >80% silencing rises from 50% to 88.5%. Further, of the siRNA duplexes with >80% silencing, a larger portion of these siRNAs actually silence >95% of the target expression (the new criteria increases the portion from 33% to 50%). Using this new criteria in pooled siRNAs, shows that, with pooling, the amount of silencing >95% increases from 79.5% to 93.8% and essentially eliminates any siRNA pool from silencing less than 70%.

[0167] Table II similarly shows the particularly beneficial results of pooling in combination with the aforementioned criteria. However, Table II, which takes into account each of the aforementioned variables, demonstrates even a greater degree of improvement in functionality.

TABLE II

	Functional Probability									
		Oligos			Pools					
	Functional	Average	Non- functional	Functional	Average	Non- functional				
Random	20	40	50	67	97	3				
Criteria 1	52	99	0.1	97	93	0.0040				
Criteria 4	89	99	0.1	99	99	0.0000				

The terms "functional," "Average," and "Non-functional" refer to siRNA that exhibit >80%, >50%, and <50% functionality, respectively. Criteria 1 and 4 refer to specific criteria described above.

[0168] The above-described algorithms may be used with or without a computer program that allows for the inputting of the sequence of the mRNA and automatically outputs the optimal siRNA. The computer program may, for example, be accessible from a local terminal or personal computer, over an internal network or over the Internet.

[0169] In addition to the formulas above, more detailed algorithms may be used for selecting siRNA. Preferably, at least one RNA duplex of between 18 and 30 base pairs is selected such that it is optimized according a formula selected from:

$$\begin{array}{lll} (-14)^*G_{13}-13^*A_1-12^*U_7-11^*U_2-10^*A_{11}-\\ 10^*U_4-10^*C_3-10^*C_5-10^*C_6-9^*A_{10}-9^*U_9-\\ 9^*C_{18}-8^*G_{10}-7^*U_1-7^*U_{16}-7^*C_{17}-7^*C_{19}+\\ 7^*U_{17}+8^*A_2+8^*A_4+8^*A_5+8^*C_4+9^*G_8+10^*A_7+\\ 10^*U_{18}+11^*A_{19}+11^*C_9+15^*G_1+18^*A_3+19^*U_{10}-\\ Tm-3^*(GC_{total})-6^*(GC_{15-19})-30^*X; and \end{array} \quad \begin{array}{ll} \text{Formula VIII} \\ (14.1)^*A_3+(14.9)^*A_6+(17.6)^*A_{13}+(24.7)^*A_{19}+\\ (14.2)^*U_{10}+(10.5)^*C_9+(23.9)^*G_1+(16.3)^*G_2+(-12.3)^*A_{11}+(-19.3)^*U_1+(-12.1)^*U_2+(-11)^*U_3+\\ (-15.2)^*U_{15}+(-11.3)^*U_{16}+(-11.8)^*C_3+(-17.4)^*C_6+(-10.5)^*C_7+(-13.7)^*G_{13}+(-17.4)^*C_6+(-10.5)^*C_7+(-13.7)^*G_{13}+(-17.4)^*C_9+(-17.4$$

wherein

- [0170] A₁=1 if A is the base at position 1 of the sense strand, otherwise its value is 0;
- [0171] $A_2=1$ if A is the base at position 2 of the sense strand, otherwise its value is 0;
- [0172] $A_3=1$ if A is the base at position 3 of the sense strand, otherwise its value is 0;
- [0173] A₄=1 if A is the base at position 4 of the sense strand, otherwise its value is 0;
- [0174] A₅=1 if A is the base at position 5 of the sense strand, otherwise its value is 0;
- [0175] $A_6=1$ if A is the base at position 6 of the sense strand, otherwise its value is 0;
- [0176] A_7 =1 if A is the base at position 7 of the sense strand, otherwise its value is 0;
- [0177] A₁₀=1 if A is the base at position 10 of the sense strand, otherwise its value is 0;
- [0178] $A_{11}=1$ if A is the base at position 11 of the sense strand, otherwise its value is 0;

[0179] $A_{13}=1$ if A is the base at position 13 of the sense strand, otherwise its value is 0;

May 8, 2008

- [0180] A₁₉=1 if A is the base at position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0;
- [0181] $C_3=1$ if C is the base at position 3 of the sense strand, otherwise its value is 0;
- [0182] C_4 =1 if C is the base at position 4 of the sense strand, otherwise its value is 0;
- [0183] C₅=1 if C is the base at position 5 of the sense strand, otherwise its value is 0;
- [0184] $C_6=1$ if C is the base at position 6 of the sense strand, otherwise its value is 0;
- [0185] C₇=1 if C is the base at position 7 of the sense strand, otherwise its value is 0;
- [0186] C₉=1 if C is the base at position 9 of the sense strand, otherwise its value is 0;
- [0187] $C_{17}=1$ if C is the base at position 17 of the sense strand, otherwise its value is 0;
- [0188] $C_{18}=1$ if C is the base at position 18 of the sense strand, otherwise its value is 0;
- [0189] $C_{19}=1$ if C is the base at position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0;
- [0190] G_1 =1 if G is the base at position 1 on the sense strand, otherwise its value is 0;
- [0191] $G_2=1$ if G is the base at position 2 of the sense strand, otherwise its value is 0;
- [0192] $G_8=1$ if G is the base at position 8 on the sense strand, otherwise its value is 0;
- [0193] G₁₀=1 if G is the base at position 10 on the sense strand, otherwise its value is 0;
- [0194] G₁₃=1 if G is the base at position 13 on the sense strand, otherwise its value is 0;
- [0195] $G_{19}=1$ if G is the base at position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0;
- [0196] U₁=1 if U is the base at position 1 on the sense strand, otherwise its value is 0;
- [0197] U₂=1 if U is the base at position 2 on the sense strand, otherwise its value is 0;

- [0198] $U_3=1$ if U is the base at position 3 on the sense strand, otherwise its value is 0;
- [0199] U₄=1 if U is the base at position 4 on the sense strand, otherwise its value is 0;
- [0200] $U_7=1$ if U is the base at position 7 on the sense strand, otherwise its value is 0;
- [0201] U₉=1 if U is the base at position 9 on the sense strand, otherwise its value is 0;
- [0202] U₁₀=1 if U is the base at position 10 on the sense strand, otherwise its value is 0;
- [0203] U₁₅=1 if U is the base at position 15 on the sense strand, otherwise its value is 0;
- [0204] U₁₆=1 if U is the base at position 16 on the sense strand, otherwise its value is 0;
- [0205] $U_{17}=1$ if U is the base at position 17 on the sense strand, otherwise its value is 0;
- [0206] U₁₈=1 if U is the base at position 18 on the sense strand, otherwise its value is 0;
- [0207] GC₁₅₋₁₉=the number of G and C bases within positions 15-19 of the sense strand, or within positions 15-18 if the sense strand is only 18 base pairs in length;
- [0208] GC_{total}=the number of G and C bases in the sense strand;
- [0209] Tm=100 if the siRNA oligo has the internal repeat longer then 4 base pairs, otherwise its value is 0; and
- [0210] X=the number of times that the same nucleotide repeats four or more times in a row.
- [0211] The above formulas VIII and IX, as well as formulas I-VII, provide methods for selecting siRNA in order to increase the efficiency of gene silencing. A subset of variables of any of the formulas may be used, though when fewer variables are used, the optimization hierarchy becomes less reliable.
- [0212] With respect to the variables of the above-referenced formulas, a single letter of A or C or G or U followed by a subscript refers to a binary condition. The binary condition is that either the particular base is present at that particular position (wherein the value is "1") or the base is not present (wherein the value is "0"). Because position 19 is optional, i.e. there might be only 18 base pairs, when there are only 18 base pairs, any base with a subscript of 19 in the formulas above would have a zero value for that parameter. Before or after each variable is a number followed by *, which indicates that the value of the variable is to be multiplied or weighed by that number.
- [0213] The numbers preceding the variables A, or G, or C, or U in Formulas VIII and IX (or after the variables in Formula I-VII) were determined by comparing the difference in the frequency of individual bases at different positions in functional siRNA and total siRNA. Specifically, the frequency in which a given base was observed at a particular position in functional groups was compared with the frequency that that same base was observed in the total, randomly selected siRNA set. If the absolute value of the difference between the functional and total values was found to be greater than 6%, that parameter was included in the equation. Thus for instance, if the frequency of finding a "G" at position

- 13 (G_{13}) is found to be 6% in a given functional group, and the frequency of G_{13} in the total population of siRNAs is 20%, the difference between the two values is 6%-20%=-14%. As the absolute value is greater than six (6), this factor (-14) is included in the equation. Thus in Formula VIII, in cases where the siRNA under study has a G in position 13, the accrued value is (-14)*(1)=-14. In contrast, when a base other than G is found at position 13, the accrued value is (-14)*(0)=0.
- [0214] When developing a means to optimize siRNAs, the inventors observed that a bias toward low internal thermodynamic stability of the duplex at the 5'-antisense (AS) end is characteristic of naturally occurring miRNA precursors. The inventors extended this observation to siRNAs for which functionality had been assessed in tissue culture.
- [0215] With respect to the parameter GC_{15-19} , a value of 0-5 will be ascribed depending on the number of G or C bases at positions 15 to 19. If there are only 18 base pairs, the value is between 0 and 4.
- [0216] $\,$ With respect to the criterion $GC_{\rm total}$ content, a number from 0-30 will be ascribed, which correlates to the total number of G and C nucleotides on the sense strand, excluding overhangs. Without wishing to be bound by any one theory, it is postulated that the significance of the GC content (as well as AU content at positions 15-19, which is a parameter for formulas III-VII) relates to the easement of the unwinding of a double-stranded siRNA duplex. Duplex unwinding is believed to be crucial for siRNA functionality in vivo and overall low internal stability, especially low internal stability of the first unwound base pair is believed to be important to maintain sufficient processivity of RISC complex-induced duplex unwinding. If the duplex has 19 base pairs, those at positions 15-19 on the sense strand will unwind first if the molecule exhibits a sufficiently low internal stability at that position. As persons skilled in the art are aware, RISC is a complex of approximately twelve proteins; Dicer is one, but not the only, helicase within this complex. Accordingly, although the GC parameters are believed to relate to activity with Dicer, they are also important for activity with other RISC proteins.
- [0217] The value of the parameter Tm is 0 when there are no internal repeats longer than (or equal to) four base pairs present in the siRNA duplex; otherwise the value is 1. Thus for example, if the sequence ACGUACGU, or any other four nucleotide (or more) palindrome exists within the structure, the value will be one (1). Alternatively if the structure ACG-GACG, or any other 3 nucleotide (or less) palindrome exists, the value will be zero (0).
- [0218] The variable "X" refers to the number of times that the same nucleotide occurs contiguously in a stretch of four or more units. If there are, for example, four contiguous As in one part of the sequence and elsewhere in the sequence four contiguous Cs, X=2. Further, if there are two separate contiguous stretches of four of the same nucleotides or eight or more of the same nucleotides in a row, then X=2. However, X does not increase for five, six or seven contiguous nucleotides.
- [0219] Again, when applying Formula VIII or Formula IX to a given mRNA, (the "target RNA" or "target molecule"), one may use a computer program to evaluate the criteria for every sequence of 18-30 base pairs or only sequences of a

fixed length, e.g., 19 base pairs. Preferably the computer program is designed such that it provides a report ranking of all of the potential siRNAs between 18 and 30 base pairs, ranked according to which sequences generate the highest value. A higher value refers to a more efficient siRNA for a particular target gene. The computer program that may be used, may be developed in any computer language that is known to be useful for scoring nucleotide sequences, or it may be developed with the assistance of commercially available product such as Microsoft's product net. Additionally, rather than run every sequence through one and/or another formula, one may compare a subset of the sequences, which may be desirable if for example only a subset are available. For instance, it may be desirable to first perform a BLAST (Basic Local Alignment Search Tool) search and to identify sequences that have no homology to other targets. Alternatively, it may be desirable to scan the sequence and to identify regions of moderate GC context, then perform relevant calculations using one of the above-described formulas on these regions. These calculations can be done manually or with the aid of a computer.

[0220] As with Formulas I-VII, either Formula VIII or Formula IX may be used for a given mRNA target sequence. However, it is possible that according to one or the other formula more than one siRNA will have the same value. Accordingly, it is beneficial to have a second formula by which to differentiate sequences. Formula IX was derived in a similar fashion as Formula VIII, yet used a larger data set and thus yields sequences with higher statistical correlations to highly functional duplexes. The sequence that has the highest value ascribed to it may be referred to as a "first optimized duplex." The sequence that has the second highest value ascribed to it may be referred to as a "second optimized duplex." Similarly, the sequences that have the third and fourth highest values ascribed to them may be referred to as a third optimized duplex and a fourth optimized duplex, respectively. When more than one sequence has the same value, each of them may, for example, be referred to as first optimized duplex sequences or co-first optimized duplexes.

[0221] SiRNA sequences identified using Formula VIII are contained within the enclosed compact disks. The data included on the enclosed compact disks is described more fully below. The sequences identified by Formula VIII that are disclosed in the compacts disks may be used in gene silencing applications.

[0222] It should be noted that for Formulas VIII and IX all of the aforementioned criteria are identified as positions on the sense strand when oriented in the 5' to 3' direction as they are identified in connection with Formulas I-VII unless otherwise specified.

[0223] Formulas I-IX, may be used to select or to evaluate one, or more than one, siRNA in order to optimize silencing. Preferably, at least two optimized siRNAs that have been selected according to at least one of these formulas are used to silence a gene, more preferably at least three and most preferably at least four. The siRNAs may be used individually or together in a pool or kit. Further, they may be applied to a cell simultaneously or separately. Preferably, the at least two siR-NAs are applied simultaneously. Pools are particularly beneficial for many research applications. However, for therapeutics, it may be more desirable to employ a single hyperfunctional siRNA as described elsewhere in this application.

[0224] When planning to conduct gene silencing, and it is necessary to choose between two or more siRNAs, one should do so by comparing the relative values when the siRNA are subjected to one of the formulas above. In general a higher scored siRNA should be used.

[0225] Useful applications include, but are not limited to, target validation, gene functional analysis, research and drug discovery, gene therapy and therapeutics. Methods for using siRNA in these applications are well known to persons of skill in the art.

[0226] Because the ability of siRNA to function is dependent on the sequence of the RNA and not the species into which it is introduced, the present invention is applicable across a broad range of species, including but not limited to all mammalian species, such as humans, dogs, horses, cats, cows, mice, hamsters, chimpanzees and gorillas, as well as other species and organisms such as bacteria, viruses, insects, plants and *C. elegans*.

[0227] The present invention is also applicable for use for silencing a broad range of genes, including but not limited to the roughly 45,000 genes of a human genome, and has particular relevance in cases where those genes are associated with diseases such as diabetes, Alzheimer's, cancer, as well as all genes in the genomes of the aforementioned organisms.

[0228] The siRNA selected according to the aforementioned criteria or one of the aforementioned algorithms are also, for example, useful in the simultaneous screening and functional analysis of multiple genes and gene families using high throughput strategies, as well as in direct gene suppression or silencing.

Development of the Algorithms

[0229] To identify siRNA sequence features that promote functionality and to quantify the importance of certain currently accepted conventional factors—such as G/C content and target site accessibility—the inventors synthesized an siRNA panel consisting of 270 siRNAs targeting three genes, Human Cyclophilin, Firefly Luciferase, and Human DBI. In all three cases, siRNAs were directed against specific regions of each gene. For Human Cyclophilin and Firefly Luciferase, ninety siRNAs were directed against a 199 bp segment of each respective mRNA. For DBI, 90 siRNAs were directed against a smaller, 109 base pair region of the mRNA. The sequences to which the siRNAs were directed are provided below.

[0230] It should be noted that in certain sequences, "t" is present. This is because many databases contain information in this manner. However, the t denotes a uracil residue in mRNA and siRNA. Any algorithm will, unless otherwise specified, process at in a sequence as a u.

[0231] Human Cyclophilin: 193-390, M60857

[0232] Firefly Luciferase: 1434-1631. U47298 (pGL3, Promega)

SEQ. ID NO. 30: tgaacttcccgccgccgttgttgtttttggagcacggaaagacgatgacgg aaaaagagatcgtggattacgtcgccagtcaagtaacaaccgcgaaaaag ttgcgcggaggagttgttttgtggacgaagtaccgaaaggtcttaccgg aaaactcgacgcaagaaaaatcagagagatcctcataaaggccaagaagg

[0233] DBI, NM_020548 (202-310) (Every Position)

SEQ. ID NO. 0031: acgggcaaggccaagtgggatgcctggaatgagctgaaagggacttccaa ggaagatgccatgaaagcttacatcaacaaagtagaagagctaaagaaaa aatacggg

A list of the siRNAs appears in Table III (see Examples Section, Example II)

[0234] The set of duplexes was analyzed to identify correlations between siRNA functionality and other biophysical or thermodynamic properties. When the siRNA panel was analyzed in functional and non-functional subgroups, certain nucleotides were much more abundant at certain positions in functional or non-functional groups. More specifically, the frequency of each nucleotide at each position in highly functional siRNA duplexes was compared with that of nonfunctional duplexes in order to assess the preference for or against any given nucleotide at every position. These analyses were used to determine important criteria to be included in the siRNA algorithms (Formulas VIII and IX).

[0235] The data set was also analyzed for distinguishing biophysical properties of siRNAs in the functional group, such as optimal percent of GC content, propensity for internal structures and regional thermodynamic stability. Of the presented criteria, several are involved in duplex recognition, RISC activation/duplex unwinding, and target cleavage catalysis.

[0236] The original data set that was the source of the statistically derived criteria is shown in FIG. 2. Additionally, this figure shows that random selection yields siRNA duplexes with unpredictable and widely varying silencing potencies as measured in tissue culture using HEK293 cells. In the figure, duplexes are plotted such that each x-axis tickmark represents an individual siRNA, with each subsequent siRNA differing in target position by two nucleotides for Human Cyclophilin and Firefly Luciferase, and by one nucleotide for Human DBI. Furthermore, the y-axis denotes the level of target expression remaining after transfection of the duplex into cells and subsequent silencing of the target.

[0237] SiRNA identified and optimized in this document work equally well in a wide range of cell types. FIG. 3A shows the evaluation of thirty siRNAs targeting the DBI gene in three cell lines derived from different tissues. Each DBI siRNA displays very similar functionality in HEK293 (ATCC, CRL-1573, human embryonic kidney), HeLa (ATCC, CCL-2, cervical epithelial adenocarcinoma) and DU145 (HTB-81, prostate) cells as determined by the B-DNA assay. Thus, siRNA functionality is determined by

the primary sequence of the siRNA and not by the intracellular environment. Additionally, it should be noted that although the present invention provides for a determination of the functionality of siRNA for a given target, the same siRNA may silence more than one gene. For example, the complementary sequence of the silencing siRNA may be present in more than one gene. Accordingly, in these circumstances, it may be desirable not to use the siRNA with highest SMART-scoreTM. In such circumstances, it may be desirable to use the siRNA with the next highest SMARTscoreTM.

[0238] To determine the relevance of G/C content in siRNA function, the G/C content of each duplex in the panel was calculated and the functional classes of siRNAs (<F50, \geq F50, \geq F80, \geq F95 where F refers to the percent gene silencing) were sorted accordingly. The majority of the highlyfunctional siRNAs (≥F95) fell within the G/C content range of 36%-52% (FIG. 3B). Twice as many non-functional (<F50) duplexes fell within the high G/C content groups (>57% GC content) compared to the 36%-52% group. The group with extremely low GC content (26% or less) contained a higher proportion of non-functional siRNAs and no highlyfunctional siRNAs. The G/C content range of 30%-52% was therefore selected as Criterion I for siRNA functionality, consistent with the observation that a G/C range 30%-70% promotes efficient RNAi targeting. Application of this criterion alone provided only a marginal increase in the probability of selecting functional siRNAs from the panel: selection of F50 and F95 siRNAs was improved by 3.6% and 2.2%, respectively. The siRNA panel presented here permitted a more systematic analysis and quantification of the importance of this criterion than that used previously.

[0239] A relative measure of local internal stability is the A/U base pair (bp) content; therefore, the frequency of A/U bp was determined for each of the five terminal positions of the duplex (5' sense (S)/5' antisense (AS)) of all siRNAs in the panel. Duplexes were then categorized by the number of A/U bp in positions 1-5 and 15-19 of the sense strand. The thermodynamic flexibility of the duplex 5'-end (positions 1-5; S) did not appear to correlate appreciably with silencing potency, while that of the 3'-end (positions 15-19; S) correlated with efficient silencing. No duplexes lacking A/U bp in positions 15-19 were functional. The presence of one A/U bp in this region conferred some degree of functionality, but the presence of three or more A/Us was preferable and therefore defined as Criterion II. When applied to the test panel, only a marginal increase in the probability of functional siRNA selection was achieved: a 1.8% and 2.3% increase for F50 and F95 duplexes, respectively (Table IV).

[0240] The complementary strands of siRNAs that contain internal repeats or palindromes may form internal fold-back structures. These hairpin-like structures exist in equilibrium with the duplexed form effectively reducing the concentration of functional duplexes. The propensity to form internal hairpins and their relative stability can be estimated by predicted melting temperatures. High Tm reflects a tendency to form hairpin structures. Lower Tm values indicate a lesser tendency to form hairpins. When the functional classes of siRNAs were sorted by $T_{\rm m}$ (FIG. 3C), the following trends were identified: duplexes lacking stable internal repeats were the most potent silencers (no F95 duplex with predicted hairpin structure $T_{\rm m}{>}60^{\circ}$ C.). In contrast, about 60% of the duplexes in the groups having internal hairpins with calculated $T_{\rm m}$ values less than 20° C. were F80. Thus, the stability

of internal repeats is inversely proportional to the silencing effect and defines Criterion III (predicted hairpin structure $T_m \le 20^{\circ}$ C.).

Sequence-Based Determinants of siRNA Functionality

[0241] When the siRNA panel was sorted into functional and non-functional groups, the frequency of a specific nucleotide at each position in a functional siRNA duplex was compared with that of a nonfunctional duplex in order to assess the preference for or against a certain nucleotide. FIG. 4 shows the results of these queries and the subsequent resorting of the data set (from FIG. 2). The data is separated into two sets: those duplexes that meet the criteria, a specific nucleotide in a certain position—grouped on the left (Selected) and those that do not-grouped on the right (Eliminated). The duplexes are further sorted from most functional to least functional with the y-axis of FIGS. 4A-E representing the % expression i.e. the amount of silencing that is elicited by the duplex (Note: each position on the X-axis represents a different duplex). Statistical analysis revealed correlations between silencing and several sequence-related properties of siRNAs. FIGS. 4A-4E and Table IV show quantitative analysis for the following five sequence-related properties of siRNA: (4A) an A at position 19 of the sense strand; (4B) an A at position 3 of the sense strand; (4C) a U at position 10 of the sense strand; (4D) a base other than G at position 13 of the sense strand; and (4E) a base other than C at position 19 of the sense strand.

[0242] When the siRNAs in the panel were evaluated for the presence of an A at position 19 of the sense strand, the percentage of non-functional duplexes decreased from 20% to 11.8%, and the percentage of F95 duplexes increased from 21.7% to 29.4% (Table IV). Thus, the presence of an A in this position defined Criterion IV.

[0243] Another sequence-related property correlated with silencing was the presence of an A in position 3 of the sense strand (FIG. 4B). Of the siRNAs with A3, 34.4% were F95, compared with 21.7% randomly selected siRNAs. The presence of a U base in position 10 of the sense strand exhibited an even greater impact (FIG. 4C). Of the duplexes in this group, 41.7% were F95. These properties became criteria V and VI, respectively.

[0244] Two negative sequence-related criteria that were identified also appear on FIG. 4. The absence of a G at position 13 of the sense strand, conferred a marginal increase in selecting functional duplexes (FIG. 4D). Similarly, lack of a C at position 19 of the sense strand also correlated with functionality (FIG. 4E). Thus, among functional duplexes, position 19 was most likely occupied by A, and rarely occupied by C. These rules were defined as criteria VII and VIII, respectively.

[0245] Application of each criterion individually provided marginal but statistically significant increases in the probability of selecting a potent siRNA. Although the results were informative, the inventors sought to maximize potency and therefore consider multiple criteria or parameters. Optimization is particularly important when developing therapeutics. Interestingly, the probability of selecting a functional siRNA based on each thermodynamic criteria was 2%-4% higher than random, but 4%-8% higher for the sequence-related determinates. Presumably, these sequence-related increases reflect the complexity of the RNAi mechanism and the multitude of protein-RNA interactions that are involved in RNAimediated silencing.

TABLE IV

Criterion	% Fu	nctional	Improvement over Random
I. 30%-52% G/C content	<f50< td=""><td>16.4%</td><td>-3.6%</td></f50<>	16.4%	-3.6%
	≧F50	83.6%	3.6%
	≧F80	60.4%	4.3%
	≧F95	23.9%	2.2%
II. At least 3 A/U bases at positions	<f50< td=""><td>18.2%</td><td>-1.8%</td></f50<>	18.2%	-1.8%
15-19 of the sense strand	≧F50	81.8%	1.8%
	≧F80	59.7%	3.6%
	≧F95	24.0%	2.3%
III. Absence of internal repeats,	<f50< td=""><td>16.7%</td><td>-3.3%</td></f50<>	16.7%	-3.3%
as measured by T _m of	≧F50	83.3%	3.3%
secondary structure ≦20° C.	≧F80	61.1%	5.0%
•	≧F95	24.6%	2.9%
IV. An A base at position 19	<f50< td=""><td>11.8%</td><td>-8.2%</td></f50<>	11.8%	-8.2%
of the sense strand	≧F50	88.2%	8.2%
	≥F80	75.0%	18.9%
	≧F95	29.4%	7.7%
V. An A base at position 3	<f50< td=""><td>17.2%</td><td>-2.8%</td></f50<>	17.2%	-2.8%
of the sense strand	≥F50	82.8%	2.8%
	≥F80	62.5%	6.4%
	≥F95	34.4%	12.7%
VI. A U base at position 10	<f50< td=""><td>13.9%</td><td>-6.1%</td></f50<>	13.9%	-6.1%
of the sense strand	≥F50	86.1%	6.1%
	≥F80	69.4%	13.3%
	≧F95	41.7%	20%
VII. A base other than C at	<f50< td=""><td>18.8%</td><td>-1.2%</td></f50<>	18.8%	-1.2%
position 19 of the sense strand	≥F50	81.2%	1.2%
•	≥F80	59.7%	3.6%
	≧F95	24.2%	2.5%
VIII. A base other than G at	<f50< td=""><td>15.2%</td><td>-4.8%</td></f50<>	15.2%	-4.8%
position 13 of the sense strand	≧F50	84.8%	4.8%
•	≧F80	61.4%	5.3%
	≧F95	26.5%	4.8%

The siRNA Selection Algorithm

[0246] In an effort to improve selection further, all identified criteria, including but not limited to those listed in Table IV were combined into the algorithms embodied in Formula VIII and Formula IX. Each siRNA was then assigned a score (referred to as a SMARTscoreTM) according to the values derived from the formulas. Duplexes that scored higher than 0 or 20, for Formulas VIII and IX, respectively, effectively selected a set of functional siRNAs and excluded all nonfunctional siRNAs. Conversely, all duplexes scoring lower than 0 and 20 according to formulas VIII and IX, respectively, contained some functional siRNAs but included all nonfunctional siRNAs. A graphical representation of this selection is shown in FIG. 5.

[0247] The methods for obtaining the seven criteria embodied in Table IV are illustrative of the results of the process used to develop the information for Formulas VIII and IX. Thus similar techniques were used to establish the other variables and their multipliers. As described above, basic statistical methods were use to determine the relative values for these multipliers.

[0248] To determine the value for "Improvement over Random" the difference in the frequency of a given attribute (e.g. GC content, base preference) at a particular position is determined between individual functional groups (e.g. <F50) and the total siRNA population studied (e.g. 270 siRNA molecules selected randomly). Thus, for instance, in Criterion I (30%-52% GC content) members of the <F50 group were observed to have GC contents between 30-52% in 16.4% of

the cases. In contrast, the total group of 270 siRNAs had GC contents in this range, 20% of the time. Thus for this particular attribute, there is a small negative correlation between 30%-52% GC content and this functional group (i.e. 16.4%-20%= -3.6%). Similarly, for Criterion VI, (a "U" at position 10 of the sense strand), the >F95 group contained a "U" at this position 41.7% of the time. In contrast, the total group of 270 siRNAs had a "U" at this position 21.7% of the time, thus the improvement over random is calculated to be 20% (or 41.7%-21.7%).

Identifying the Average Internal Stability Profile of Strong siRNA

[0249] In order to identify an internal stability profile that is characteristic of strong siRNA, 270 different siRNAs derived from the cyclophilin B, the diazepam binding inhibitor (DBI), and the luciferase gene were individually transfected into HEK293 cells and tested for their ability to induce RNAi of the respective gene. Based on their performance in the in vivo assay, the sequences were then subdivided into three groups, (i) >95% silencing; (ii) 80-95% silencing; and (iii) less than 50% silencing. Sequences exhibiting 51-84% silencing were eliminated from further consideration to reduce the difficulties in identifying relevant thermodynamic patterns.

[0250] Following the division of siRNA into three groups, a statistical analysis was performed on each member of each group to determine the average internal stability profile (AISP) of the siRNA. To accomplish this the Oligo 5.0 Primer Analysis Software and other related statistical packages (e.g. Excel) were exploited to determine the internal stability of pentamers using the nearest neighbor method described by Freier et al., (1986) *Improved free-energy parameters for predictions of RNA duplex stability*, Proc Natl. Acad. Sci. U.S.A. 83(24): 9373-7. Values for each group at each position were then averaged, and the resulting data were graphed on a linear coordinate system with the Y-axis expressing the ΔG (free energy) values in kcal/mole and the X-axis identifying the position of the base relative to the 5' end.

[0251] The results of the analysis identified multiple key regions in siRNA molecules that were critical for successful gene silencing. At the 3'-most end of the sense strand (5' antisense), highly functional siRNA (>95% gene silencing, see FIG. 6A, >F95) have a low internal stability (AISP of position $19 = \sim -7.6$ kcal/mol). In contrast low-efficiency siRNA (i.e. those exhibiting less than 50% silencing, <F50) display a distinctly different profile, having high ΔG values $(\sim -8.4 \text{ kcal/mol})$ for the same position. Moving in a 5 (sense strand) direction, the internal stability of highly efficient siRNA rises (position $12 = \sim -8.3$ kcal/mole) and then drops again (position $7 = \sim -7.7$ kcal/mol) before leveling off at a value of approximately -8.1 kcal/mol for the 5' terminus. SiRNA with poor silencing capabilities show a distinctly different profile. While the AISP value at position 12 is nearly identical with that of strong siRNAs, the values at positions 7 and 8 rise considerably, peaking at a high of ~ -9.0 kcal/mol. In addition, at the 5' end of the molecule the AISP profile of strong and weak siRNA differ dramatically. Unlike the relatively strong values exhibited by siRNA in the >95% silencing group, siRNAs that exhibit poor silencing activity have weak AISP values (-7.6, -7.5, and -7.5 kcal/mol for positions 1, 2 and 3 respectively).

[0252] Overall the profiles of both strong and weak siRNAs form distinct sinusoidal shapes that are roughly 180° out-of-

phase with each other. While these thermodynamic descriptions define the archetypal profile of a strong siRNA, it will likely be the case that neither the ΔG values given for key positions in the profile or the absolute position of the profile along the Y-axis (i.e. the ΔG -axis) are absolutes. Profiles that are shifted upward or downward (i.e. having on an average, higher or lower values at every position) but retain the relative shape and position of the profile along the X-axis can be foreseen as being equally effective as the model profile described here. Moreover, it is likely that siRNA that have strong or even stronger gene-specific silencing effects might have exaggerated ΔG values (either higher or lower) at key positions. Thus, for instance, it is possible that the 5'-most position of the sense strand (position 19) could have ΔG values of 7.4 kcal/mol or lower and still be a strong siRNA if, for instance, a G-C→G-T/U mismatch were substituted at position 19 and altered duplex stability. Similarly, position 12 and position 7 could have values above 8.3 kcal/mol and below 7.7 kcal/mole, respectively, without abating the silencing effectiveness of the molecule. Thus, for instance, at position 12, a stabilizing chemical modification (e.g. a chemical modification of the 2' position of the sugar backbone) could be added that increases the average internal stability at that position. Similarly, at position 7, mismatches similar to those described previously could be introduced that would lower the AG values at that position.

[0253] Lastly, it is important to note that while functional and non-functional siRNA were originally defined as those molecules having specific silencing properties, both broader or more limiting parameters can be used to define these molecules. As used herein, unless otherwise specified, "nonfunctional siRNA" are defined as those siRNA that induce less than 50% (<50%) target silencing, "semi-functional siRNA" induce 50-79% target silencing, "functional siRNA" are molecules that induce 80-95% gene silencing, and "highly-functional siRNA" are molecules that induce great than 95% gene silencing. These definitions are not intended to be rigid and can vary depending upon the design and needs of the application. For instance, it is possible that a researcher attempting to map a gene to a chromosome using a functional assay, may identify an siRNA that reduces gene activity by only 30%. While this level of gene silencing may be "nonfunctional" for e.g. therapeutic needs, it is sufficient for gene mapping purposes and is, under these uses and conditions, "functional." For these reasons, functional siRNA can be defined as those molecules having greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% silencing capabilities at 100 nM transfection conditions. Similarly, depending upon the needs of the study and/or application, non-functional and semi-functional siRNA can be defined as having different parameters. For instance, semi-functional siRNA can be defined as being those molecules that induce 20%, 30%, 40%, 50%, 60%, or 70% silencing at 100 nM transfection conditions. Similarly, non-functional siRNA can be defined as being those molecules that silence gene expression by less than 70%, 60%, 50%, 40%, 30%, or less. Nonetheless, unless otherwise stated, the descriptions stated in the "Definitions" section of this text should be applied.

[0254] Functional attributes can be assigned to each of the key positions in the AISP of strong siRNA. The low 5' (sense strand) AISP values of strong siRNAs may be necessary for determining which end of the molecule enters the RISC complex. In contrast, the high and low AISP values observed in

the central regions of the molecule may be critical for siRNAtarget mRNA interactions and product release, respectively.

[0255] If the AISP values described above accurately define the thermodynamic parameters of strong siRNA, it would be expected that similar patterns would be observed in strong siRNA isolated from nature. Natural siRNAs exist in a harsh, RNase-rich environment and it can be hypothesized that only those siRNA that exhibit heightened affinity for RISC (i.e. siRNA that exhibit an average internal stability profile similar to those observed in strong siRNA) would survive in an intracellular environment. This hypothesis was tested using GFPspecific siRNA isolated from N. benthamiana. Llave et al. (2002) Endogenous and Silencing-Associated Small RNAs in Plants, The Plant Cell 14, 1605-1619, introduced long double-stranded GFP-encoding RNA into plants and subsequently re-isolated GFP-specific siRNA from the tissues. The AISP of fifty-nine of these GFP-siRNA were determined, averaged, and subsequently plotted alongside the AISP profile obtained from the cyclophilin B/DBI/luciferase siRNA having >90% silencing properties (FIG. 6B). Comparison of the two groups show that profiles are nearly identical. This finding validates the information provided by the internal stability profiles and demonstrates that: (1) the profile identified by analysis of the cyclophilin B/DBI/luciferase siRNAs are not gene specific; and (2) AISP values can be used to search for strong siRNAs in a variety of species.

[0256] Both chemical modifications and base-pair mismatches can be incorporated into siRNA to alter the duplex's AISP and functionality. For instance, introduction of mismatches at positions 1 or 2 of the sense strand destabilized the 5' end of the sense strand and increases the functionality of the molecule (see Luc, FIG. 7). Similarly, addition of 2'-O-methyl groups to positions 1 and 2 of the sense strand can also alter the AISP and (as a result) increase both the functionality of the molecule and eliminate off-target effects that results from sense strand homology with the unrelated targets (FIG. 8).

Rationale for Criteria in a Biological Context

[0257] The fate of siRNA in the RNAi pathway may be described in 5 major steps: (1) duplex recognition and pre-RISC complex formation; (2) ATP-dependent duplex unwinding/strand selection and RISC activation; (3) mRNA target identification; (4) mRNA cleavage, and (5) product release (FIG. 1). Given the level of nucleic acid-protein interactions at each step, siRNA functionality is likely influenced by specific biophysical and molecular properties that promote efficient interactions within the context of the multi-component complexes. Indeed, the systematic analysis of the siRNA test set identified multiple factors that correlate well with functionality. When combined into a single algorithm, they proved to be very effective in selecting active siRNAs.

[0258] The factors described here may also be predictive of key functional associations important for each step in RNAi. For example, the potential formation of internal hairpin structures correlated negatively with siRNA functionality. Complementary strands with stable internal repeats are more likely to exist as stable hairpins thus decreasing the effective concentration of the functional duplex form. This suggests that the duplex is the preferred conformation for initial pre-RISC association. Indeed, although single complementary strands can induce gene silencing, the effective concentration required is at least two orders of magnitude higher than that of the duplex form.

[0259] siRNA-pre-RISC complex formation is followed by an ATP-dependent duplex unwinding step and "activation" of the RISC. The siRNA functionality was shown to correlate with overall low internal stability of the duplex and low internal stability of the 3' sense end (or differential internal stability of the 3' sense compare to the 5' sense strand), which may reflect strand selection and entry into the RISC. Overall duplex stability and low internal stability at the 3' end of the sense strand were also correlated with siRNA functionality. Interestingly, siRNAs with very high and very low overall stability profiles correlate strongly with non-functional duplexes. One interpretation is that high internal stability prevents efficient unwinding while very low stability reduces siRNA target affinity and subsequent mRNA cleavage by the RISC.

[0260] Several criteria describe base preferences at specific positions of the sense strand and are even more intriguing when considering their potential mechanistic roles in target recognition and mRNA cleavage. Base preferences for A at position 19 of the sense strand but not C, are particularly interesting because they reflect the same base preferences observed for naturally occurring miRNA precursors. That is, among the reported miRNA precursor sequences 75% contain a U at position 1 which corresponds to an A in position 19 of the sense strand of siRNAs, while G was underrepresented in this same position for miRNA precursors. These observations support the hypothesis that both miRNA precursors and siRNA duplexes are processed by very similar if not identical protein machinery. The functional interpretation of the predominance of a U/A base pair is that it promotes flexibility at the 5' antisense ends of both siRNA duplexes and miRNA precursors and facilitates efficient unwinding and selective strand entrance into an activated RISC.

[0261] Among the criteria associated with base preferences that are likely to influence mRNA cleavage or possibly product release, the preference for U at position 10 of the sense strand exhibited the greatest impact, enhancing the probability of selecting an F80 sequence by 13.3%. Activated RISC preferentially cleaves target mRNA between nucleotides 10 and 11 relative to the 5' end of the complementary targeting strand. Therefore, it may be that U, the preferred base for most endoribonucleases, at this position supports more efficient cleavage. Alternatively, a U/A bp between the targeting siRNA strand and its cognate target mRNA may create an optimal conformation for the RISC-associated "slicing" activity.

Pooling

[0262] According to another embodiment, the present invention provides a pool of at least two siRNAs, preferably in the form of a kit or therapeutic reagent, wherein one strand of each of the siRNAs, the sense strand comprises a sequence that is substantially similar to a sequence within a target mRNA. The opposite strand, the antisense strand, will preferably comprise a sequence that is substantially complementary to that of the target mRNA. More preferably, one strand of each siRNA will comprise a sequence that is identical to a sequence that is contained in the target mRNA. Most preferably, each siRNA will be 19 base pairs in length, and one strand of each of the siRNAs will be 100% complementary to a portion of the target mRNA.

[0263] By increasing the number of siRNAs directed to a particular target using a pool or kit, one is able both to

increase the likelihood that at least one siRNA with satisfactory functionality will be included, as well as to benefit from additive or synergistic effects. Further, when two or more siRNAs directed against a single gene do not have satisfactory levels of functionality alone, if combined, they may satisfactorily promote degradation of the target messenger RNA and successfully inhibit translation. By including multiple siR-NAs in the system, not only is the probability of silencing increased, but the economics of operation are also improved when compared to adding different siRNAs sequentially. This effect is contrary to the conventional wisdom that the concurrent use of multiple siRNA will negatively impact gene silencing (e.g. Holen, T. et al. (2003) "Similar behavior of single strand and double strand siRNAs suggests they act through a common RNAi pathway." NAR 31: 2401-21407).

[0264] In fact, when two siRNAs were pooled together, 54% of the pools of two siRNAs induced more than 95% gene silencing. Thus, a 2.5-fold increase in the percentage of functionality was achieved by randomly combining two siRNAs. Further, over 84% of pools containing two siRNAs induced more than 80% gene silencing.

[0265] More preferably, the kit is comprised of at least three siRNAs, wherein one strand of each siRNA comprises a sequence that is substantially similar to a sequence of the target mRNA and the other strand comprises a sequence that is substantially complementary to the region of the target mRNA. As with the kit that comprises at least two siRNAs, more preferably one strand will comprise a sequence that is identical to a sequence that is contained in the mRNA and another strand that is 100% complementary to a sequence that is contained in the mRNA. During experiments, when three siRNAs were combined together, 60% of the pools induced more than 95% gene silencing and 92% of the pools induced more than 80% gene silencing.

[0266] Further, even more preferably, the kit is comprised of at least four siRNAs, wherein one strand of each siRNA comprises a sequence that is substantially similar to a region of the sequence of the target mRNA, and the other strand comprises a sequence that is substantially complementary to the region of the target mRNA. As with the kit or pool that comprises at least two siRNAs, more preferably one strand of each of the siRNA duplexes will comprise a sequence that is identical to a sequence that is contained in the mRNA, and another strand that is 100% complementary to a sequence that is contained in the mRNA.

[0267] Additionally, kits and pools with at least five, at least six, and at least seven siRNAs may also be useful with the present invention. For example, pools of five siRNA induced 95% gene silencing with 77% probability and 80% silencing with 98.8% probability. Thus, pooling of siRNAs together can result in the creation of a target-specific silencing reagent with almost a 99% probability of being functional. The fact that such high levels of success are achievable using such pools of siRNA, enables one to dispense with costly and time-consuming target-specific validation procedures.

[0268] For this embodiment, as well as the other aforementioned embodiments, each of the siRNAs within a pool will preferably comprise between 18 and 30 base pairs, more preferably between 18 and 25 base pairs, and most preferably 19 base pairs. Within each siRNA, preferably at least 18 contiguous bases of the antisense strand will be 100% complementary to the target mRNA. More preferably, at least

19 contiguous bases of the antisense strand will be 100% complementary to the target mRNA. Additionally, there may be overhangs on either the sense strand or the antisense strand, and these overhangs may be at either the 5' end or the 3' end of either of the strands, for example there may be one or more overhangs of 1-6 bases. When overhangs are present, they are not included in the calculation of the number of base pairs. The two nucleotide 3' overhangs mimic natural siRNAs and are commonly used but are not essential. Preferably, the overhangs should consist of two nucleotides, most often dTdT or UU at the 3' end of the sense and antisense strand that are not complementary to the target sequence. The siRNAs may be produced by any method that is now known or that comes to be known for synthesizing double stranded RNA that one skilled in the art would appreciate would be useful in the present invention. Preferably, the siRNAs will be produced by Dharmacon's proprietary ACE® technology. However, other methods for synthesizing siRNAs are well known to persons skilled in the art and include, but are not limited to, any chemical synthesis of RNA oligonucleotides, ligation of shorter oligonucleotides, in vitro transcription of RNA oligonucleotides, the use of vectors for expression within cells, recombinant Dicer products and PCR products.

[0269] The siRNA duplexes within the aforementioned pools of siRNAs may correspond to overlapping sequences within a particular mRNA, or non-overlapping sequences of the mRNA. However, preferably they correspond to non-overlapping sequences. Further, each siRNA may be selected randomly, or one or more of the siRNA may be selected according to the criteria discussed above for maximizing the effectiveness of siRNA.

[0270] Included in the definition of siRNAs are siRNAs that contain substituted and/or labeled nucleotides that may, for example, be labeled by radioactivity, fluorescence or mass. The most common substitutions are at the 2' position of the ribose sugar, where moieties such as H (hydrogen) F, NH₃, OCH₃ and other O-alkyl, alkenyl, alkynyl, and orthoesters, may be substituted, or in the phosphorous backbone, where sulfur, amines or hydrocarbons may be substituted for the bridging of non-bridging atoms in the phosphodiester bond. Examples of modified siRNAs are explained more fully in commonly assigned U.S. patent application Ser. No. 10/613, 077, filed Jul. 1, 2003, which is incorporated by reference herein.

[0271] Additionally, as noted above, the cell type into which the siRNA is introduced may affect the ability of the siRNA to enter the cell; however, it does not appear to affect the ability of the siRNA to function once it enters the cell. Methods for introducing double-stranded RNA into various cell types are well known to persons skilled in the art.

[0272] As persons skilled in the art are aware, in certain species, the presence of proteins such as RdRP, the RNA-dependent RNA polymerase, may catalytically enhance the activity of the siRNA. For example, RdRP propagates the RNAi effect in *C. elegans* and other non-mammalian organisms. In fact, in organisms that contain these proteins, the siRNA may be inherited. Two other proteins that are well studied and known to be a part of the machinery are members of the Argonaute family and Dicer, as well as their homologues. There is also initial evidence that the RISC complex might be associated with the ribosome so the more efficiently translated mRNAs will be more susceptible to silencing than others.

[0273] Another very important factor in the efficacy of siRNA is mRNA localization. In general, only cytoplasmic mRNAs are considered to be accessible to RNAi to any appreciable degree. However, appropriately designed siRNAs, for example, siRNAs modified with internucleotide linkages, may be able to cause silencing by acting in the nucleus. Examples of these types of modifications are described in commonly assigned U.S. patent application Ser. Nos. 10/431, 027 and 10/613,077, each of which is incorporated by reference herein.

[0274] As described above, even when one selects at least two siRNAs at random, the effectiveness of the two may be greater than one would predict based on the effectiveness of two individual siRNAs. This additive or synergistic effect is particularly noticeable as one increases to at least three siR-NAs, and even more noticeable as one moves to at least four siRNAs. Surprisingly, the pooling of the non-functional and semi-functional siRNAs, particularly more than five siRNAs, can lead to a silencing mixture that is as effective if not more effective as any one particular functional siRNA.

[0275] Within the kit of the present invention, preferably each siRNA will be present in a concentration of between 0.001 and 200 μ M, more preferably between 0.01 and 200 nM, and most preferably between 0.1 and 10 nM.

[0276] In addition to preferably comprising at least four or five siRNAs, the kit of the present invention will also preferably comprise a buffer to keep the siRNA duplex stable. Persons skilled in the art are aware of buffers suitable for keeping siRNA stable. For example, the buffer may be comprised of 100 mM KCl, 30 mM HEPES-pH 7.5, and 1 mM MgCl₂. Alternatively, kits might contain complementary strands that contain any one of a number of chemical modifications (e.g. a 2'-O-ACE) that protect the agents from degradation by nucleases. In this instance, the user may (or may not) remove the modifying protective group (e.g. deprotect) before annealing the two complementary strands together.

[0277] By way of example, the kit may be organized such that pools of siRNA duplexes are provided on an array or microarray of wells or drops for a particular gene set or for unrelated genes. The array may, for example, be in 96 wells, 384 wells or 1284 wells arrayed in a plastic plate or on a glass slide using techniques now known or that come to be known to persons skilled in the art. Within an array, preferably there will be controls such as functional anti-lamin A/C, cyclophilin and two siRNA duplexes that are not specific to the gene of interest.

[0278] In order to ensure stability of the siRNA pools prior to usage, they may be retained in lyophilized form at minus twenty degrees (-20° C.) until they are ready for use. Prior to usage, they should be resuspended; however, even once resuspended, for example, in the aforementioned buffer, they should be kept at minus twenty degrees, (-20° C.) until used. The aforementioned buffer, prior to use, may be stored at approximately 4° C. or room temperature. Effective temperatures at which to conduct transfections are well known to persons skilled in the art and include for example, room temperature.

[0279] The kit may be applied either in vivo or in vitro. Preferably, the siRNA of the pools or kits is applied to a cell through transfection, employing standard transfection protocols. These methods are well known to persons skilled in the

art and include the use of lipid-based carriers, electroporation, cationic carriers, and microinjection. Further, one could apply the present invention by synthesizing equivalent DNA sequences (either as two separate, complementary strands, or as hairpin molecules) instead of siRNA sequences and introducing them into cells through vectors. Once in the cells, the cloned DNA could be transcribed, thereby forcing the cells to generate the siRNA. Examples of vectors suitable for use with the present application include but are not limited to the standard transient expression vectors, adenoviruses, retroviruses, lentivirus-based vectors, as well as other traditional expression vectors. Any vector that has an adequate siRNA expression and procession module may be used. Furthermore, certain chemical modifications to siRNAs, including but not limited to conjugations to other molecules, may be used to facilitate delivery. For certain applications it may be preferable to deliver molecules without transfection by simply formulating in a physiological acceptable solution.

[0280] This embodiment may be used in connection with any of the aforementioned embodiments. Accordingly, the sequences within any pool may be selected by rational design.

Multigene Silencing

[0281] In addition to developing kits that contain multiple siRNA directed against a single gene, another embodiment includes the use of multiple siRNA targeting multiple genes. Multiple genes may be targeted through the use of high- or hyperfunctional siRNA. High- or hyper-functional siRNA that exhibit increased potency, require lower concentrations to induce desired phenotypic (and thus therapeutic) effects. This circumvents RISC saturation. It therefore reasons that if lower concentrations of a single siRNA are needed for knockout or knockdown expression of one gene, then the remaining (uncomplexed) RISC will be free and available to interact with siRNA directed against two, three, four, or more, genes. Thus in this embodiment, the authors describe the use of highly functional or hyper-functional siRNA to knock out three separate genes. More preferably, such reagents could be combined to knockout four distinct genes. Even more preferably, highly functional or hyperfunctional siRNA could be used to knock out five distinct genes. Most preferably, siRNA of this type could be used to knockout or knockdown the expression of six or more genes.

Hyperfunctional siRNA

[0282] The term hyperfunctional siRNA (hf-siRNA) describes a subset of the siRNA population that induces RNAi in cells at low- or sub-nanomolar concentrations for extended periods of time. These traits, heightened potency and extended longevity of the RNAi phenotype, are highly attractive from a therapeutic standpoint. Agents having higher potency require lesser amounts of the molecule to achieve the desired physiological response, thus reducing the probability of side effects due to "off-target" interference. In addition to the potential therapeutic benefits associated with hyperfunctional siRNA, hf-siRNA are also desirable from an economic position. Hyperfunctional siRNA may cost less on a pertreatment basis, thus reducing the overall expenditures to both the manufacturer and the consumer.

[0283] Identification of hyperfunctional siRNA involves multiple steps that are designed to examine an individual siRNA agent's concentration- and/or longevity-profiles. In one non-limiting example, a population of siRNA directed

against a single gene are first analyzed using the previously described algorithm (Formula VIII). Individual siRNA are then introduced into a test cell line and assessed for the ability to degrade the target mRNA. It is important to note that when performing this step it is not necessary to test all of the siRNA. Instead, it is sufficient to test only those siRNA having the highest SMARTscores[™] (i.e. SMARTscore[™]>-10). Subsequently, the gene silencing data is plotted against the SMARTscoresTM (see FIG. 9). SiRNA that (1) induce a high degree of gene silencing (i.e. they induce greater than 80% gene knockdown) and (2) have superior SMARTscoresTM (i.e. a SMARTscoreTM of > -10, suggesting a desirable average internal stability profile) are selected for further investigations designed to better understand the molecule's potency and longevity. In one, non-limiting study dedicated to understanding a molecule's potency, an siRNA is introduced into one (or more) cell types in increasingly diminishing concentrations (e.g. 3.0→0.3 nM). Subsequently, the level of gene silencing induced by each concentration is examined and siRNA that exhibit hyperfunctional potency (i.e. those that induce 80% silencing or greater at e.g. picomolar concentrations) are identified. In a second study, the longevity profiles of siRNA having high (>−10) SMARTscoresTM and greater than 80% silencing are examined. In one non-limiting example of how this is achieved, siRNA are introduced into a test cell line and the levels of RNAi are measured over an extended period of time (e.g. 24-168 hrs). SiRNAs that exhibit strong RNA interference patterns (i.e. >80% interference) for periods of time greater than, e.g., 120 hours are thus identified. Studies similar to those described above can be performed on any and all of the $> 10^6$ siRNA included in this document to further define the most functional molecule for any given gene. Molecules possessing one or both properties (extended longevity and heightened potency) are labeled "hyperfunctional siRNA," and earmarked as candidates for future therapeutic studies.

[0284] While the example(s) given above describe one means by which hyperfunctional siRNA can be isolated, neither the assays themselves nor the selection parameters used are rigid and can vary with each family of siRNA. Families of siRNA include siRNAs directed against a single gene, or directed against a related family of genes.

[0285] The highest quality siRNA achievable for any given gene may vary considerably. Thus, for example, in the case of one gene (gene X), rigorous studies such as those described above may enable the identification of an siRNA that, at picomolar concentrations, induces 99+% silencing for a period of 10 days. Yet identical studies of a second gene (gene Y) may yield an siRNA that at high nanomolar concentrations (e.g. 100 nM) induces only 75% silencing for a period of 2 days. Both molecules represent the very optimum siRNA for their respective gene targets and therefore are designated "hyperfunctional." Yet due to a variety of factors including but not limited to target concentration, siRNA stability, cell type, off-target interference, and others, equivalent levels of potency and longevity are not achievable. Thus, for these reasons, the parameters described in the before mentioned assays, can vary. While the initial screen selected siRNA that had SMARTscores[™] above −10 and a gene silencing capability of greater than 80%, selections that have stronger (or weaker) parameters can be implemented. Similarly, in the subsequent studies designed to identify molecules with high potency and longevity, the desired cutoff criteria (i.e. the lowest concentration that induces a desirable level of interference, or the longest period of time that interference can be observed) can vary. The experimentation subsequent to application of the rational criteria of this application is significantly reduced where one is trying to obtain a suitable hyperfunctional siRNA for, for example, therapeutic use. When, for example, the additional experimentation of the type described herein is applied by one skilled in the art with this disclosure in hand, a hyperfunctional siRNA is readily identified.

[0286] The siRNA may be introduced into a cell by any method that is now known or that comes to be known and that from reading this disclosure, persons skilled in the art would determine would be useful in connection with the present invention in enabling siRNA to cross the cellular membrane. These methods include, but are not limited to, any manner of transfection, such as for example transfection employing DEAE-Dextran, calcium phosphate, cationic lipids/liposomes, micelles, manipulation of pressure, microinjection, electroporation, immunoporation, use of vectors such as viruses, plasmids, cosmids, bacteriophages, cell fusions, and coupling of the polynucleotides to specific conjugates or ligands such as antibodies, antigens, or receptors, passive introduction, adding moieties to the siRNA that facilitate its uptake, and the like.

[0287] Having described the invention with a degree of particularity, examples will now be provided. These examples are not intended to and should not be construed to limit the scope of the claims in any way.

EXAMPLES

General Techniques and Nomenclatures

[0288] siRNA nomenclature. All siRNA duplexes are referred to by sense strand. The first nucleotide of the 5'-end of the sense strand is position 1, which corresponds to position 19 of the antisense strand for a 19-mer. In most cases, to compare results from different experiments, silencing was determined by measuring specific transcript mRNA levels or enzymatic activity associated with specific transcript levels, 24 hours post-transfection, with siRNA concentrations held constant at 100 nM. For all experiments, unless otherwise specified transfection efficiency was ensured to be over 95%. and no detectable cellular toxicity was observed. The following system of nomenclature was used to compare and report siRNA-silencing functionality: "F" followed by the degree of minimal knockdown. For example, F50 signifies at least 50% knockdown, F80 means at least 80%, and so forth. For this study, all sub-F50 siRNAs were considered non-functional.

[0289] Cell culture and transfection. 96-well plates are coated with 50 μ l of 50 mg/ml poly-L-lysine (Sigma) for 1 hr, and then washed 3× with distilled water before being dried for 20 min. HEK293 cells or HEK293Lucs or any other cell type of interest are released from their solid support by trypsinization, diluted to 3.5×10^5 cells/ml, followed by the addition of 100 μ L of cells/well. Plates are then incubated overnight at 37° C., 5% CO₂. Transfection procedures can vary widely depending on the cell type and transfection reagents. In one non-limiting example, a transfection mixture consisting of 2 mL Opti-MEM I (Gibco-BRL), 80 μ l Lipofectamine 2000 (Invitrogen), 15 μ L SUPERNasin at 20 U/ μ l (Ambion), and 1.5 μ l of reporter gene plasmid at 1 μ g/ μ l is prepared in 5-ml polystyrene round bottom tubes. 100 μ l of transfection reagent is then combined with 100 μ l of siRNAs

in polystyrene deep-well titer plates (Beckman) and incubated for 20 to 30 min at room temp. $550\,\mu$ l of Opti-MEM is then added to each well to bring the final siRNA concentration to 100 nM. Plates are then sealed with parafilm and mixed. Media is removed from HEK293 cells and replaced with 95 μ l of transfection mixture. Cells are incubated overnight at 37° C., 5% CO₂.

[0290] Quantification of gene knockdown. A variety of quantification procedures can be used to measure the level of silencing induced by siRNA or siRNA pools. In one non-limiting example: to measure mRNA levels 24 hrs post-transfection, QuantiGene branched-DNA (bDNA) kits (Bayer) (Wang, et al, *Regulation of insulin preRNA splicing by glucose*. Proc Natl Acad Sci 1997, 94:4360) are used according to manufacturer instructions. To measure luciferase activity, media is removed from HEK293 cells 24 hrs post-transfection, and 50 μ l of Steady-GLO reagent (Promega) is added. After 5 min, plates are analyzed on a plate reader.

Example I

Sequences Used to Develop the Algorithm

[0291] Anti-Firefly and anti-Cyclophilin siRNAs panels (FIGS. 5A, B) sorted according to using Formula VIII predicted values. All siRNAs scoring more than 0 (formula VIII) and more then 20 (formula IX) are fully functional. All ninety sequences for each gene (and DBI) appear below in Table III.

			\mathbf{T}_{i}	ABLE	III
Cyclo	1	SEQ.	ID	0032	GUUCCAAAAACAGUGGAUA
Cyclo	2	SEQ.	ID	0033	UCCAAAAACAGUGGAUAAU
Cyclo	3	SEQ.	ID	0034	CAAAAACAGUGGAUAAUUU
Cyclo	4	SEQ.	ID	0035	AAAACAGUGGAUAAUUUUG
Cyclo	5	SEQ.	ID	0036	AACAGUGGAUAAUUUUGUG
Cyclo	6	SEQ.	ID	0037	CAGUGGAUAAUUUUGUGGC
Cyclo	7	SEQ.	ID	0038	GUGGAUAAUUUUGUGGCCU
Cyclo	8	SEQ.	ID	0039	GGAUAAUUUUGUGGCCUUA
Cyclo	9	SEQ.	ID	0040	AUAAUUUUGUGGCCUUAGC
Cyclo	10	SEQ.	ID	0041	AAUUUUGUGGCCUUAGCUA
Cyclo	11	SEQ.	ID	0042	UUUUGUGGCCUUAGCUACA
Cyclo	12	SEQ.	ID	0043	UUGUGGCCUUAGCUACAGG
Cyclo	13	SEQ.	ID	0044	GUGGCCUUAGCUACAGGAG
Cyclo	14	SEQ.	ID	0045	GGCCUUAGCUACAGGAGAG
Cyclo	15	SEQ.	ID	0046	CCUUAGCUACAGGAGAGAA
Cyclo	16	SEQ.	ID	0047	UUAGCUACAGGAGAGAAAG
Cyclo	17	SEQ.	ID	0048	AGCUACAGGAGAGAAAGGA
Cyclo	18	SEQ.	ID	0049	CUACAGGAGAGAAAGGAUU
Cyclo	19	SEQ.	ID	0050	ACAGGAGAGAAAGGAUUUG
Cyclo	20	SEQ.	ID	0051	AGGAGAGAAAGGAUUUGGC

SEQ. ID 0052 GAGAGAAAGGAUUUGGCUA

Cyclo

TABLE III-continued

Cyclo	22	SEQ.	ID	0053	GAGAAAGGAUUUGGCUACA
Cyclo	23	SEQ.	ID	0054	GAAAGGAUUUGGCUACAAA
Cyclo	24	SEQ.	ID	0055	AAGGAUUUGGCUACAAAAA
Cyclo	25	SEQ.	ID	0056	GGAUUUGGCUACAAAAACA
Cyclo	26	SEQ.	ID	0057	AUUUGGCUACAAAAACAGC
Cyclo	27	SEQ.	ID	0058	UUGGCUACAAAAACAGCAA
Cyclo	28	SEQ.	ID	0059	GGCUACAAAAACAGCAAAU
Cyclo	29	SEQ.	ID	0060	CUACAAAAACAGCAAAUUC
Cyclo	30	SEQ.	ID	0061	ACAAAAACAGCAAAUUCCA
Cyclo	31	SEQ.	ID	0062	AAAAACAGCAAAUUCCAUC
Cyclo	32	SEQ.	ID	0063	AAACAGCAAAUUCCAUCGU
Cyclo	33	SEQ.	ID	0064	ACAGCAAAUUCCAUCGUGU
Cyclo	34	SEQ.	ID	0065	AGCAAAUUCCAUCGUGUAA
Cyclo	35	SEQ.	ID	0066	CAAAUUCCAUCGUGUAAUC
Cyclo	36	SEQ.	ID	0067	AAUUCCAUCGUGUAAUCAA
Cyclo	37	SEQ.	ID	0068	UUCCAUCGUGUAAUCAAGG
Cyclo	38	SEQ.	ID	0069	CCAUCGUGUAAUCAAGGAC
Cyclo	39	SEQ.	ID	0070	AUCGUGUAAUCAAGGACUU
Cyclo	40	SEQ.	ID	0071	CGUGUAAUCAAGGACUUCA
Cyclo	41	SEQ.	ID	0072	UGUAAUCAAGGACUUCAUG
Cyclo	42	SEQ.	ID	0073	UAAUCAAGGACUUCAUGAU
Cyclo	43	SEQ.	ID	0074	AUCAAGGACUUCAUGAUCC
Cyclo	44	SEQ.	ID	0075	CAAGGACUUCAUGAUCCAG
Cyclo	45	SEQ.	ID	0076	AGGACUUCAUGAUCCAGGG
Cyclo	46	SEQ.	ID	0077	GACUUCAUGAUCCAGGGCG
Cyclo	47	SEQ.	ID	0078	CUUCAUGAUCCAGGGCGGA
Cyclo	48	SEQ.	ID	0079	UCAUGAUCCAGGGCGGAGA
Cyclo	49	SEQ.	ID	0800	AUGAUCCAGGGCGGAGACU
Cyclo	50	SEQ.	ID	0081	GAUCCAGGGCGGAGACUUC
Cyclo	51	SEQ.	ID	0082	UCCAGGGCGGAGACUUCAC
Cyclo	52	SEQ.	ID	0083	CAGGGCGGAGACUUCACCA
Cyclo	53	SEQ.	ID	0084	GGGCGGAGACUUCACCAGG
Cyclo	54	SEQ.	ID	0085	GCGGAGACUUCACCAGGGG
Cyclo	55	SEQ.	ID	0086	GGAGACUUCACCAGGGGAG
Cyclo	56	SEQ.	ID	0087	AGACUUCACCAGGGGAGAU
Cyclo	57	SEQ.	ID	0088	ACUUCACCAGGGGAGAUGG
Cyclo	58	SEQ.	ID	0089	UUCACCAGGGGAGAUGGCA
Cyclo	59	SEQ.	ID	0090	CACCAGGGGAGAUGGCACA

		TABLE III-0	continued	_	TABLE III-continued				
Cyclo	60	SEQ. ID 0091	CCAGGGGAGAUGGCACAGG	DB	8	SEQ. ID 0128	AGGCCAAGUGGGAUGCCUG		
Cyclo	61	SEQ. ID 0092	AGGGGAGAUGGCACAGGAG	DB	9	SEQ. ID 0129	GGCCAAGUGGGAUGCCUGG		
Cyclo	62	SEQ. ID 0093	GGGAGAUGGCACAGGAGGA	DB	10	SEQ. ID 0130	GCCAAGUGGGAUGCCUGGA		
Cyclo	63	SEQ. ID 0437	GAGAUGGCACAGGAGGAAA	DB	11	SEQ. ID 0131	CCAAGUGGGAUGCCUGGAA		
Cyclo	64	SEQ. ID 0095	GAUGGCACAGGAGGAAAGA	DB	12	SEQ. ID 0132	CAAGUGGGAUGCCUGGAAU		
Cyclo	65	SEQ. ID 0094	UGGCACAGGAGGAAAGAGC	DB	13	SEQ. ID 0133	AAGUGGGAUGCCUGGAAUG		
Cyclo	66	SEQ. ID 0096	GCACAGGAGGAAAGAGCAU	DB	14	SEQ. ID 0134	AGUGGGAUGCCUGGAAUGA		
Cyclo	67	SEQ. ID 0097	ACAGGAGGAAAGAGCAUCU	DB	15	SEQ. ID 0135	GUGGGAUGCCUGGAAUGAG		
Cyclo	68	SEQ. ID 0098	AGGAGGAAAGAGCAUCUAC	DB	16	SEQ. ID 0136	UGGGAUGCCUGGAAUGAGC		
Cyclo	69	SEQ. ID 0099	GAGGAAAGAGCAUCUACGG	DB	17	SEQ. ID 0137	GGGAUGCCUGGAAUGAGCU		
Cyclo	70	SEQ. ID 0100	GGAAAGAGCAUCUACGGUG	DB	18	SEQ. ID 0138	GGAUGCCUGGAAUGAGCUG		
Cyclo	71	SEQ. ID 0101	AAAGAGCAUCUACGGUGAG	DB	19	SEQ. ID 0139	GAUGCCUGGAAUGAGCUGA		
Cyclo	72	SEQ. ID 0102	AGAGCAUCUACGGUGAGCG	DB	20	SEQ. ID 0140	AUGCCUGGAAUGAGCUGAA		
Cyclo	73	SEQ. ID 0103	AGCAUCUACGGUGAGCGCU	DB	21	SEQ. ID 0141	UGCCUGGAAUGAGCUGAAA		
Cyclo	74	SEQ. ID 0104	CAUCUACGGUGAGCGCUUC	DB	22	SEQ. ID 0142	GCCUGGAAUGAGCUGAAAG		
Cyclo	75	SEQ. ID 0105	UCUACGGUGAGCGCUUCCC	DB	23	SEQ. ID 0143	CCUGGAAUGAGCUGAAAGG		
Cyclo	76	SEQ. ID 0106	UACGGUGAGCGCUUCCCCG	DB	24	SEQ. ID 0144	CUGGAAUGAGCUGAAAGGG		
Cyclo	77	SEQ. ID 0107	CGGUGAGCGCUUCCCCGAU	DB	25	SEQ. ID 0145	UGGAAUGAGCUGAAAGGGA		
Cyclo	78	SEQ. ID 0108	GUGAGCGCUUCCCCGAUGA	DB	26	SEQ. ID 0146	GGAAUGAGCUGAAAGGGAC		
Cyclo	79	SEQ. ID 0109	GAGCGCUUCCCCGAUGAGA	DB	27	SEQ. ID 0147	GAAUGAGCUGAAAGGGACU		
Cyclo	80	SEQ. ID 0110	GCGCUUCCCCGAUGAGAAC	DB	28	SEQ. ID 0148	AAUGAGCUGAAAGGGACUU		
Cyclo	81	SEQ. ID 0111	GCUUCCCCGAUGAGAACUU	DB	29	SEQ. ID 0149	AUGAGCUGAAAGGGACUUC		
Cyclo	82	SEQ. ID 0112	UUCCCCGAUGAGAACUUCA	DB	30	SEQ. ID 0150	UGAGCUGAAAGGGACUUCC		
Cyclo	83	SEQ. ID 0113	CCCCGAUGAGAACUUCAAA	DB	31	SEQ. ID 0151	GAGCUGAAAGGGACUUCCA		
Cyclo	84	SEQ. ID 0114	CCGAUGAGAACUUCAAACU	DB	32	SEQ. ID 0152	AGCUGAAAGGGACUUCCAA		
Cyclo	85	SEQ. ID 0115	GAUGAGAACUUCAAACUGA	DB	33	SEQ. ID 0153	GCUGAAAGGGACUUCCAAG		
Cyclo	86	SEQ. ID 0116	UGAGAACUUCAAACUGAAG	DB	34	SEQ. ID 0154	CUGAAAGGGACUUCCAAGG		
Cyclo	87	SEQ. ID 0117	AGAACUUCAAACUGAAGCA	DB	35	SEQ. ID 0155	UGAAAGGGACUUCCAAGGA		
Cyclo	88	SEQ. ID 0118	AACUUCAAACUGAAGCACU	DB	36	SEQ. ID 0156	GAAAGGGACUUCCAAGGAA		
Cyclo	89	SEQ. ID 0119	CUUCAAACUGAAGCACUAC	DB	37	SEQ. ID 0157	AAAGGGACUUCCAAGGAAG		
Cyclo	90	SEQ. ID 0120	UCAAACUGAAGCACUACGG	DB	38	SEQ. ID 0158	AAGGGACUUCCAAGGAAGA		
DB	1	SEQ. ID 0121	ACGGGCAAGGCCAAGUGGG	DB	39	SEQ. ID 0159	AGGGACUUCCAAGGAAGAU		
DB	2	SEQ. ID 0122	CGGGCAAGGCCAAGUGGGA	DB	40	SEQ. ID 0160	GGGACUUCCAAGGAAGAUG		
DB	3	SEQ. ID 0123	GGGCAAGGCCAAGUGGGAU	DB	41	SEQ. ID 0161	GGACUUCCAAGGAAGAUGC		
DB	4	SEQ. ID 0124	GGCAAGGCCAAGUGGGAUG	DB	42	SEQ. ID 0162	GACUUCCAAGGAAGAUGCC		
DB	5	SEQ. ID 0125	GCAAGGCCAAGUGGGAUGC	DB	43	SEQ. ID 0163	ACUUCCAAGGAAGAUGCCA		
DB	6	SEQ. ID 0126	CAAGGCCAAGUGGGAUGCC	DB	44	SEQ. ID 0164	CUUCCAAGGAAGAUGCCAU		
DB	7	SEQ. ID 0127	AAGGCCAAGUGGGAUGCCU	DB	45	SEQ. ID 0165	UUCCAAGGAAGAUGCCAUG		

		TABLE III-0	continued		TABLE III-continued				
DB	46	SEQ. ID 0166	UCCAAGGAAGAUGCCAUGA	DB	84	SEQ. ID 0204	AGAAGAGCUAAAGAAAAAA		
DB	47	SEQ. ID 0167	CCAAGGAAGAUGCCAUGAA	DB	85	SEQ. ID 0205	GAAGAGCUAAAGAAAAAU		
DB	48	SEQ. ID 0168	CAAGGAAGAUGCCAUGAAA	DB	86	SEQ. ID 0206	AAGAGCUAAAGAAAAAUA		
DB	49	SEQ. ID 0169	AAGGAAGAUGCCAUGAAAG	DB	87	SEQ. ID 0207	AGAGCUAAAGAAAAAAUAC		
DB	50	SEQ. ID 0170	AGGAAGAUGCCAUGAAAGC	DB	88	SEQ. ID 0208	GAGCUAAAGAAAAAUACG		
DB	51	SEQ. ID 0171	GGAAGAUGCCAUGAAAGCU	DB	89	SEQ. ID 0209	AGCUAAAGAAAAAUACGG		
DB	52	SEQ. ID 0172	GAAGAUGCCAUGAAAGCUU	DB	90	SEQ. ID 0210	GCUAAAGAAAAAUACGGG		
DB	53	SEQ. ID 0173	AAGAUGCCAUGAAAGCUUA	Luc	1	SEQ. ID 0211	AUCCUCAUAAAGGCCAAGA		
DB	54	SEQ. ID 0174	AGAUGCCAUGAAAGCUUAC	Luc	2	SEQ. ID 0212	AGAUCCUCAUAAAGGCCAA		
DB	55	SEQ. ID 0175	GAUGCCAUGAAAGCUUACA	Luc	3	SEQ. ID 0213	AGAGAUCCUCAUAAAGGCC		
DB	56	SEQ. ID 0176	AUGCCAUGAAAGCUUACAU	Luc	4	SEQ. ID 0214	AGAGAGAUCCUCAUAAAGG		
DB	57	SEQ. ID 0177	UGCCAUGAAAGCUUACAUC	Luc	5	SEQ. ID 0215	UCAGAGAGAUCCUCAUAAA		
DB	58	SEQ. ID 0178	GCCAUGAAAGCUUACAUCA	Luc	6	SEQ. ID 0216	AAUCAGAGAGAUCCUCAUA		
DB	59	SEQ. ID 0179	CCAUGAAAGCUUACAUCAA	Luc	7	SEQ. ID 0217	AAAAUCAGAGAGAUCCUCA		
DB	60	SEQ. ID 0180	CAUGAAAGCUUACAUCAAC	Luc	8	SEQ. ID 0218	GAAAAAUCAGAGAGAUCCU		
DB	61	SEQ. ID 0181	AUGAAAGCUUACAUCAACA	Luc	9	SEQ. ID 0219	AAGAAAAAUCAGAGAGAUC		
DB	62	SEQ. ID 0182	UGAAAGCUUACAUCAACAA	Luc	10	SEQ. ID 0220	GCAAGAAAAUCAGAGAGA		
DB	63	SEQ. ID 0183	GAAAGCUUACAUCAACAAA	Luc	11	SEQ. ID 0221	ACGCAAGAAAAAUCAGAGA		
DB	64	SEQ. ID 0184	AAAGCUUACAUCAACAAAG	Luc	12	SEQ. ID 0222	CGACGCAAGAAAAUCAGA		
DB	65	SEQ. ID 0185	AAGCUUACAUCAACAAAGU	Luc	13	SEQ. ID 0223	CUCGACGCAAGAAAAAUCA		
DB	66	SEQ. ID 0186	AGCUUACAUCAACAAAGUA	Luc	14	SEQ. ID 0224	AACUCGACGCAAGAAAAAU		
DB	67	SEQ. ID 0187	GCUUACAUCAACAAAGUAG	Luc	15	SEQ. ID 0225	AAAACUCGACGCAAGAAAA		
DB	68	SEQ. ID 0188	CUUACAUCAACAAAGUAGA	Luc	16	SEQ. ID 0226	GGAAAACUCGACGCAAGAA		
DB	69	SEQ. ID 0189	UUACAUCAACAAAGUAGAA	Luc	17	SEQ. ID 0227	CCGGAAAACUCGACGCAAG		
DB	70	SEQ. ID 0190	UACAUCAACAAAGUAGAAG	Luc	18	SEQ. ID 0228	UACCGGAAAACUCGACGCA		
DB	71	SEQ. ID 0191	ACAUCAACAAAGUAGAAGA	Luc	19	SEQ. ID 0229	CUUACCGGAAAACUCGACG		
DB	72	SEQ. ID 0192	CAUCAACAAAGUAGAAGAG	Luc	20	SEQ. ID 0230	GUCUUACCGGAAAACUCGA		
DB	73	SEQ. ID 0193	AUCAACAAAGUAGAAGAGC	Luc	21	SEQ. ID 0231	AGGUCUUACCGGAAAACUC		
DB	74	SEQ. ID 0194	UCAACAAAGUAGAAGAGCU	Luc	22	SEQ. ID 0232	AAAGGUCUUACCGGAAAAC		
DB	75	SEQ. ID 0195	CAACAAAGUAGAAGAGCUA	Luc	23	SEQ. ID 0233	CGAAAGGUCUUACCGGAAA		
DB	76	SEQ. ID 0196	AACAAAGUAGAAGAGCUAA	Luc	24	SEQ. ID 0234	ACCGAAAGGUCUUACCGGA		
DB	77	SEQ. ID 0197	ACAAAGUAGAAGAGCUAAA	Luc	25	SEQ. ID 0235	GUACCGAAAGGUCUUACCG		
DB	78	SEQ. ID 0198	CAAAGUAGAAGAGCUAAAG	Luc	26	SEQ. ID 0236	AAGUACCGAAAGGUCUUAC		
DB	79	SEQ. ID 0199	AAAGUAGAAGAGCUAAAGA	Luc	27	SEQ. ID 0237	CGAAGUACCGAAAGGUCUU		
DB	80	SEQ. ID 0200	AAGUAGAAGAGCUAAAGAA	Luc	28	SEQ. ID 0238	GACGAAGUACCGAAAGGUC		
DB	81	SEQ. ID 0201	AGUAGAAGAGCUAAAGAAA	Luc	29	SEQ. ID 0239	UGGACGAAGUACCGAAAGG		
DB	82	SEQ. ID 0202	GUAGAAGAGCUAAAGAAAA	Luc	30	SEQ. ID 0240	UGUGGACGAAGUACCGAAA		
DB	83	SEQ. ID 0203	UAGAAGAGCUAAAGAAAAA	Luc	31	SEQ. ID 0241	UUUGUGGACGAAGUACCGA		

_		TABLE	III-c	continued
Luc	32	SEQ. ID	0242	UGUUUGUGGACGAAGUAGC
Luc	33	SEQ. ID	0243	UGUGUUUGUGGACGAAGUA
Luc	34	SEQ. ID	0244	GUUGUGUUUGUGGACGAAG
Luc	35	SEQ. ID	0245	GAGUUGUGUUUGUGGACGA
Luc	36	SEQ. ID	0246	AGGAGUUGUGUUUGUGGAC
Luc	37	SEQ. ID	0247	GGAGGAGUUGUGUUUGUGG
Luc	38	SEQ. ID	0248	GCGGAGGAGUUGUGUUUGU
Luc	39	SEQ. ID	0249	GCGCGGAGGAGUUGUGUUU
Luc	40	SEQ. ID	0250	UUGCGCGGAGGAGUUGUGU
Luc	41	SEQ. ID	0251	AGUUGCGCGGAGGAGUUGU
Luc	42	SEQ. ID	0252	AAAGUUGCGCGGAGGAGUU
Luc	43	SEQ. ID	0253	AAAAAGUUGCGCGGAGGAG
Luc	44	SEQ. ID	0254	CGAAAAAGUUGCGCGGAGG
Luc	45	SEQ. ID	0255	CGCGAAAAAGUUGCGCGGA
Luc	46	SEQ. ID	0256	ACCGCGAAAAAGUUGCGCG
Luc	47	SEQ. ID	0257	CAACCGCGAAAAAGUUGCG
Luc	48	SEQ. ID	0258	AACAACCGCGAAAAAGUUG
Luc	49	SEQ. ID	0259	GUAACAACCGCGAAAAAGU
Luc	50	SEQ. ID	0260	AAGUAACAACCGCGAAAAA
Luc	51	SEQ. ID	0261	UCAAGUAACAACCGCGAAA
Luc	52	SEQ. ID	0262	AGUCAAGUAACAACCGCGA
Luc	53	SEQ. ID	0263	CCAGUCAAGUAACAACCGC
Luc	54	SEQ. ID	0264	CGCCAGUCAAGUAACAACC
Luc	55	SEQ. ID	0265	GUCGCCAGUCAAGUAACAA
Luc	56	SEQ. ID	0266	ACGUCGCCAGUCAAGUAAC
Luc	57	SEQ. ID	0267	UUACGUCGCCAGUCAAGUA
Luc	58	SEQ. ID	0268	GAUUACGUCGCCAGUCAAG
Luc	59	SEQ. ID	0269	UGGAUUACGUCGCCAGUCA
Luc	60	SEQ. ID	0270	CGUGGAUUACGUCGCCAGU
Luc	61	SEQ. ID	0271	AUCGUGGAUUACGUCGCCA
Luc	62	SEQ. ID	0272	AGAUCGUGGAUUACGUCGC
Luc	63	SEQ. ID	0273	AGAGAUCGUGGAUUACGUC
Luc	64	SEQ. ID	0274	AAAGAGAUCGUGGAUUACG
Luc	65	SEQ. ID	0275	AAAAAGAGAUCGUGGAUUA
Luc	66	SEQ. ID	0276	GGAAAAAGAGAUCGUGGAU
Luc	67	SEQ. ID	0277	ACGGAAAAAGAGAUCGUGG
Luc	68	SEQ. ID	0278	UGACGGAAAAAGAGAUCGU
-		ana m		

SEQ. ID 0279 GAUGACGGAAAAAGAGAUC

Luc

TABLE III-continued

Luc 70 SEQ. ID 0280 ACGAUGACGGAAAAAGAA Luc 71 SEQ. ID 0281 AGACGAUGACGGAAAAAAAA Luc 72 SEQ. ID 0282 AAAGACGAUGACGGAAAAAA Luc 73 SEQ. ID 0283 GGAAAGACGAUGACGGAAA Luc 74 SEQ. ID 0284 ACGGAAAGACGAUGACGGAAA Luc 75 SEQ. ID 0285 GCACGGAAAGACGAUGACG Luc 76 SEQ. ID 0287 UGGAGCACGGAAAGACGAUGA Luc 77 SEQ. ID 0287 UGGAGCACGGAAAGACGAUGA Luc 78 SEQ. ID 0288 UUUUGGAGCACGGAAAGACG Luc 79 SEQ. ID 0289 GUUUUUGGAGCACGGAAAA Luc 80 SEQ. ID 0290 UUGUUUUUGGAGCACGGAAA Luc 81 SEQ. ID 0291 UGUUGUUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACG Luc 83 SEQ. ID 0293 CCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAGCA Luc 85 SEQ. ID 0295 GCCGCCGCUGUUGUUGUUUUGGAGCA						
Luc 72 SEQ. ID 0282 AAAGACGAUGACGGAAAAA Luc 73 SEQ. ID 0283 GGAAAGACGAUGACGGAAA Luc 74 SEQ. ID 0284 ACGGAAAGACGAUGACGGA Luc 75 SEQ. ID 0285 GCACGGAAAGACGAUGACGG Luc 76 SEQ. ID 0286 GAGCACGGAAAGACGAUGACG Luc 77 SEQ. ID 0287 UGGAGCACGGAAAGACGAUGA Luc 78 SEQ. ID 0288 UUUGGAGCACGGAAAGACGAU Luc 79 SEQ. ID 0289 GUUUUGGAGCACGGAAAGA Luc 80 SEQ. ID 0290 UUGUUUUGGAGCACGGAAAG Luc 81 SEQ. ID 0291 UGUUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUUUGGAGCACGGA Luc 83 SEQ. ID 0292 GUUGUUUUUGGAGCACG Luc 84 SEQ. ID 0294 CGCCGUUGUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUUUUUGGAG Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGUU	Luc	70	SEQ.	ID	0280	ACGAUGACGGAAAAAGAGA
Luc 73 SEQ. ID 0283 GGAAAGACGAUGACGGAAA Luc 74 SEQ. ID 0284 ACGGAAAGACGAUGACGGA Luc 75 SEQ. ID 0285 GCACGGAAAGACGAUGACG Luc 76 SEQ. ID 0286 GAGCACGGAAAGACGAUGA Luc 77 SEQ. ID 0287 UGGAGCACGGAAAGACGAU Luc 78 SEQ. ID 0288 UUUGGAGCACGGAAAGACGA Luc 79 SEQ. ID 0289 GUUUUGGAGCACGGAAAGA Luc 80 SEQ. ID 0290 UUGUUUUUGGAGCACGGAAA Luc 81 SEQ. ID 0291 UGUUGUUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACGA Luc 83 SEQ. ID 0293 CCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUGGAG Luc 86 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGGAG Luc 86 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU	Luc	71	SEQ.	ID	0281	AGACGAUGACGGAAAAAGA
Luc 74 SEQ. ID 0284 ACGGAAAGACGAUGACGGA Luc 75 SEQ. ID 0285 GCACGGAAAGACGAUGACG Luc 76 SEQ. ID 0286 GAGCACGGAAAGACGAUGA Luc 77 SEQ. ID 0287 UGGAGCACGGAAAGACGAU Luc 78 SEQ. ID 0288 UUUUGGAGCACGGAAAGACG Luc 79 SEQ. ID 0289 GUUUUUGGAGCACGGAAAGA Luc 80 SEQ. ID 0290 UUGUUUUUGGAGCACGGAAAA Luc 81 SEQ. ID 0291 UGUUGUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACG Luc 83 SEQ. ID 0292 GUUGUUGUUUUUGGAGCAC Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAGCA Luc 85 SEQ. ID 0294 CGCCGUUGUUGUUUUUUGGAGCA Luc 86 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUU Luc 86 SEQ. ID 0296 CCGCCGCCGCUUGUUGUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGCUUGUUGUU Luc 88 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGU <td>Luc</td> <td>72</td> <td>SEQ.</td> <td>ID</td> <td>0282</td> <td>AAAGACGAUGACGGAAAAA</td>	Luc	72	SEQ.	ID	0282	AAAGACGAUGACGGAAAAA
Luc 75 SEQ. ID 0285 GCACGGAAAGACGAUGACG Luc 76 SEQ. ID 0286 GAGCACGGAAAGACGAUGA Luc 77 SEQ. ID 0287 UGGAGCACGGAAAGACGAU Luc 78 SEQ. ID 0288 UUUGGAGCACGGAAAGACG Luc 79 SEQ. ID 0289 GUUUUGGAGCACGGAAAGA Luc 80 SEQ. ID 0290 UUGUUUUGGAGCACGGAAAGA Luc 81 SEQ. ID 0291 UGUUGUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACGGA Luc 83 SEQ. ID 0292 GUUGUUGUUUUUGGAGCAC Luc 84 SEQ. ID 0293 CCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGGAG Luc 86 SEQ. ID 0295 CCGCCGCCGUUGUUGUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUG	Luc	73	SEQ.	ID	0283	GGAAAGACGAUGACGGAAA
Luc 76 SEQ. ID 0286 GAGCACGGAAAGACGAUGA Luc 77 SEQ. ID 0287 UGGAGCACGGAAAGACGAU Luc 78 SEQ. ID 0288 UUUUGGAGCACGGAAAGACG Luc 79 SEQ. ID 0289 GUUUUGGAGCACGGAAAGA Luc 80 SEQ. ID 0290 UUGUUUUGGAGCACGGAAA Luc 81 SEQ. ID 0291 UGUUGUUUUGGAGCACGGAAA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACGA Luc 83 SEQ. ID 0292 GUUGUUGUUUUUGGAGCAC Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUU Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUGUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGCUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUGU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGU	Luc	74	SEQ.	ID	0284	ACGGAAAGACGAUGACGGA
Luc 77 SEQ. ID 0288 UGGAGCACGGAAAGACGAU Luc 78 SEQ. ID 0288 UUUGGAGCACGGAAAGACG Luc 79 SEQ. ID 0289 GUUUUGGAGCACGGAAAGA Luc 80 SEQ. ID 0290 UUGUUUUGGAGCACGGAAA Luc 81 SEQ. ID 0291 UGUUGUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACG Luc 83 SEQ. ID 0293 CCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGGAG Luc 86 SEQ. ID 0295 GCCGCCGCUUGUUGUUUUUU Luc 87 SEQ. ID 0296 CCGCCGCCGCUUGUUGUUU Luc 88 SEQ. ID 0297 UCCCGCCGCCGCUUGUUGUU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUG	Luc	75	SEQ.	ID	0285	GCACGGAAAGACGAUGACG
Luc 78 SEQ. ID 0288 UUUGGAGCACGGAAAGACG Luc 79 SEQ. ID 0289 GUUUUGGAGCACGGAAAGA Luc 80 SEQ. ID 0290 UUGUUUUGGAGCACGGAAA Luc 81 SEQ. ID 0291 UGUUGUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACG Luc 83 SEQ. ID 0293 CCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGGAG Luc 86 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUU Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUGUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGCUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGCUUGUUGU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGU	Luc	76	SEQ.	ID	0286	GAGCACGGAAAGACGAUGA
Luc 79 SEQ. ID 0290 GUUUUGGAGCACGGAAAGA Luc 80 SEQ. ID 0290 UUGUUUUGGAGCACGGAAA Luc 81 SEQ. ID 0291 UGUUGUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACG Luc 83 SEQ. ID 0293 CCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGG Luc 86 SEQ. ID 0295 CCGCCGCCGUUGUUGUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0297 UCCCGCCGCCGCUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUGU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGU	Luc	77	SEQ.	ID	0287	UGGAGCACGGAAAGACGAU
Luc 80 SEQ. ID 0290 UUGUUUUGGAGCACGGAAA Luc 81 SEQ. ID 0291 UGUUGUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACG Luc 83 SEQ. ID 0293 CCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGG Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUGUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUGUU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGU	Luc	78	SEQ.	ID	0288	UUUGGAGCACGGAAAGACG
Luc 81 SEQ. ID 0291 UGUUGUUUUGGAGCACGGA Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACG Luc 83 SEQ. ID 0293 CCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGG Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUGUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUGU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGU	Luc	79	SEQ.	ID	0289	GUUUUGGAGCACGGAAAGA
Luc 82 SEQ. ID 0292 GUUGUUGUUUUGGAGCACG Luc 83 SEQ. ID 0293 CCGUUGUUGUUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGG Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUGUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUGU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGU	Luc	80	SEQ.	ID	0290	UUGUUUUGGAGCACGGAAA
Luc 83 SEQ. ID 0293 CCGUUGUUGUUUUGGAGCA Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUUGG Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUGUUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUGU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUU	Luc	81	SEQ.	ID	0291	UGUUGUUUUGGAGCACGGA
Luc 84 SEQ. ID 0294 CGCCGUUGUUGUUUUUGGAG Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUUUGG Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUGUUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGCUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUGU Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGUUGU	Luc	82	SEQ.	ID	0292	GUUGUUGUUUUGGAGCACG
Luc 85 SEQ. ID 0295 GCCGCCGUUGUUGUUUUGG Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUGUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUG Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGU	Luc	83	SEQ.	ID	0293	CCGUUGUUGUUUUGGAGCA
Luc 86 SEQ. ID 0296 CCGCCGCCGUUGUUGUUUUU Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUG Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGU	Luc	84	SEQ.	ID	0294	CGCCGUUGUUGUUUUGGAG
Luc 87 SEQ. ID 0297 UCCCGCCGCCGUUGUUGUU Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUG Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGU	Luc	85	SEQ.	ID	0295	GCCGCCGUUGUUGUUUUGG
Luc 88 SEQ. ID 0298 CUUCCCGCCGCCGUUGUUG Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGU	Luc	86	SEQ.	ID	0296	ccgccgccguuguuguuuu
Luc 89 SEQ. ID 0299 AACUUCCCGCCGCCGUUGU	Luc	87	SEQ.	ID	0297	nccceccecennennenn
~	Luc	88	SEQ.	ID	0298	CUUCCCGCCGCCGUUGUUG
Luc 90 SEQ. ID 0300 UGAACUUCCCGCCGCCGUU	Luc	89	SEQ.	ID	0299	AACUUCCCGCCGCCGUUGU
	Luc	90	SEQ.	ID	0300	UGAACUUCCCGCCGCCGUU

Example II

Validation of the Algorithm Using DBI, Luciferase, PLK, EGFR, and SEAP

[0292] The algorithm (Formula VIII) identified siRNAs for five genes, human DBI, firefly luciferase (fLuc), renilla luciferase (rLuc), human PLK, and human secreted alkaline phosphatase (SEAP). Four individual siRNAs were selected on the basis of their SMARTscoresTM derived by analysis of their sequence using Formula VIII (all of the siRNAs would be selected with Formula IX as well) and analyzed for their ability to silence their targets' expression. In addition to the scoring, a BLAST search was conducted for each siRNA. To minimize the potential for off-target silencing effects, only those target sequences with more than three mismatches against un-related sequences were selected. Semizarov, et al, Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6347. These duplexes were analyzed individually and in pools of 4 and compared with several siRNAs that were randomly selected. The functionality was measured a percentage of targeted gene knockdown as compared to controls. All siRNAs were transfected as described by the methods above at 100 nM concentration into HEK293 using Lipofectamine 2000. The level of the targeted gene expression was evaluated by B-DNA as described above and normalized to

the non-specific control. FIG. 10 shows that the siRNAs selected by the algorithm disclosed herein were significantly more potent than randomly selected siRNAs. The algorithm increased the chances of identifying an F50 siRNA from 48% to 91%, and an F80 siRNA from 13% to 57%. In addition, pools of SMART siRNA silence the selected target better than randomly selected pools (see FIG. 10F).

Example III

Validation of the Algorithm Using Genes Involved in Clathrin-Dependent Endocytosis

[0293] Components of clathrin-mediated endocytosis pathway are key to modulating intracellular signaling and play important roles in disease. Chromosomal rearrangements that result in fusion transcripts between the Mixed-Lineage Leukemia gene (MLL) and CALM (Clathrin assembly lymphoid myeloid leukemia gene) are believed to play a role in leukemogenesis. Similarly, disruptions in Rab7 and Rab9, as well as HIP1 (Huntingtin-interacting protein), genes that are believed to be involved in endocytosis, are potentially responsible for ailments resulting in lipid storage, and neuronal diseases, respectively. For these reasons, siRNA directed against clathrin and other genes involved in the clathrin-mediated endocytotic pathway are potentially important research and therapeutic tools.

[0294] siRNAs directed against genes involved in the clathrin-mediated endocytosis pathways were selected using Formula VIII. The targeted genes were clathrin heavy chain (CHC, accession # NM_004859), clathrin light chain A (CLCa, NM_001833), clathrin light chain B (CLCb, NM_001834), CALM (U45976), β2 subunit of AP-2 (β2, NM_001282), Eps15 (NM_001981), Eps15R(NM_021235), dynamin II (DYNII, NM_004945), Rab5a (BC001267), Rab5b (NM_02868), Rab5c (AF141304), and EEA.1 (XM_018197).

[0295] For each gene, four siRNAs duplexes with the highest scores were selected and a BLAST search was conducted for each of them using the Human EST database. In order to minimize the potential for off-target silencing effects, only those sequences with more than three mismatches against un-related sequences were used. All duplexes were synthesized at Dharmacon, Inc. as 21-mers with 3'-UU overhangs using a modified method of 2'-ACE chemistry Scaringe, Advanced 5'-silyl-2'-orthoester approach to RNA oligonucleotide synthesis, Methods Enzymol 2000, 317:3 and the antisense strand was chemically phosphorylated to insure maximized activity.

[0296] HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, antibiotics and glutamine. siRNA duplexes were resuspended in $1\times$ siRNA Universal buffer (Dharmacon, Inc.) to 20 μ M prior to transfection. HeLa cells in 12-well plates were transfected twice with 4 μ l of 20 μ M siRNA duplex in 3 μ l Lipofectamine 2000 reagent (Invitrogen, Carlsbad, Calif., USA) at 24-hour intervals. For the transfections in which 2 or 3 siRNA duplexes were included, the amount of each duplex was decreased, so that the total amount was the same as in transfections with single siRNAs. Cells were plated into normal culture medium 12 hours prior to experiments, and protein levels were measured 2 or 4 days after the first transfection.

[0297] Equal amounts of lysates were resolved by electrophoresis, blotted, and stained with the antibody specific to targeted protein, as well as antibodies specific to unrelated proteins, PP1 phosphatase and Tsg101 (not shown). The cells were lysed in Triton X-100/glycerol solubilization buffer as described previously. Tebar, Bohlander, & Sorkin, Clathrin Assembly Lymphoid Myeloid Leukemia (CALM) Protein. Localization in Endocytic-coated Pits, Interactions with Clathrin, and the Impact of Overexpression on Clathrin-mediated Traffic, Mol. Biol. Cell August 1999, 10:2687. Cell lysates were electrophoresed, transferred to nitrocellulose membranes, and Western blotting was performed with several antibodies followed by detection using enhanced chemiluminescence system (Pierce, Inc). Several x-ray films were analyzed to determine the linear range of the chemiluminescence signals, and the quantifications were performed using densitometry and AlphaImager v5.5 software (Alpha Innotech Corporation). In experiments with Eps15R-targeted siRNAs, cell lysates were subjected to immunoprecipitation with Ab860, and Eps15R was detected in immunoprecipitates by Western blotting as described above.

[0298] The antibodies to assess the levels of each protein by Western blot were obtained from the following sources: monoclonal antibody to clathrin heavy chain (TD. 1) was obtained from American Type Culture Collection (Rockville, Md., USA); polyclonal antibody to dynamin II was obtained from Affinity Bioreagents, Inc. (Golden, Colo., USA); monoclonal antibodies to EEA.1 and Rab5a were purchased from BD Transduction Laboratories (Los Angeles, Calif., USA); the monoclonal antibody to Tsg101 was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif., USA); the monoclonal antibody to GFP was from ZYMED Laboratories Inc. (South San Francisco, Calif., USA); the rabbit polyclonal antibodies Ab32 specific to α-adaptins and Ab20 to CALM were described previously Sorkin, et al, Stoichiometric Interaction of the Epidermal Growth Factor Receptor with the Clathrin-associated Protein Complex AP-2, J. Biol. Chem. January 1995, 270:619, the polyclonal antibodies to clathrin light chains A and B were kindly provided by Dr. F. Brodsky (UCSF); monoclonal antibodies to PP1 (BD Transduction Laboratories) and α -Actinin (Chemicon) were kindly provided by Dr. M. Dell'Acqua (University of Colorado); Eps15 Ab577 and Eps15R Ab860 were kindly provided by Dr. P. P. Di Fiore (European Cancer Institute).

[0299] FIG. 11 demonstrates the in vivo functionality of 48 individual siRNAs, selected using Formula VIII (most of them will meet the criteria incorporated by Formula IX as well) targeting 12 genes. Various cell lines were transfected with siRNA duplexes (Dup1-4) or pools of siRNA duplexes (Pool), and the cells were lysed 3 days after transfection with the exception of CALM (2 days) and β 2 (4 days).

[0300] Note a \(\beta\)1-adaptin band (part of AP-1 Golgi adaptor complex) that runs slightly slower than β2 adaptin. CALM has two splice variants, 66 and 72 kD. The full-length Eps15R (a doublet of ~130 kD) and several truncated spliced forms of ~100 kD and ~70 kD were detected in Eps15R immunoprecipitates (shown by arrows). The cells were lysed 3 days after transfection. Equal amounts of lysates were resolved by electrophoresis and blotted with the antibody specific to a targeted protein (GFP antibody for YFP fusion proteins) and the antibody specific to unrelated proteins PP1 phosphatase or α-actinin, and TSG101. The amount of protein in each specific band was normalized to the amount of non-specific proteins in each lane of the gel. Nearly all of them appear to be functional, which establishes that Formula VIII and IX can be used to predict siRNAs' functionality in general in a genome wide manner.

[0301] To generate the fusion of yellow fluorescent protein (YFP) with Rab5b or Rab5c (YFP-Rab5b or YFP-Rab5c), a

DNA fragment encoding the full-length human Rab5b or Rab5c was obtained by PCR using Pfu polymerase (Stratagene) with a SacI restriction site introduced into the 5' end and a KpnI site into the 3' end and cloned into pEYFP-C1 vector (CLONTECH, Palo Alto, Calif., USA). GFP-CALM and YFP-Rab5a were described previously Tebar, Bohlander, & Sorkin, Clathrin Assembly Lymphoid Myeloid Leukemia (CALM) Protein: Localization in Endocytic-coated Pits, Interactions with Clathrin, and the Impact of Overexpression on Clathrin-mediated Traffic, Mol. Biol. Cell August 1999, 10:2687.

Example IV

Validation of the Algorithm Using Eg5, GADPH, ATE1, MEK2, MEK1, QB, LaminA/C, c-myc, Human Cyclophilin, and Mouse Cyclophilin

[0302] A number of genes have been identified as playing potentially important roles in disease etiology. Expression

profiles of normal and diseased kidneys has implicated Edg5 in immunoglobulin A neuropathy, a common renal glomerular disease. Myc1, MEK1/2 and other related kinases have been associated with one or more cancers, while lamins have been implicated in muscular dystrophy and other diseases. For these reasons, siRNA directed against the genes encoding these classes of molecules would be important research and therapeutic tools.

[0303] FIG. 12 illustrates four siRNAs targeting 10 different genes (Table V for 10 sequence and accession number information) that were selected according to the Formula VIII and assayed as individuals and pools in HEK293 cells. The level of siRNA induced silencing was measured using the B-DNA assay. These studies demonstrated that thirty-six out of the forty individual SMART-selected siRNA tested are functional (90%) and all 10 pools are fully functional.

TABLE V

Gene Name	Accession Number	SE	EQ.	ID N	ю.	FTIISeqTence	Formula VIII	Formula IX
CLTC	NM_004859	SEQ.	ID	NO.	0427	GAAAGAATCTGTAGAGAAA	76	94.2
CLTC	NM_004859	SEQ.	ID	NO.	0428	GCAATGAGCTGTTTGAAGA	65	39.9
CLTC	NM_004859	SEQ.	ID	NO.	0429	TGACAAAGGTGGATAAATT	57	38.2
CLTC	NM_004859	SEQ.	ID	NO.	0430	GGAAATGGATCTCTTTGAA	54	49.4
CLTA	NM_001833	SEQ.	ID	NO.	0431	GGAAAGTAATGGTCCAACA	22	55.5
CLTA	NM_001833	SEQ.	ID	NO.	0432	AGACAGTTATGCAGCTATT	4	22.9
CLTA	NM_001833	SEQ.	ID	NO.	0433	CCAATTCTCGGAAGCAAGA	1	17
CLTA	NM_001833	SEQ.	ID	NO.	0434	GAAAGTAATGGTCCAACAG	-1	-13
CLTB	NM_001834	SEQ.	ID	NO.	0435	GCGCCAGAGTGAACAAGTA	17	57.5
CLTB	NM_001834	SEQ.	ID	NO.	0436	GAAGGTGGCCCAGCTATGT	15	-8.6
CLTB	NM_001834	SEQ.	ID	NO.	0311	GGAACCAGCGCCAGAGTGA	13	40.5
CLTB	NM_001834	SEQ.	ID	NO.	0312	GAGCGAGATTGCAGGCATA	20	61.7
CALM	U45976	SEQ.	ID	NO.	0313	GTTAGTATCTGATGACTTG	36	-34.6
CALM	U45976	SEQ.	ID	NO.	0314	GAAATGGAACCACTAAGAA	33	46.1
CALM	U45976	SEQ.	ID	NO.	0315	GGAAATGGAACCACTAAGA	30	61.2
CALM	U45976	SEQ.	ID	NO.	0316	CAACTACACTTTCCAATGC	28	6.8
EPS15	NM_001981	SEQ.	ID	NO.	0317	CCACCAAGATTTCATGATA	48	25.2
EPS15	NM_001981	SEQ.	ID	NO.	0318	GATCGGAACTCCAACAAGA	43	49.3
EPS15	NM_001981	SEQ.	ID	NO.	0319	AAACGGAGCTACAGATTAT	39	11.5
EPS15	NM_001981	SEQ.	ID	NO.	0320	CCACACAGCATTCTTGTAA	33	-23.6
EPS15R	NM_021235	SEQ.	ID	NO.	0321	GAAGTTACCTTGAGCAATC	48	33
EPS15R	NM_021235	SEQ.	ID	NO.	0322	GGACTTGGCCGATCCAGAA	27	33
EPS15R	NM_021235	SEQ.	ID	NO.	0323	GCACTTGGATCGAGATGAG	20	1.3
EPS15R	NM_021235	SEQ.	ID	NO.	0324	CAAAGACCAATTCGCGTTA	17	27.7
DNM2	NM_004945	SEQ.	ID	NO.	0325	CCGAATCAATCGCATCTTC	6	-29.6

TABLE V-continued

Gene Name	Accession Number	SE	Q. ID N	O. FTIISeqTence	Formula VIII	Formula IX
DNM2	NM_004945	SEQ.	ID NO.	0326 GACATGATCCTGCAGTTCA	5	-14
DNM2	NM_004945	SEQ.	ID NO.	0327 GAGCGAATCGTCACCACTT	5	24
DNM2	NM_004945	SEQ.	ID NO.	0328 CCTCCGAGCTGGCGTCTAC	-4	-63.6
ARF6	AF93885	SEQ.	ID NO.	0329 TCACATGGTTAACCTCTAA	27	-21.1
ARF6	AF93885	SEQ.	ID NO.	0330 GATGAGGGACGCCATAATC	7	-38.4
ARF6	AF93885	SEQ.	ID NO.	0331 CCTCTAACTACAAATCTTA	4	16.9
ARF6	AF93885	SEQ.	ID NO.	0332 GGAAGGTGCTATCCAAAAT	4	11.5
RAB5A	BC001267	SEQ.	ID NO.	0333 GCAAGCAAGTCCTAACATT	40	25.1
RAB5A	BC001267	SEQ.	ID NO.	0334 GGAAGAGGAGTAGACCTTA	17	50.1
RAB5A	BC001267	SEQ.	ID NO.	0335 AGGAATCAGTGTTGTAGTA	16	11.5
RAB5A	BC001267	SEQ.	ID NO.	0336 GAAGAGGAGTAGACCTTAC	12	7
RAB5B	NM_002868	SEQ.	ID NO.	0337 GAAAGTCAAGCCTGGTATT	14	18.1
RAB5B	NM_002868	SEQ.	ID NO.	0338 AAAGTCAAGCCTGGTATTA	6	-17.8
RAB5B	NM_002868	SEQ.	ID NO.	0339 GCTATGAACGTGAATGATC	3	-21.1
RAB5B	NM_002868	SEQ.	ID NO.	0340 CAAGCCTGGTATTACGTTT	-7	-37.5
RAB5C	AF141304	SEQ.	ID NO.	0341 GGAACAAGATCTGTCAATT	38	51.9
RAB5C	AF141304	SEQ.	ID NO.	0342 GCAATGAACGTGAACGAAA	29	43.7
RAB5C	AF141304	SEQ.	ID NO.	0343 CAATGAACGTGAACGAAAT	18	43.3
RAB5C	AF141304	SEQ.	ID NO.	0344 GGACAGGAGCGGTATCACA	6	18.2
EEA1	XM_018197	SEQ.	ID NO.	0345 AGACAGAGCTTGAGAATAA	67	64.1
EEA1	XM_018197	SEQ.	ID NO.	0346 GAGAAGATCTTTATGCAAA	60	48.7
EEA1	XM_018197	SEQ.	ID NO.	0347 GAAGAGAAATCAGCAGATA	58	45.7
EEA1	XM_018197	SEQ.	ID NO.	0348 GCAAGTAACTCAACTAACA	56	72.3
AP2B1	NM_001282	SEQ.	ID NO.	0349 GAGCTAATCTGCCACATTG	49	-12.4
AP2B1	NM_001282	SEQ.	ID NO.	0350 GCAGATGAGTTACTAGAAA	44	48.9
AP2B1	NM_001282	SEQ.	ID NO.	0351 CAACTTAATTGTCCAGAAA	41	28.2
AP2B1	NM_001282	SEQ.	ID NO.	0352 CAACACAGGATTCTGATAA	33	-5.8
PLK	NM_005030	SEQ.	ID NO.	0353 AGATTGTGCCTAAGTCTCT	-35	-3.4
PLK	NM_005030	SEQ.	ID NO.	0354 ATGAAGATCTGGAGGTGAA	0	-4.3
PLK	NM_005030	SEQ.	ID NO.	0355 TTTGAGACTTCTTGCCTAA	-5	-27.7
PLK	NM_005030	SEQ.	ID NO.	0356 AGATCACCCTCCTTAAATA	15	72.3
GAPDH	NM_002046	SEQ.	ID NO.	0357 CAACGGATTTGGTCGTATT	27	-2.8
GAPDH	NM_002046	SEQ.	ID NO.	0358 GAAATCCCATCACCATCTT	24	3.9
GAPDH	NM_002046	SEQ.	ID NO.	0359 GACCTCAACTACATGGTTT	22	-22.9
GAPDH	NM_002046	SEQ.	ID NO.	0360 TGGTTTACATGTTCCAATA	9	9.8
c-Myc		SEQ.	ID NO.	0361 GAAGAAATCGATGTTGTTT	31	-11.7
c-Myc		SEQ.	ID NO.	0362 ACACAAACTTGAACAGCTA	22	51.3

TABLE V-continued

Gene	Accession	1.	ABLE	v - CC	ricinuea	Formula	Formula
Name	Number	SE	Q. ID	NO.	FTIISeqTence	VIII	IX
c-Myc		SEQ.	ID NO	. 0363	GGAAGAAATCGATGTTGTT	18	26
c-Myc		SEQ.	ID NO	. 0364	GAAACGACGAGAACAGTTG	18	-8.9
MAP2K1	NM_002755	SEQ.	ID NO	. 0365	GCACATGGATGGAGGTTCT	26	16
MAP2K1	NM_002755	SEQ.	ID NO	. 0366	GCAGAGAGAGCAGATTTGA	16	0.4
MAP2K1	NM_002755	SEQ.	ID NO	. 0367	GAGGTTCTCTGGATCAAGT	14	15.5
MAP2K1	NM_002755	SEQ.	ID NO	. 0368	GAGCAGATTTGAAGCAACT	14	18.5
MAP2K2	NM_030662	SEQ.	ID NO	. 0369	CAAAGACGATGACTTCGAA	37	26.4
MAP2K2	NM_030662	SEQ.	ID NO	. 0370	GATCAGCATTTGCATGGAA	24	-0.7
MAP2K2	NM_030662	SEQ.	ID NO	. 0371	. TCCAGGAGTTTGTCAATAA	17	-4.5
MAP2K2	NM_030662	SEQ.	ID NO	. 0372	GGAAGCTGATCCACCTTGA	16	59.2
KNSL1 (EG5)	NM_004523	SEQ.	ID NO	. 0373	GCAGAAATCTAAGGATATA	53	35.8
KNSL1 (EG5)	NM_004523	SEQ.	ID NO	. 0374	CAACAAGGATGAAGTCTAT	50	18.3
KNSL1 (EG5)	NM_004523	SEQ.	ID NO	. 0375	CAGCAGAAATCTAAGGATA	41	32.7
KNSL1 (EG5)	NM_004523	SEQ.	ID NO	. 0376	CTAGATGGCTTTCTCAGTA	39	3.9
CyclophilinA_	_NM_021130	SEQ.	ID NO	. 0377	AGACAAGGTCCCAAAGACA	-16	58.1
CyclophilinA_	_NM_021130	SEQ.	ID NO	. 0378	GGAATGGCAAGACCAGCAA	-6	36
CyclophilinA_	_NM_021130	SEQ.	ID NO	. 0379	AGAATTATTCCAGGGTTTA	-3	16.1
CyclophilinA_	_NM_021130	SEQ.	ID NO	. 0380	GCAGACAAGGTCCCAAAGA	8	8.9
LAMIN A/C	NM_170707	SEQ.	ID NO	. 0381	. AGAAGCAGCTTCAGGATGA	31	38.8
LAMIN A/C	NM_170707	SEQ.	ID NO	. 0382	GAGCTTGACTTCCAGAAGA	33	22.4
LAMIN A/C	NM_170707	SEQ.	ID NO	. 0383	CCACCGAAGTTCACCCTAA	21	27.5
LAMIN A/C	NM_170707	SEQ.	ID NO	. 0384	GAGAAGAGCTCCTCCATCA	55	30.1
CyclophilinB	M60857	SEQ.	ID NO	. 0385	GAAAGAGCATCTACGGTGA	41	83.9
CyclophilinB	M60857	SEQ.	ID NO	. 0386	GAAAGGATTTGGCTACAAA	53	59.1
CyclophilinB	M60857	SEQ.	ID NO	. 0387	ACAGCAAATTCCATCGTGT	-20	28.8
CyclophilinB	M60857	SEQ.	ID NO	. 0388	GGAAAGACTGTTCCAAAAA	2	27
DBI1	NM_020548	SEQ.	ID NO	. 0389	CAACACGCCTCATCCTCTA	27	-7.6
DBI2	NM_020548	SEQ.	ID NO	0390) CATGAAAGCTTACATCAAC	25	-30.8
DBI3	NM_020548	SEQ.	ID NO	. 0391	AAGATGCCATGAAAGCTTA	17	22
DBI4	NM_020548	SEQ.	ID NO	0392	GCACATACCGCCTGAGTCT	15	3.9
rLUC1		SEQ.	ID NO	0393	GATCAAATCTGAAGAAGGA	57	49.2
rLUC2		SEQ.	ID NO	. 0394	GCCAAGAAGTTTCCTAATA	50	13.7
rLUC3		SEQ.	ID NO	. 0395	CAGCATATCTTGAACCATT	41	-2.2
rLUC4		SEQ.	ID NO	. 0396	GAACAAAGGAAACGGATGA	39	29.2
SeAP1	NM_031313	SEQ.	ID NO	. 0397	CGGAAACGGTCCAGGCTAT	6	26.9
SeAP2	NM_031313	SEQ.	ID NO	. 0398	GCTTCGAGCAGACATGATA	4	-11.2

28

TABLE V-continued

Gene Name	Accession Number	SE	Q. :	ID N	ο.	FTIISeqTence	Formula VIII	Formula IX
SeAP3	NM_031313	SEQ.	ID	ио.	0399	CCTACACGGTCCTCCTATA	4	4.9
SeAP4	NM_031313	SEQ.	ID	NO.	0400	GCCAAGAACCTCATCATCT	1	-9.9
fLUC1		SEQ.	ID	NO.	0401	GATATGGGCTGAATACAAA	54	40.4
fLUC2		SEQ.	ID	NO.	0402	GCACTCTGATTGACAAATA	47	54.7
fLUC3		SEQ.	ID	NO.	0403	TGAAGTCTCTGATTAAGTA	46	34.5
fLUC4		SEQ.	ID	NO.	0404	TCAGAGAGATCCTCATAAA	40	11.4
mCyclo_1	NM_008907	SEQ.	ID	NO.	0405	GCAAGAAGATCACCATTTC	52	46.4
mCyclo_2	NM_008907	SEQ.	ID	NO.	0406	GAGAGAAATTTGAGGATGA	36	70.7
mCyclo_3	NM_008907	SEQ.	ID	NO.	0407	GAAAGGATTTGGCTATAAG	35	-1.5
mCyclo_4	NM_008907	SEQ.	ID	NO.	0408	GAAAGAAGGCATGAACATT	27	10.3
BCL2_1	NM_000633	SEQ.	ID	NO.	0409	GGGAGATAGTGATGAAGTA	21	72
BCL2_2	NM_000633	SEQ.	ID	NO.	0410	GAAGTACATCCATTATAAG	1	3.3
BCL2_3	NM_000633	SEQ.	ID	NO.	0411	GTACGACAACCGGGAGATA	1	35.9
BCL2_4	NM_000633	SEQ.	ID	NO.	0412	AGATAGTGATGAAGTACAT	-12	22.1
BCL2_5	NM_000633	SEQ.	ID	NO.	0413	TGAAGACTCTGCTCAGTTT	36	19.1
BCL2_6	NM_000633	SEQ.	ID	NO.	0414	GCATGCGGCCTCTGTTTGA	5	-9.7
QB1	NM_003365.1	SEQ.	ID	NO.	0415	GCACACAGCUUACUACAUC	52	-4.8
QB2	NM_003365.1	SEQ.	ID	NO.	0416	GAAAUGCCCUGGUAUCUCA	49	22.1
QB3	NM_003365.1	SEQ.	ID	NO.	0417	GAAGGAACGUGAUGUGAUG	34	22.9
QB4	NM_003365.1	SEQ.	ID	NO.	0418	GCACUACUCCUGUGUGUGA	28	20.4
ATE1-1	NM_007041	SEQ.	ID	NO.	0419	GAACCCAGCUGGAGAACUU	45	15.5
ATE1-2	NM_007041	SEQ.	ID	NO.	0420	GAUAUACAGUGUGAUCUUA	40	12.2
ATE1-3	NM_007041	SEQ.	ID	NO.	0421	GUACUACGAUCCUGAUUAU	37	32.9
ATE1-4	NM_007041	SEQ.	ID	NO.	0422	GUGCCGACCUUUACAAUUU	35	18.2
EGFR-1	NM_005228	SEQ.	ID	NO.	0423	GAAGGAAACTGAATTCAAA	68	79.4
EGFR-1	NM_005228	SEQ.	ID	NO.	0424	GGAAATATGTACTACGAAA	49	49.5
EGFR-1	NM_005228	SEQ.	ID	NO.	0425	CCACAAAGCAGTGAATTTA	41	7.6
EGFR-1	NM_005228	SEQ.	ID	NO.	0426	GTAACAAGCTCACGCAGTT	40	25.9

Example V

Validation of the Algorithm Using Bcl2

[0304] Bcl-2 is a ~25 kD, 205-239 amino acid, anti-apoptotic protein that contains considerable homology with other members of the BCL family including BCLX, MCL1, BAX, BAD, and BIK. The protein exists in at least two forms (Bcl2a, which has a hydrophobic tail for membrane anchorage, and Bcl2b, which lacks the hydrophobic tail) and is predominantly localized to the mitochondrial membrane. While Bcl2 expression is widely distributed, particular interest has focused on the expression of this molecule in B and T cells. Bcl2 expression is down-regulated in normal germinal

center B cells yet in a high percentage of follicular lymphomas, Bcl2 expression has been observed to be elevated. Cytological studies have identified a common translocation ((14; 18) (q32; q32)) amongst a high percentage (>70%) of these lymphomas. This genetic lesion places the Bcl2 gene in juxtaposition to immunoglobulin heavy chain gene (IgH) encoding sequences and is believed to enforce inappropriate levels of gene expression, and resistance to programmed cell death in the follicle center B cells. In other cases, hypomethylation of the Bcl2 promoter leads to enhanced expression and again, inhibition of apoptosis. In addition to cancer, dysregulated expression of Bcl-2 has been correlated with multiple sclerosis and various neurological diseases.

[0305] The correlation between Bcl-2 translocation and cancer makes this gene an attractive target for RNAi. Identification of siRNA directed against the bcl2 transcript (or Bcl2-IgH fusions) would further our understanding Bcl2 gene function and possibly provide a future therapeutic agent to battle diseases that result from altered expression or function of this gene.

In Silico Identification of Functional siRNA

[0306] To identify functional and hyperfunctional siRNA against the Bcl2 gene, the sequence for Bcl-2 was downloaded from the NCBI Unigene database and analyzed using the Formula VIII algorithm. As a result of these procedures, both the sequence and SMARTscores™ of the Bcl2 siRNA were obtained and ranked according to their functionality. Subsequently, these sequences were BLAST'ed (database) to insure that the selected sequences were specific and contained minimal overlap with unrelated genes. The SMARTscores™ for the top 10 Bcl-2 siRNA are identified in FIG. 13.

In Vivo Testing of Bcl-2 SiRNA

[0307] Bcl-2 siRNAs having the top ten SMARTscoresTM were selected and tested in a functional assay to determine silencing efficiency. To accomplish this, each of the ten duplexes were synthesized using 2'-O-ACE chemistry and transfected at 100 nM concentrations into cells. Twenty-four hours later assays were performed on cell extracts to assess the degree of target silencing. Controls used in these experiments included mock transfected cells, and cells that were transfected with a non-specific siRNA duplex.

[0308] The results of these experiments are presented below (and in FIG. 14) and show that all ten of the selected siRNA induce 80% or better silencing of the Bcl2 message at 100 nM concentrations. These data verify that the algorithm successfully identified functional Bcl2 siRNA and provide a set of functional agents that can be used in experimental and therapeutic environments.

Bcl2 siF siRNA		Sense Strand, 5'→3' GGGAGAUAGUGAUGAAGUA	SEQ.	ID NO. 301
siRNA	2	GAAGUACAUCCAUUAUAAG	SEQ.	ID NO. 302
siRNA	3	GUACGACAACCGGGAGAUA	SEQ.	ID NO. 303
siRNA	4	AGAUAGUGAUGAAGUACAU	SEQ.	ID NO. 304
siRNA	5	UGAAGACUCUGCUCAGUUU	SEQ.	ID NO. 305
siRNA	6	GCAUGCGGCCUCUGUUUGA	SEQ.	ID NO. 306
siRNA	7	UGCGGCCUCUGUUUGAUUU	SEQ.	ID NO. 307
siRNA	8	GAGAUAGUGAUGAAGUACA	SEQ.	ID NO. 308
siRNA	9	GGAGAUAGUGAUGAAGUAC	SEQ.	ID NO. 309
siRNA	10	GAAGACUCUGCUCAGUUUG	SEQ.	ID NO. 310

Example VI

Evidence for the Benefits of Pooling

[0309] Evidence for the benefits of pooling have been demonstrated using the reporter gene, luciferase. Ninety siRNA duplexes were synthesized using Dharmacon proprietary ACE® chemistry against one of the standard reporter genes:

firefly luciferase. The duplexes were designed to start two base pairs apart and to cover approximately 180 base pairs of the luciferase gene (see sequences in Table III). Subsequently, the siRNA duplexes were co-transfected with a luciferase expression reporter plasmid into HEK293 cells using standard transfection protocols and luciferase activity was assayed at 24 and 48 hours.

[0310] Transfection of individual siRNAs showed standard distribution of inhibitory effect. Some duplexes were active, while others were not. FIG. 15 represents a typical screen of ninety siRNA duplexes (SEQ. ID NO. 0032-0120) positioned two base pairs apart. As the figure suggests, the functionality of the siRNA duplex is determined more by a particular sequence of the oligonucleotide than by the relative oligonucleotide position within a gene or excessively sensitive part of the mRNA, which is important for traditional anti-sense technology.

[0311] When two continuous oligonucleotides were pooled together, a significant increase in gene silencing activity was observed (see FIGS. 16A and 16B). A gradual increase in efficacy and the frequency of pools functionality was observed when the number of siRNAs increased to 3 and 4 (see FIGS. 16A, 16B, 17A, and 17B). Further, the relative positioning of the oligonucleotides within a pool did not determine whether a particular pool was functional (see FIGS. 18A and 18B, in which 100% of pools of oligonucleotides distanced by 2, 10 and 20 base pairs were functional).

[0312] However, relative positioning may nonetheless have an impact. An increased functionality may exist when the siRNA are positioned continuously head to toe (5' end of one directly adjacent to the 3' end of the others).

[0313] Additionally, siRNA pools that were tested performed at least as well as the best oligonucleotide in the pool, under the experimental conditions whose results are depicted in FIG. 19. Moreover, when previously identified non-functional and marginally (semi) functional siRNA duplexes were pooled together in groups of five at a time, a significant functional cooperative action was observed. (See FIG. 20) In fact, pools of semi-active oligonucleotides were 5 to 25 times more functional than the most potent oligonucleotide in the pool. Therefore, pooling several siRNA duplexes together does not interfere with the functionality of the most potent siRNAs within a pool, and pooling provides an unexpected significant increase in overall functionality

Example VII

Pooling Across Species

[0314] Experiments were performed on the following genes: β -galactosidase, Renilla luciferase, and Secreted alkaline phosphatase, which demonstrate the benefits of pooling. (see FIG. 21) Approximately 50% of individual siRNAs designed to silence the above-specified genes were functional, while 100% of the pools that contain the same siRNA duplexes were functional.

Example VIII

Highly Functional siRNA

[0315] Pools of five siRNAs in which each two siRNAs overlap to 10-90% resulted in 98% functional entities (>80% silencing). Pools of siRNAs distributed throughout the

mRNA that were evenly spaced, covering an approximate 20-2000 base pair range, were also functional. When the pools of siRNA were positioned continuously head to tail relative to mRNA sequences and mimicked the natural products of Dicer cleaved long double stranded RNA, 98% of the pools evidenced highly functional activity (>95% silencing).

Example IX

Human Cyclophyline

[0316] Table III above lists the siRNA sequences for the human cyclophyline protein. A particularly functional siRNA may be selected by applying these sequences to any of Formula I to VII above.

[0317] Alternatively, one could pool 2, 3, 4, 5 or more of these sequences to create a kit for silencing a gene. Preferably, within the kit there would be at least one sequence that has a relatively high predicted functionality when any of Formulas I-VII is applied.

Example X

Validation of Multigene Knockout Using Rab5 and Eps

[0318] Two or more genes having similar, overlapping functions often leads to genetic redundancy. Mutations that knockout only one of, e.g., a pair of such genes (also referred to as homologs) result in little or no phenotype due to the fact that the remaining intact gene is capable of fulfilling the role of the disrupted counterpart. To fully understand the function of such genes in cellular physiology, it is often necessary to knockout or knockdown both homologs simultaneously. Unfortunately, concomitant knockdown of two or more genes is frequently difficult to achieve in higher organisms (e.g. mice) thus it is necessary to introduce new technologies dissect gene function. One such approach to knocking down multiple genes simultaneously is by using siRNA. For example, FIG. 11 showed that rationally designed siRNA directed against a number of genes involved in the clathrinmediated endocytosis pathway resulted in significant levels of protein reduction (e.g. >80%). To determine the effects of gene knockdown on clathrin-related endocytosis, internalization assays were performed using epidermal growth factor and transferrin. Specifically, mouse receptor-grade EGF (Collaborative Research Inc.) and iron-saturated human transferrin (Sigma) were iodinated as described previously (Jiang, X., Huang, F., Marusyk, A. & Sorkin, A. (2003) Mol Biol Cell 14, 858-70). HeLa cells grown in 12-well dishes were incubated with ¹²⁵I-EGF (1 ng/ml) or ¹²⁵I-transferrin (1 μg/ml) in binding medium (DMEM, 0.1% bovine serum albumin) at 37° C., and the ratio of internalized and surface radioactivity was determined during 5-min time course to calculate specific internalization rate constant k, as described previously (Jiang, X et al.). The measurements of the uptakes of radiolabeled transferrin and EGF were performed using short time-course assays to avoid influence of the recycling on the uptake kinetics, and using low ligand concentration to avoid saturation of the clathrin-dependent pathway (for EGF Lund, K. A., Opresko, L. K., Strarbuck, C., Walsh, B. J. & Wiley, H. S. (1990) J. Biol. Chem. 265, 15713-13723).

[0319] The effects of knocking down Rab5a, 5b, 5c, Eps, or Eps 15R (individually) are shown in FIG. 22 and demonstrate that disruption of single genes has little or no effect on EGF or

Tfn internalization. In contrast, simultaneous knock down of Rab5a, 5b, and 5c, or Eps and Eps 15R, leads to a distinct phenotype (note: total concentration of siRNA in these experiments remained constant with that in experiments in which a single siRNA was introduced, see FIG. 23). These experiments demonstrate the effectiveness of using rationally designed siRNA to knockdown multiple genes and validates the utility of these reagents to override genetic redundancy.

Example XI

Validation of Multigene Targeting Using G6PD, GAPDH, PLK, and UQC

[0320] Further demonstration of the ability to knock down expression of multiple genes using rationally designed siRNA was performed using pools of siRNA directed against four separate genes. To achieve this, siRNA were transfected into cells (total siRNA concentration of 100 nM) and assayed twenty-four hours later by B-DNA. Results shown in FIG. 24 show that pools of rationally designed molecules are capable of simultaneously silencing four different genes.

Example XII

Identifying Hyperfunctional siRNA

Identification of Hyperfunctional Bcl-2 siRNA

[0321] The ten rationally designed Bcl2 siRNA (identified in FIGS. 13, 14) were tested to identify hyperpotent reagents. To accomplish this, each of the ten Bcl-2 siRNA were individually transfected into cells at a 300 μM (0.3 nM) concentrations. Twenty-four hours later, transcript levels were assessed by B-DNA assays and compared with relevant controls. As shown in FIG. 25, while the majority of Bcl-2 siRNA failed to induce functional levels of silencing at this concentration, siRNA 1 and 8 induced >80% silencing, and siRNA 6 exhibited greater than 90% silencing at this subnanomolar concentration.

Example XIII

Gene Silencing

Prophetic Example

[0322] Below is an example of how one might transfect a cell.

- [0323] a. Select a cell line. The selection of a cell line is usually determined by the desired application. The most important feature to RNAi is the level of expression of the gene of interest. It is highly recommended to use cell lines for which siRNA transfection conditions have been specified and validated.
- [0324] b. Plate the cells. Approximately 24 hours prior to transfection, plate the cells at the appropriate density so that they will be approximately 70-90% confluent, or approximately 1×10⁵ cells/ml at the time of transfection. Cell densities that are too low may lead to toxicity due to excess exposure and uptake of transfection reagent-siRNA complexes. Cell densities that are too high may lead to low transfection efficiencies and little or no silencing. Incubate the cells overnight. Standard incubation conditions for mammalian cells are 37° C. in 5% CO₂. Other cell types, such as insect cells, require

different temperatures and CO₂ concentrations that are readily ascertainable by persons skilled in the art. Use conditions appropriate for the cell type of interest.

[0325] c. SiRNA re-suspension. Add 20 μ l siRNA universal buffer to each siRNA to generate a final concentration of 50 μ M.

[0326] d. SiRNA-lipid complex formation. Use RNase-free solutions and tubes. Using the following table, Table VI:

TABLE VI

	96-well	24-well
Mixture 1 (TransIT-TKC)-Plasmid dilution r	nixture)
Opti-MEM	9.3 ш	46.5 μl
TransIT-TKO (1 μ g/ μ l)	_0.5 μl	2.5 µl
Mixture 1 Final Volume	10.0 µl	50.0 μl
Mixture 2 (siRN	A dilution mixture)	_
Opti-MEM	9.0 µl	45.0 μl
siRNA (1 μM)	_1.0 μl	5.0 μl
Mixture 2 Final Volume	10.0 µl	50.0 µl
Mixture 3 (siRNA-Tran	nsfection reagent m	ixture)
Mixture 1	10 μl	50 µl
Mixture 2	10_µl	50 μl
Mixture 3 Final Volume	20 ш	100 µl
Incubate 20 minutes at room ten		
Mixture 4 (Media-siRNA/	Transfection reagen	t mixture)
Mixture 3	20 µl	100 μl
Complete media	80 ш	400 μl
Mixture 4 Final Volume	100 ul	500 ul

[0327] Transfection. Create a Mixture 1 by combining the specified amounts of OPTI-MEM serum free media and transfection reagent in a sterile polystyrene tube. Create a Mixture 2 by combining specified amounts of each siRNA with OPTI-MEM media in sterile 1 ml tubes. Create a Mixture 3 by combining specified amounts of Mixture 1 and Mixture 2. Mix gently (do not vortex) and incubate at room temperature for 20 minutes. Create a Mixture 4 by combining specified amounts of Mixture 3 to complete media. Add appropriate volume to each cell culture well. Incubate cells with transfection reagent mixture for 24-72 hours at 37° C. This incubation time is flexible. The ratio of silencing will remain consistent at any point in the time period. Assay for gene silencing using an appropriate detection method such as RT-PCR, Western blot analysis, immunohistochemistry, phenotypic analysis, mass spectrometry, fluorescence, radioactive decay, or any other method that is now known or that comes to be known to persons skilled in the art and that from reading this disclosure would useful with the present invention. The optimal window for observing a knockdown phenotype is related to the mRNA turnover of the gene of interest, although 24-72 hours is standard. Final Volume reflects amount needed in each well for the desired cell culture format. When adjusting volumes for a Stock Mix, an additional 10% should be used to accommodate variability in pipetting, etc. Duplicate or triplicate assays should be carried out when

[0328] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departure from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims.

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 437
<210> SEQ ID NO 1
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18 <223> OTHER INFORMATION: n is any nucleotide
<400> SEOUENCE: 1
nnanannnnu cnaannnna
<210> SEQ ID NO 2
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
```

<220> FEATURE:

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

19

```
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 2
                                                                       19
nnanannnu gnaannna
<210> SEQ ID NO 3
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 3
nnanannnu unaannna
                                                                       19
<210> SEQ ID NO 4
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 4
nnanannnnu cncannnna
                                                                       19
<210> SEQ ID NO 5
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 5
nnanannnnu gncannnna
                                                                       19
<210> SEQ ID NO 6
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 6
nnanannnu uncannna
                                                                       19
<210> SEQ ID NO 7
<211> LENGTH: 19
<212> TYPE: RNA
```

nnancnnnnu gnaannnna

-continued

```
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18 <223> OTHER INFORMATION: n is any nucleotide
<400> SEOUENCE: 7
nnanannnnu cnuannnna
                                                                          19
<210> SEQ ID NO 8
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 8
nnanannnu gnuannna
                                                                          19
<210> SEQ ID NO 9
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 9
nnanannnnu unuannnna
                                                                          19
<210> SEQ ID NO 10
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 10
nnancnnnu cnaannnna
                                                                          19
<210> SEQ ID NO 11
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 11
```

19

```
<210> SEO ID NO 12
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 12
nnancnnnnu unaannnna
                                                                            19
<210> SEQ ID NO 13
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 13
nnancnnnu cncannna
                                                                            19
<210> SEQ ID NO 14
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 14
nnancnnnnu gncannnna
                                                                            19
<210> SEQ ID NO 15
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 15
nnancnnnu uncannnna
                                                                            19
<210> SEQ ID NO 16
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
```

```
<400> SEOUENCE: 16
nnancnnnnu cnuannnna
                                                                          19
<210> SEQ ID NO 17
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 17
nnancnnnnu gnuannnna
                                                                          19
<210> SEQ ID NO 18
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 18
nnancnnnnu unuannnna
                                                                          19
<210> SEQ ID NO 19
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18 <223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 19
nnangnnnnu cnaannnna
                                                                          19
<210> SEQ ID NO 20
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 20
nnangnnnnu gnaannnna
                                                                          19
<210> SEQ ID NO 21
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
```

```
<221> NAME/KEY: misc_feature
<221> MANIE, NET: MISS_leature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 21
                                                                           19
nnangnnnnu unaannnna
<210> SEQ ID NO 22
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 22
nnangnnnnu cncannnna
                                                                           19
<210> SEQ ID NO 23
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 23
nnangnnnnu gncannnna
                                                                           19
<210> SEQ ID NO 24
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 24
nnangnnnnu uncannnna
                                                                           19
<210> SEQ ID NO 25
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 25
nnangnnnnu cnuannnna
                                                                           19
<210> SEQ ID NO 26
<211> LENGTH: 19
<212> TYPE: RNA
```

```
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18 <223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 26
nnangnnnnu gnuannnna
                                                                          19
<210> SEQ ID NO 27
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-2, 4, 6-9, 12, 15-18
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 27
nnangnnnnu unuannnna
                                                                          19
<210> SEQ ID NO 28
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 4-5,7,9-12,15,18-21
<223> OTHER INFORMATION: n is any nucleotide
<400> SEQUENCE: 28
                                                                          22
quennanann nnuenaannn na
<210> SEQ ID NO 29
<211> LENGTH: 208
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)...(208)
<223> OTHER INFORMATION: human cyclophilin fragment
<400> SEOUENCE: 29
gttccaaaaa cagtggataa ttttgtggcc ttagctacag gagagaaagg atttggctac
                                                                          60
aaaaacagca aattccatcg tgtaatcaag gacttcatga tccagggcgg agacttcacc
                                                                        120
aggggagatg gcacaggagg aaagagcatc tacggtgagc gcttccccga tgagaacttc
aaactgaagc actacgggcc tggctggg
                                                                        208
<210> SEQ ID NO 30
<211> LENGTH: 200
<212> TYPE: DNA
<213> ORGANISM: Photinus pyralis
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)...(200)
<223> OTHER INFORMATION: firefly luciferase fragment
<400> SEQUENCE: 30
```

-concinued	
tgaacttccc gccgccgttg ttgttttgga gcacggaaag acgatgacgg aaaaagagat	60
cgtggattac gtcgccagtc aagtaacaac cgcgaaaaag ttgcgcggag gagttgtgtt	120
tgtggacgaa gtaccgaaag gtcttaccgg aaaactcgac gcaagaaaaa tcagagagat	180
cctcataaag gccaagaagg	200
<210> SEQ ID NO 31 <211> LENGTH: 108 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)(108) <223> OTHER INFORMATION: human DBL fragment	
<400> SEQUENCE: 31	
acgggcaagg ccaagtggga tgcctggaat gagctgaaag ggacttccaa ggaagatgcc	60
atgaaagett acatcaacaa agtagaagag etaaagaaaa aataeggg	108
<210> SEQ ID NO 32 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 32	
guuccaaaaa caguggaua	19
<pre><210> SEQ ID NO 33 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 33</pre>	
uccaaaaaca guggauaau	19
<210> SEQ ID NO 34 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 34	
caaaaacagu ggauaauuu	19
<210> SEQ ID NO 35 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 35	10
aaaacagugg auaauuuug	19
<210> SEQ ID NO 36 <211> LENGTH: 19 <212> TYPE: RNA	

<pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 36	
aacaguggau aauuuugug	19
<pre><210> SEQ ID NO 37 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 37	
caguggauaa uuuuguggc	19
<210> SEQ ID NO 38 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 38	
guggauaauu uuguggccu	19
<pre><210> SEQ ID NO 39 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 39</pre>	
ggauaauuuu guggccuua	19
<pre><210> SEQ ID NO 40 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 40	
auaauuuugu ggccuuagc	19
<pre><210> SEQ ID NO 41 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 41</pre>	
aauuuugugg ccuuagcua	19
<pre><210> SEQ ID NO 42 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	

<400> SEQUENCE: 42	
uuuuguggcc uuagcuaca	19
<210> SEQ ID NO 43	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 43	
uuguggeeuu ageuaeagg	19
<210> SEQ ID NO 44	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 44	
guggccuuag cuacaggag	19
<210> SEQ ID NO 45	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 45	
ggccuuagcu acaggagag	19
<210> SEQ ID NO 46	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 46	
ccuuagcuac aggagagaa	19
<210> SEQ ID NO 47	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 47	
uuagcuacag gagagaaag	19
<210> SEQ ID NO 48	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 48	
agcuacagga gagaaagga	19

<211> <212>	SEQ ID NO 49 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence		
<220>	FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 49		
cuacaç	ggaga gaaaggauu	19	
<211> <212> <213> <220>	SEQ ID NO 50 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 50		
acagga	agaga aaggauuug	19	
<211> <212> <213> <220>	SEQ ID NO 51 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 51		
aggaga	agaaa ggauuuggc	19	
<211> <212> <213> <220> <223>	SEQ ID NO 52 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 52		
gagaga	aaagg auuuggcua	19	
<211> <212> <213> <220>	SEQ ID NO 53 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 53		
gagaaa	aggau uuggcuaca	19	
<211> <212> <213> <220> <223>	SEQ ID NO 54 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
	SEQUENCE: 54 gauuu ggcuacaaa	19	
<211>	SEQ ID NO 55 LENGTH: 19 TYPE: RNA		

<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic		
4400 CEOHENGE FF		
<400> SEQUENCE: 55		
aaggauuugg cuacaaaaa	19	
<210> SEQ ID NO 56		
<211> LENGTH: 19		
<212> TYPE: RNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic		
400 00000000000000000000000000000000000		
<400> SEQUENCE: 56		
ggauuuggcu acaaaaaca	19	
<210> SEQ ID NO 57		
<211> LENGTH: 19		
<212> TYPE: RNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic		
<400> SEQUENCE: 57		
auuuggcuac aaaaacagc	19	
<210> SEQ ID NO 58		
<211> LENGTH: 19		
<212> TYPE: RNA		
<pre><213> ORGANISM: Artificial Sequence</pre>		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic		
<400> SEQUENCE: 58		
uuggcuacaa aaacagcaa	19	
<210> SEO ID NO 59		
<210> SEQ ID NO 59		
<211> LENGTH: 19		
<211> LENGTH: 19 <212> TYPE: RNA		
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence		
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:		
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence		
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic		
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:		
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic		
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19	
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59	19	
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59	19	
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau	19	
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60	19	
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19	19	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau </pre> <pre><210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA</pre>	19	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence</pre>	19	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	19	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence</pre>	19	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	19	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	19	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	19	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 60</pre>		
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	19	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 60</pre>		
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 60 cuacaaaaac agcaaauuc</pre>		
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 60 cuacaaaaac agcaaauuc</pre>		
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 60 cuacaaaaac agcaaauuc <210> SEQ ID NO 61 <211> LENGTH: 19</pre>		
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 60 cuacaaaaac agcaaauuc <210> SEQ ID NO 61 <211> LENGTH: 19 <212> TYPE: RNA</pre>		
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 60 cuacaaaaac agcaaauuc <210> SEQ ID NO 61 <211> LENGTH: 19 <212> TYPE: RNA <313> ORGANISM: Artificial Sequence <400> SEQUENCE: 60</pre>		
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 60 cuacaaaaac agcaaauuc <210> SEQ ID NO 61 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>		
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 59 ggcuacaaaa acagcaaau <210> SEQ ID NO 60 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 60 cuacaaaaac agcaaauuc <210> SEQ ID NO 61 <211> LENGTH: 19 <212> TYPE: RNA <313> ORGANISM: Artificial Sequence <400> SEQUENCE: 60</pre>		

<400> SEQUENCE: 61	
acaaaaacag caaauucca	19
<210> SEQ ID NO 62 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 62	
aaaaacagca aauuccauc	19
<210> SEQ ID NO 63 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 63	
aaacagcaaa uuccaucgu	19
<210> SEQ ID NO 64 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 64	
acagcaaauu ccaucgugu	19
acagcaaauu ccaucgugu <210> SEQ ID NO 65 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 65 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 65 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 65 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 65	
<pre><210> SEQ ID NO 65 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 65 agcaaauucc aucguguaa <210> SEQ ID NO 66 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<pre><210> SEQ ID NO 65 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 65 agcaaauucc aucguguaa <210> SEQ ID NO 66 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<pre><210> SEQ ID NO 65 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 65 agcaaauucc aucguguaa <210> SEQ ID NO 66 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 66 Caaauuccau cguguaauc <210> SEQUENCE: 66 Caaauuccau cguguaauc <210> SEQUENCE: 66 Caaauuccau cguguaauc <210> SEQ ID NO 67 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic </pre>	19
<pre><210> SEQ ID NO 65 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 65 agcaaauucc aucguguaa <210> SEQ ID NO 66 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 66 caaauuccau cguguaauc <210> SEQ ID NO 67 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <220> FEATURE: 66</pre>	19

<211> <212> <213> <220>	SEQ ID NO 68 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 68	
uuccau	icgug uaaucaagg	19
<211> <212> <213> <220>	SEQ ID NO 69 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 69	
ccauc	gugua aucaaggac	19
<211> <212> <213> <220>	SEQ ID NO 70 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 70	
aucguç	uaau caaggacuu	19
<211> <212> <213> <220> <223>	SEQ ID NO 71 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 71	
cgugua	auca aggacuuca	19
<211> <212> <213> <220>	SEQ ID NO 72 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 72	
uguaaı	icaag gacuucaug	19
<211> <212> <213> <220> <223>	SEQ ID NO 73 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
	SEQUENCE: 73 lagga cuucaugau	19
<210> <211>	SEQ ID NO 74 LENGTH: 19 TYPE: RNA	

	Colletified
<pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<pre><400> SEQUENCE: 74</pre>	
aucaaggacu ucaugaucc	19
<210> SEQ ID NO 75 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 75	
caaggacuuc augauccag	19
<210> SEQ ID NO 76 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 76	
aggacuucau gauccaggg	19
<pre><210> SEQ ID NO 77 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 77</pre>	
gacuucauga uccagggcg	19
<210> SEQ ID NO 78 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 78	
cuucaugauc cagggcgga	19
<pre><210> SEQ ID NO 79 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 79</pre>	
ucaugaucca gggcggaga	19
<210> SEQ ID NO 80 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
12257 OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 80	
augauccagg gcggagacu	19
<pre><210> SEQ ID NO 81 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 81	
gauccagggc ggagacuuc	19
<pre><210> SEQ ID NO 82 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 82</pre>	
uccagggcgg agacuucac	19
<210> SEQ ID NO 83 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 83	
cagggcggag acuucacca	19
<pre><210> SEQ ID NO 84 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 84	
gggcggagac uucaccagg	19
<pre><210> SEQ ID NO 85 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 85</pre>	
gcggagacuu caccagggg	19
<210> SEQ ID NO 86 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 86	
ggagacuuca ccaggggag	19

<211> <212> <213> <220>	SEQ ID NO 87 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 87	
agacui	ıcacc aggggagau	19
<211> <212> <213> <220>	SEQ ID NO 88 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 88	
acuuca	accag gggagaugg	19
<211> <212> <213> <220>	SEQ ID NO 89 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 89	
uucac	caggg gagauggca	19
<211><212><213><223>	SEQ ID NO 90 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 90	
cacca	ggga gauggcaca	19
<211> <212> <213> <220>	SEQ ID NO 91 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 91	
ccagg	ggaga uggcacagg	19
<211> <212> <213> <220> <223>	SEQ ID NO 92 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
	SEQUENCE: 92 agaug gcacaggag	19
<210> <211>	SEQ ID NO 93 LENGTH: 19 TYPE: RNA	

	Concinaca
<pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<pre><400> SEQUENCE: 93</pre>	
gggagauggc acaggagga	19
3333	-2-
<210> SEQ ID NO 94 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 94	
uggcacagga ggaaagagc	19
<210> SEQ ID NO 95 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 95	
gauggcacag gaggaaaga	19
<pre><210> SEQ ID NO 96 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 96</pre>	
gcacaggagg aaagagcau	19
<210> SEQ ID NO 97 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 97	
acaggaggaa agagcaucu	19
<pre><210> SEQ ID NO 98 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 98</pre>	
aggaggaaag agcaucuac	19
<pre><210> SEQ ID NO 99 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	

<400> SEQUENCE: 99	
gaggaaagag caucuacgg	19
<210> SEQ ID NO 100 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 100	
ggaaagagca ucuacggug	19
<210> SEQ ID NO 101 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 101	10
aaagagcauc uacggugag	19
<210> SEQ ID NO 102 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 102	
agagcaucua cggugagcg	19
<210> SEQ ID NO 103 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 103	19
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 103 agcaucuacg gugagcgcu </pre> <pre><210> SEQ ID NO 104 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	19
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 103 agcaucuacg gugagcgcu <210> SEQ ID NO 104 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	19
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 103 agcaucuacg gugagcgcu </pre> <pre><210> SEQ ID NO 104 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre> <400> SEQUENCE: 104	
<pre><211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 103 agcaucuacg gugagcgcu <210> SEQ ID NO 104 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 104 caucuacggu gagcgcuuc <210> SEQ ID NO 105 <211> LENGTH: 19 <222> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	

<210> SEQ ID NO 106 <211> LENGTH: 19	
<211> HANGIH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 106	
uacggugage geuuceceg	19
<210> SEQ ID NO 107	
<211> LENGTH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 107	
7991190 7999 1119 7999011	10
eggugagege uuceeegau	19
<210> SEQ ID NO 108	
<211> LENGTH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 108	
AUG. 2224011 2224012	19
gugagegeuu eecegauga	19
<210> SEQ ID NO 109	
<211> LENGTH: 19	
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 109	
gagegeuuee eegaugaga	19
<210> SEQ ID NO 110	
<211> LENGTH: 19	
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 110	
gcgcuucccc gaugagaac	19
<210> SEQ ID NO 111	
<211> LENGTH: 19	
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 111	
gcuuccccga ugagaacuu	19
<210> SEQ ID NO 112	
<211> LENGTH: 19	
<212> TYPE: RNA	

<220>	ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 112	
uuccc	gaug agaacuuca	19
<211> <212> <213> <220>	SEQ ID NO 113 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 113	
ccccga	ugag aacuucaaa	19
<211> <212> <213> <220> <223>	SEQ ID NO 114 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
	SEQUENCE: 114	19
eegaug	agaa cuucaaacu	19
<211> <212> <213> <220> <223>	SEQ ID NO 115 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 115	
	gaacu ucaaacuga	19
<211> <212> <213> <220>	SEQ ID NO 116 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 116	
ugagaa	acuuc aaacugaag	19
<211> <212> <213> <220> <223>	SEQ ID NO 117 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 117	
	uucaa acugaagca	19
<210><211><211><212><213><220>	SEQ ID NO 118 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 118	
aacuucaaac ugaagcacu	19
<210> SEQ ID NO 119 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 119	
cuucaaacug aagcacuac	19
<210> SEQ ID NO 120 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 120	
ucaaacugaa gcacuacgg	19
<210> SEQ ID NO 121 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 121	
acgggcaagg ccaaguggg	19
<210> SEQ ID NO 122 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 122	
cgggcaaggc caaguggga	19
<pre><210> SEQ ID NO 123 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 123</pre>	
gggcaaggcc aagugggau	19
<210> SEQ ID NO 124 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 124	
ggcaaggcca agugggaug	19

-010-	CEO ID NO 10E	
	SEQ ID NO 125	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 125	
gcaage	ccaa gugggaugc	19
<210>	SEQ ID NO 126	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
	OTHER INFORMATION: Synthetic	
\2252	OTHER INFORMATION. Synthetic	
-1005	CEOUENCE 126	
<400>	SEQUENCE: 126	
		10
caaggo	caag ugggaugcc	19
	SEQ ID NO 127	
	LENGTH: 19	
<212>	TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 127	
aaggco	aagu gggaugccu	19
<210>	SEQ ID NO 128	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
	OTHER INFORMATION: Synthetic	
	•	
<400>	SEQUENCE: 128	
aggcca	agug ggaugccug	19
<210>	SEQ ID NO 129	
<211>	LENGTH: 19	
<212>	TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
	FEATURE:	
	OTHER INFORMATION: Synthetic	
	4	
<400>	SEQUENCE: 129	
	~	
ggccaa	gugg gaugeeugg	19
-		
<210>	SEQ ID NO 130	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 130	
	-	
qccaac	juggg augccugga	19
J		
<210>	SEQ ID NO 131	
	SEQ ID NO 131 LENGTH: 19	

	ORGANISM: Artificial Sequence FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 131	
ccaagı	1ggga ugccuggaa	19
<211>	SEQ ID NO 132 LENGTH: 19	
	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 132	
caagug	gggau gccuggaau	19
	SEQ ID NO 133 LENGTH: 19	
<213>	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 133	
aagugg	ggaug ccuggaaug	19
	SEQ ID NO 134 LENGTH: 19	
<212>	TYPE: RNA	
<220>	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
	SEQUENCE: 134	19
aguggg	gaugc cuggaauga	19
	SEQ ID NO 135	
	LENGTH: 19 TYPE: RNA	
	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 135	
guggga	augee uggaaugag	19
<210>	SEQ ID NO 136	
	LENGTH: 19	
	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 136	
ugggau	ıgccu ggaaugagc	19
	SEQ ID NO 137	
	LENGTH: 19 TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 137	
gggaugccug gaaugagcu	19
<210> SEQ ID NO 138 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 138	
ggaugccugg aaugagcug	19
<210> SEQ ID NO 139 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 139	
gaugccugga augagcuga	19
<210> SEQ ID NO 140 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 140	
	1.0
augecuggaa ugageugaa	19
augccuggaa ugagcugaa <210> SEQ ID NO 141 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 141 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 141 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 141 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 141	
<pre><210> SEQ ID NO 141 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 141 ugccuggaau gagcugaaa <210> SEQ ID NO 142 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<pre><210> SEQ ID NO 141 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 141 ugccuggaau gagcugaaa <210> SEQ ID NO 142 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<pre><210> SEQ ID NO 141 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 141 ugccuggaau gagcugaaa <210> SEQ ID NO 142 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre> <400> SEQUENCE: 142	19
<pre><210> SEQ ID NO 141 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 141 ugccuggaau gagcugaaa <210> SEQ ID NO 142 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 142 gccuggaaug agcugaaag <210> SEQ ID NO 143 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <221> GCCUGGAAUSM: Artificial Sequence <210> SEQ ID NO 143 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	19

2010. GEO ID NO 144	
<210> SEQ ID NO 144	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 144	
cuggaaugag cugaaaggg	19
<210> SEQ ID NO 145	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
2232 OTHER INFORMATION. Synthetic	
<400> SEQUENCE: 145	
Closs Bigomical. 115	
uggaaugagc ugaaaggga	19
aggaaagage agaaaggga	
2010- CEO TD NO 146	
<210> SEQ ID NO 146	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 146	
ggaaugagcu gaaagggac	19
<210> SEQ ID NO 147	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
•	
<400> SEQUENCE: 147	
gaaugagcug aaagggacu	19
<210> SEQ ID NO 148	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
4	
<400> SEQUENCE: 148	
~	
aaugagcuga aagggacuu	19
<210> SEQ ID NO 149	
<211> LENGTH: 19	
<211> LENGIR: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
-400> CECHENCE. 140	
<400> SEQUENCE: 149	
aligadilidaa agggagiliid	19
augagcugaa agggacuuc	19
<210	
<210> SEQ ID NO 150	
<211> LENGTH: 19	
<212> TYPE: RNA	

<220>	ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 150	
ugagcu	gaaa gggacuucc	19
<211> (212> (213> (213> (220>)	SEQ ID NO 151 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 151	
gagcug	aaag ggacuucca	19
<211> 3 <212> 3 <213> 4 <220> 3 <223> 4	SEQ ID NO 152 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 152	
	aagg gacuuccaa	19
<211> (212> (213> (213> (220> (223>	SEQ ID NO 153 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 153	
gcugaa	aggg acuuccaag	19
<211> (212> (213> (213> (220>)	SEQ ID NO 154 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 154	
cugaaa	ggga cuuccaagg	19
<211> (212> (213> (213> (220>)	SEQ ID NO 155 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 155	
ugaaag	ggac uuccaagga	19
<211> 3 <212> 3 <213> 3 <220> 3	SEQ ID NO 156 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 156	
gaaagggacu uccaaggaa	19
<210> SEQ ID NO 157 <211> LENGTH: 19	
<pre><212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 157	
aaagggacuu ccaaggaag	19
<210> SEQ ID NO 158 <211> LENGTH: 19	
<pre><212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 158	
aagggacuuc caaggaaga	19
<210> SEQ ID NO 159 <211> LENGTH: 19	
<212> TYPE: RNA	
<pre><213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<pre><223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 159	
agggacuucc aaggaagau	19
<210> SEQ ID NO 160	
<211> LENGTH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 160	
gggacuucca aggaagaug	19
<210> SEQ ID NO 161	
<211> LENGTH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 161	
ggacuuccaa ggaagaugc	19
<210> SEQ ID NO 162 <211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE:	
<pre><220> FEATORE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 162	
gacuuccaag gaagaugcc	19

<210> SEQ ID NO 163	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 163	
	19
acuuccaagg aagaugcca	19
<210> SEQ ID NO 164	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
AAAA CEAHENCE, 164	
<400> SEQUENCE: 164	
cuuccaagga agaugccau	19
<210> SEQ ID NO 165	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 165	
uuccaaggaa gaugccaug	19
<210> SEQ ID NO 166	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 166	
uccaaggaag augccauga	19
<210> SEQ ID NO 167	
<211> LENGTH: 19	
<211> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 167	
4422442242 11444211422	19
ccaaggaaga ugccaugaa	19
<210> SEQ ID NO 168	
<211> LENGTH: 19	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 168	
TOOL SERVEROLL TOO	
caaggaagau gccaugaaa	19
<210> SEQ ID NO 169	
<211> LENGTH: 19 <212> TYPE: RNA	
NATES TIPE: NIVE	

<220>	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
	SEQUENCE: 169	
aaggaa	gaug ccaugaaag	19
<211>	SEQ ID NO 170 LENGTH: 19	
<213>	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 170	
aggaag	gauge caugaaage	19
<211>	SEQ ID NO 171 LENGTH: 19	
<213>	TYPE: RNA ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 171	
ggaaga	ugcc augaaagcu	19
	SEQ ID NO 172 LENGTH: 19	
<212>	TYPE: RNA	
<220>	ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
	SEQUENCE: 172	
	igcca ugaaagcuu	19
	SEQ ID NO 173 LENGTH: 19	
<212>	TYPE: RNA	
	ORGANISM: Artificial Sequence FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 173	
aagaug	gccau gaaagcuua	19
	SEQ ID NO 174	
	LENGTH: 19 TYPE: RNA	
	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 174	
agaugccaug aaagcuuac		19
	SEQ ID NO 175	
	LENGTH: 19 TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 175	
gaugccauga aagcuuaca	19
<210> SEQ ID NO 176 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 176	
augccaugaa agcuuacau	19
<210> SEQ ID NO 177 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 177	
ugccaugaaa gcuuacauc	19
<210> SEQ ID NO 178 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 178	
Troop bleediel. Ito	
######################################	10
gccaugaaag cuuacauca	19
<pre>gccaugaaag cuuacauca <210> SEQ ID NO 179 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	19
<210> SEQ ID NO 179 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 179 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 179 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 179	
<pre><210> SEQ ID NO 179 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 179 ccaugaaagc uuacaucaa <210> SEQ ID NO 180 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<pre><210> SEQ ID NO 179 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 179 ccaugaaagc uuacaucaa <210> SEQ ID NO 180 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<pre><210> SEQ ID NO 179 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 179 ccaugaaagc uuacaucaa <210> SEQ ID NO 180 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 180</pre>	19
<pre><210> SEQ ID NO 179 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 179 ccaugaaagc uuacaucaa <210> SEQ ID NO 180 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 180 caugaaagcu uacaucaac <210> SEQ ID NO 181 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <210> SEQ ID NO 181 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <210> SEQ ID NO 181 <211> CAUGAGANISM: Artificial Sequence <220> FEATURE:</pre>	19

<210> SEQ ID NO 182 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 182	
ugaaagcuua caucaacaa	19
<210> SEQ ID NO 183 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 183	
gaaagcuuac aucaacaaa	19
<210> SEQ ID NO 184 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 184	
aaagcuuaca ucaacaaag	19
<210> SEQ ID NO 185 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 185 aagcuuacau caacaaagu	19
<210> SEQ ID NO 186 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 186	
agcuuacauc aacaaagua	19
<210> SEQ ID NO 187 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 187	
gcuuacauca acaaaguag	19
<210> SEQ ID NO 188 <211> LENGTH: 19 <212> TYPE: RNA	

<pre></pre> <pre><213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 188	
cuuacaucaa caaaguaga	19
<210> SEQ ID NO 189	
<211> LENGTH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 189	
uuacaucaac aaaguagaa	19
<210> SEQ ID NO 190	
<211> LENGTH: 19	
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 190	
uacaucaaca aaguagaag	19
<210> SEQ ID NO 191	
<211> LENGTH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 191	
acaucaacaa aguagaaga	19
<210> SEQ ID NO 192	
<211> LENGTH: 19	
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 192	
caucaacaaa guagaagag	19
<210> SEQ ID NO 193	
<211> LENGTH: 19	
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 193	
aucaacaaag uagaagagc	19
<210> SEQ ID NO 194	
<211> LENGTH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	

<400> SEQUENCE: 194	
ucaacaaagu agaagagcu	19
<210> SEQ ID NO 195 <211> LENGTH: 19	
<pre><212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 195	
caacaaagua gaagagcua	19
<210> SEQ ID NO 196 <211> LENGTH: 19	
<pre><212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 196	
aacaaaguag aagagcuaa	19
<210> SEQ ID NO 197 <211> LENGTH: 19	
<211> HENGIN: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 197	
acaaaguaga agagcuaaa	19
<210> SEQ ID NO 198 <211> LENGTH: 19	
<211> DENGIH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 198	
caaaguagaa gagcuaaag	19
<210> SEQ ID NO 199 <211> LENGTH: 19	
<211> LENGIH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 199	
aaaguagaag agcuaaaga	19
<210> SEQ ID NO 200 <211> LENGTH: 19	
<211> DENGIH: 19 <212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 200	
aaguagaaga gcuaaagaa	19

<211> <212> <213>	SEQ ID NO 201 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 201	
aguaga	aagag cuaaagaaa	19
<211> <212> <213> <220>	SEQ ID NO 202 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 202	
guagaa	agagc uaaagaaaa	19
<211> <212> <213> <220>	SEQ ID NO 203 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 203	
uagaag	gagcu aaagaaaaa	19
<211> <212> <213> <220> <223>	SEQ ID NO 204 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 204	
agaaga	agcua aagaaaaaa	19
<211> <212> <213> <220>	SEQ ID NO 205 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 205	
gaagaq	gcuaa agaaaaaau	19
<211> <212> <213> <220> <223>	SEQ ID NO 206 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
	SEQUENCE: 206	19
3~3	J	
<211>	SEQ ID NO 207 LENGTH: 19 TYPE: RNA	

<220> FE	GANISM: Artificial Sequence ATURE: HER INFORMATION: Synthetic	
<400> SE	QUENCE: 207	
agagcuaa	ag aaaaaauac	19
<211> LEI <212> TYI <213> ORG <220> FEI	PE: RNA GANISM: Artificial Sequence	
<400> SE	QUENCE: 208	
gagcuaaa	ga aaaaauacg	19
<211> LEI <212> TYI <213> ORG <220> FEZ <223> OTI	PE: RNA GANISM: Artificial Sequence	
agcuaaag	aa aaaauacgg	19
<211> LEI <212> TYI <213> ORO <220> FEI <223> OTI	PE: RNA GANISM: Artificial Sequence	
	aa aaauacggg	19
<211> LEI <212> TYI <213> ORG <220> FEI	PE: RNA GANISM: Artificial Sequence	
<400> SE	QUENCE: 211	
auccucau	aa aggccaaga	19
<211> LEI <212> TYI <213> ORG <220> FE	PE: RNA GANISM: Artificial Sequence	
<400> SE	QUENCE: 212	
agauccuc	au aaaggccaa	19
<211> LEI <212> TYI <213> ORG <220> FEI	PE: RNA GANISM: Artificial Sequence	

<400> SEQUENCE: 213	
agagauccuc auaaaggcc	19
<210> SEQ ID NO 214 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 214	
agagagaucc ucauaaagg	19
<210> SEQ ID NO 215 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 215	
ucagagagau ccucauaaa	19
<210> SEQ ID NO 216 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 216	
aaucagagag auccucaua	19
<210> SEQ ID NO 217 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 217	
aaaaucagag agauccuca	19
<210> SEQ ID NO 218	
<211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 218 gaaaaaucag agagauccu <210> SEQ ID NO 219 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 218 gaaaaaucag agagauccu <210> SEQ ID NO 219 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19

<211> <212> <213>	SEQ ID NO 220 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
	SEQUENCE: 220	
gcaaga	aaaaa ucagagaga	19
<211> <212> <213> <220>	SEQ ID NO 221 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 221	
acgcaa	agaaa aaucagaga	19
<211> <212> <213> <220>	SEQ ID NO 222 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 222	
cgacgo	caaga aaaaucaga	19
<211> <212> <213> <220> <223>	SEQ ID NO 223 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 223	
cucgad	cgcaa gaaaaauca	19
<211> <212> <213> <220>	SEQ ID NO 224 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 224	
aacuc	gacgc aagaaaaau	19
<211> <212> <213> <220> <223>	SEQ ID NO 225 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
	SEQUENCE: 225	19
<210> <211>	SEQ ID NO 226 LENGTH: 19 TYPE: RNA	

<213>	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
	OTHER INFORMATION: Synthetic	
12237	OTHER INFORMATION. Byttenedic	
<400>	SEQUENCE: 226	
ggaaaa	cucg acgcaagaa	19
010	and the Manager	
	SEQ ID NO 227	
<211>	LENGTH: 19	
<212>	TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
	FEATURE:	
	OTHER INFORMATION: Synthetic	
12207	orner information. Dynamical	
	anarimian aan	
<400>	SEQUENCE: 227	
ccggaa	laacu cgacgcaag	19
-2105	SEQ ID NO 228	
	LENGTH: 19	
<212>	TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
	FEATURE:	
	OTHER INFORMATION: Synthetic	
	Tille Intolling ton. Dynamette	
<400>	SEQUENCE: 228	
uaccq	gaaaa cucgacgca	19
	, 3 3	
.010.	CEO TO NO DOD	
	SEQ ID NO 229	
<211>	LENGTH: 19	
<212>	TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
	FEATURE:	
\ 2232	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 229	
cuuaco	ggaa aacucgacg	19
2010s	CEO ID NO 220	
	SEQ ID NO 230	
<211>	LENGTH: 19	
<212>	TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
	OTHER INFORMATION: Synthetic	
	ornan announced by	
-100-	CEOUENCE 220	
~ 4 00>	SEQUENCE: 230	
gucuua	iccgg aaaacucga	19
<210>	SEQ ID NO 231	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
-400-	CECHENCE, 221	
~±00>	SEQUENCE: 231	
aggucı	uacc ggaaaacuc	19
<210>	SEQ ID NO 232	
	LENGTH: 19	
	TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
	OTHER INFORMATION: Synthetic	
	-2	

<400> SEQUENCE: 232	
aaaggucuua ccggaaaac	19
<210> SEQ ID NO 233 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 233	
cgaaaggucu uaccggaaa	19
<210> SEQ ID NO 234 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 234	
accgaaaggu cuuaccgga	19
<210> SEQ ID NO 235 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 235	
guaccgaaag gucuuaccg	19
guaccgaaag gucuuaccg <210> SEQ ID NO 236 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 236 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 236 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 236 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 236	
<pre><210> SEQ ID NO 236 <2112 LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 236 aaguaccgaa aggucuuac <210> SEQ ID NO 237 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<210> SEQ ID NO 236 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 236 aaguaccgaa aggucuuac <210> SEQ ID NO 237 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<pre><210> SEQ ID NO 236 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 236 aaguaccgaa aggucuuac <210> SEQ ID NO 237 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre> <pre><200> FEATURE:</pre> <pre><2210> ORGANISM: Artificial Sequence</pre> <220> FEATURE: <pre><223> OTHER INFORMATION: Synthetic</pre> <pre><400> SEQUENCE: 237</pre>	19
<pre><210> SEQ ID NO 236 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 236 aaguaccgaa aggucuuac <210> SEQ ID NO 237 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 237 Cgaaguaccg aaaggucuu <210> SEQ ID NO 238 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <221> OTHER INFORMATION: Synthetic</pre>	19

<211>	SEQ ID NO 239 LENGTH: 19 TYPE: RNA	
<220>	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
	SEQUENCE: 239 gaagu accgaaagg	19
555	,,	-
<211> <212>	SEQ ID NO 240 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence	
<220>	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 240	
ugugga	acgaa guaccgaaa	19
<211>	SEQ ID NO 241 LENGTH: 19 TYPE: RNA	
<213> <220>	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic SEQUENCE: 241	
	ggacg aaguaccga	19
55	3333	
<211>	SEQ ID NO 242 LENGTH: 19 TYPE: RNA	
<213>	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
	SEQUENCE: 242	10
uguuug	gugga cgaaguacc	19
	SEQ ID NO 243 LENGTH: 19	
<213>	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 243	
ugugut	uugug gacgaagua	19
<211>	SEQ ID NO 244 LENGTH: 19 TYPE: RNA	
<213> <220>	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic SEQUENCE: 244	
	guuug uggacgaag	19
<210>	SEQ ID NO 245	
<211>	TYPE: RNA	

<220>	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 245	
gaguug	guguu uguggacga	19
	SEQ ID NO 246 LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 246	
aggagı	lugug uuuguggac	19
	SEQ ID NO 247	
	LENGTH: 19	
	TYPE: RNA ORGANISM: Artificial Sequence	
<220>	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 247	
ggagga	aguug uguuugugg	19
<210>	SEQ ID NO 248	
	LENGTH: 19	
	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 248	
gcggag	ggagu uguguuugu	19
<210>	SEQ ID NO 249	
<211>	LENGTH: 19	
	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 249	
gcgcgg	gagga guuguguuu	19
-010-	CEO ID NO 250	
	SEQ ID NO 250 LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 250	
uugege	eggag gaguugugu	19
<210>	SEQ ID NO 251	
<211>	LENGTH: 19	
	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 251	
aguugcgcgg aggaguugu	19
<210> SEQ ID NO 252 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 252	
aaaguugcgc ggaggaguu	19
<210> SEQ ID NO 253 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 253	
aaaaaguugc gcggaggag	19
<210> SEQ ID NO 254 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 254	
cgaaaaaguu gcgcggagg	19
cgaaaaaguu gcgcggagg <210> SEQ ID NO 255 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 255 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 255 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 255 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 255	
<pre><210> SEQ ID NO 255 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 255 cgcgaaaaag uugcgcgga </pre> <pre><210> SEQ ID NO 256 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>	
<210> SEQ ID NO 255 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 255 cgcgaaaaag uugcgcgga <210> SEQ ID NO 256 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<210> SEQ ID NO 255 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 255 cgcgaaaaag uugcgcgga <210> SEQ ID NO 256 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<pre><210> SEQ ID NO 255 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 255 cgcgaaaaag uugcgcgga <210> SEQ ID NO 256 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 256 accgcgaaaa aguugcgcg </pre> <pre><210> SEQ ID NO 257 <211 LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <210> SEQ ID NO 257 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: </pre>	19

<211> <212> <213> <220>	SEQ ID NO 258 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
	SEQUENCE: 258	
aacaac	ccgcg aaaaaguug	19
<211> <212> <213> <220>	SEQ ID NO 259 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 259	
guaaca	aaccg cgaaaaagu	19
<211> <212> <213> <220>	SEQ ID NO 260 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 260	
aaguaa	acaac cgcgaaaaa	19
<211> <212> <213> <220> <223>	SEQ ID NO 261 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 261	
ucaagı	laaca accgcgaaa	19
<211> <212> <213> <220>	SEQ ID NO 262 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 262	
agucaa	aguaa caaccgcga	19
<211> <212> <213> <220> <223>	SEQ ID NO 263 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
	SEQUENCE: 263	19
<210> <211>	SEQ ID NO 264 LENGTH: 19 TYPE: RNA	

	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 264	
	_	
caccac	gucaa guaacaacc	19
ogcous	Jacaa gaaacaacc	10
-010-	CEO ID NO OCE	
	SEQ ID NO 265	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 265	
queqee	caguc aaguaacaa	19
<210×	SEQ ID NO 266	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 266	
acque	gccag ucaaguaac	19
	, ,	
<210>	SEQ ID NO 267	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 267	
uuacgı	ıcgcc agucaagua	19
<210>	SEQ ID NO 268	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<423>	OTHER INFORMATION: Synthetic	
100	GROUPINGS 0.60	
<400>	SEQUENCE: 268	
gauua	egueg eeagueaag	19
<210>	SEQ ID NO 269	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
	OTHER INFORMATION: Synthetic	
~~~ <i>~</i>	ornan information: synthetic	
-100-	CECHENCE. 260	
<400>	SEQUENCE: 269	
uggauı	lacgu cgccaguca	19
uggauı	ıacgu cgccaguca	19
uggauı	acgu cgccaguca	19
	acgu cgccaguca SEQ ID NO 270	19
<210>		19
<210> <211>	SEQ ID NO 270	19
<210> <211> <212>	SEQ ID NO 270 LENGTH: 19 TYPE: RNA	19
<210><211><211><212><213>	SEQ ID NO 270 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence	19
<210><211><211><212><213><223>	SEQ ID NO 270 LENGTH: 19 TYPE: RNA	19

<400> SEQUENCE: 270	
cguggauuac gucgccagu	19
<pre>&lt;210&gt; SEQ ID NO 271 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 271	
aucguggauu acgucgcca	19
<pre>&lt;210&gt; SEQ ID NO 272 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<pre>&lt;400&gt; SEQUENCE: 272 agaucgugga uuacgucgc</pre>	19
<210> SEQ ID NO 273 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 273	
agagaucgug gauuacguc	19
<210> SEQ ID NO 274 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 274	
aaagagaucg uggauuacg	19
<210> SEQ ID NO 275 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 275	
aaaaagagau cguggauua	19
<pre>&lt;210&gt; SEQ ID NO 276 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 276	
ggaaaaagag aucguggau	19

~210×	SEQ ID NO 277	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 277	
acgga	aaaag agaucgugg	19
<210×	SEQ ID NO 278	
	LENGTH: 19	
	TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
100	GRAVENCE AZA	
<400>	SEQUENCE: 278	
nasca.	72222 adadanddi	19
ugacg	gaaaa agagaucgu	19
<210>	SEQ ID NO 279	
<211>	LENGTH: 19	
<212>	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400×	SEQUENCE: 279	
\ <del>1</del> 002	SEQUENCE. 279	
gauga	cqqaa aaagagauc	19
-		
	SEQ ID NO 280	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 280	
acgau	gacgg aaaaagaga	19
<210>	SEQ ID NO 281	
	LENGTH: 19	
	TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
100	GRAVENCE AND	
<400>	SEQUENCE: 281	
agacg	augac ggaaaaaga	19
aga05		
<210>	SEQ ID NO 282	
	LENGTH: 19	
	TYPE: RNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<b>~</b> ∠∠3>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 282	
aaaga	cgaug acggaaaaa	19
-210-	GEO ID NO 283	
	SEQ ID NO 283 LENGTH: 19	

	ORGANISM: Artificial Sequence FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 283	
ggaaag	gacga ugacggaaa	19
<211>	SEQ ID NO 284 LENGTH: 19	
	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 284	
acggaa	aagac gaugacgga	19
	SEQ ID NO 285 LENGTH: 19	
<213>	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 285	
gcacgo	gaaag acgaugacg	19
	SEQ ID NO 286 LENGTH: 19	
<212>	TYPE: RNA	
	ORGANISM: Artificial Sequence FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 286	
gagcac	eggaa agaegauga	19
	SEQ ID NO 287	
	LENGTH: 19 TYPE: RNA	
	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 287	
uggago	cacgg aaagacgau	19
<210>	SEQ ID NO 288	
	LENGTH: 19	
	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 288	
uuugga	agcac ggaaagacg	19
<210>	SEQ ID NO 289	
<211>	LENGTH: 19 TYPE: RNA	
<213>	ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 289	
guuuuggagc acggaaaga	19
<210> SEQ ID NO 290 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 290	
uuguuuugga gcacggaaa	19
<210> SEQ ID NO 291 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 291	
uguuguuuug gagcacgga	19
<210> SEQ ID NO 292 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 292	
guuguuguuu uggagcacg	19
guuguuguuu uggagcacg  <210> SEQ ID NO 293  <211> LENGTH: 19  <212> TYPE: RNA  <213> ORGANISM: Artificial Sequence <220> FEATURE:  <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 293 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 293 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<pre>&lt;210&gt; SEQ ID NO 293 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 293  ccguuguugu uuuggagca  &lt;210&gt; SEQ ID NO 294 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<pre>&lt;210&gt; SEQ ID NO 293 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 293  ccguuguugu uuuggagca  &lt;210&gt; SEQ ID NO 294 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre> <pre>&lt;400&gt; SEQUENCE: 294</pre>	19
<pre>&lt;210&gt; SEQ ID NO 293 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 293  ccguuguugu uuuggagca  &lt;210&gt; SEQ ID NO 294 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<pre>&lt;210&gt; SEQ ID NO 293 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 293  ccguuguugu uuuggagca  &lt;210&gt; SEQ ID NO 294 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 294  cgccguuguu guuuuggag  &lt;210&gt; SEQ UD NO 295 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;313&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;400&gt; SEQUENCE: 294  cgccguuguu guuuuggag  &lt;210&gt; SEQ ID NO 295 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	19
<pre>&lt;210&gt; SEQ ID NO 293 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 293  ccguuguugu uuuggagca  &lt;210&gt; SEQ ID NO 294 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 294  cgccguuguu guuuuggag  &lt;210&gt; SEQ ID NO 295 &lt;211&gt; LENGTH: 19 &lt;222&gt; TYPE: RNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;220&gt; FEATURE: SEQUENCE: 294</pre>	19

<211> <212> <213> <220>	SEQ ID NO 296 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 296		
ccgcc	gccgu uguuguuuu	19	
<211> <212> <213> <220>	SEQ ID NO 297 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 297		
ucccg	ccgcc guuguuguu	19	
<211> <212> <213> <220>	SEQ ID NO 298 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 298		
cuucco	egeeg eeguuguug	19	
<211> <212> <213> <220> <223>	SEQ ID NO 299 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 299		
aacuud	ccegc cgccguugu	19	
<211> <212> <213> <220>	SEQ ID NO 300 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 300		
ugaacı	uuccc gccgccguu	19	
<211> <212> <213> <220> <223>	SEQ ID NO 301 LENGTH: 19 TYPE: RNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
	SEQUENCE: 301 auagu gaugaagua	19	
<211>	SEQ ID NO 302 LENGTH: 19 TYPE: RNA		

<220>	ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
	SEQUENCE: 302	
	acauc cauuauaag	19
	-	
<211>	SEQ ID NO 303 LENGTH: 19 TYPE: RNA	
<213>	ORGANISM: Artificial Sequence FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 303	
guacga	acaac cgggagaua	19
<211>	SEQ ID NO 304 LENGTH: 19	
<213>	TYPE: RNA ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
	SEQUENCE: 304	
agauag	gugau gaaguacau	19
<211>	SEQ ID NO 305 LENGTH: 19	
<213>	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 305	
ugaaga	acucu geucaguuu	19
	SEQ ID NO 306 LENGTH: 19	
<212>	TYPE: RNA ORGANISM: Artificial Sequence	
<220>	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 306	
gcaugo	cggcc ucuguuuga	19
	SEQ ID NO 307 LENGTH: 19	
	TYPE: RNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 307	
ugcggo	ccucu guuugauuu	19
	SEQ ID NO 308	
<212>	LENGTH: 19 TYPE: RNA	
<220>	ORGANISM: Artificial Sequence FEATURE:	
<223>	OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 308	
gagauaguga ugaaguaca	19
<210> SEQ ID NO 309 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 309	
ggagauagug augaaguac	19
<210> SEQ ID NO 310 <211> LENGTH: 19 <212> TYPE: RNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 310	
gaagacucug cucaguuug	19
<210> SEQ ID NO 311 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 311	
ggaaccagcg ccagagtga	19
	19
ggaaccagcg ccagagtga  <210> SEQ ID NO 312  <211> LENGTH: 19  <212> TYPE: DNA  <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
ggaaccagcg ccagagtga  <210> SEQ ID NO 312  <211> LENGTH: 19  <212> TYPE: DNA  <213> ORGANISM: Artificial Sequence  <220> FEATURE:  <223> OTHER INFORMATION: Synthetic	19
ggaaccagcg ccagagtga  <210> SEQ ID NO 312 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 312	
ggaaccagcg ccagagtga  <210> SEQ ID NO 312 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 312  gagcgagatt gcaggcata  <210> SEQ ID NO 313 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
ggaaccagcg ccagagtga  <210> SEQ ID NO 312 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic  <400> SEQUENCE: 312 gagcgagatt gcaggcata  <210> SEQ ID NO 313 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
ggaaccagcg ccagagtga  <210> SEQ ID NO 312 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic  <400> SEQUENCE: 312  gagcgagatt gcaggcata  <210> SEQ ID NO 313 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
ggaaccagcg ccagagtga  <210> SEQ ID NO 312 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 312  gagcgagatt gcaggcata  <210> SEQ ID NO 313 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQ ID NO 313 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 313  gttagtatct gatgacttg  <210> SEQ ID NO 314 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <313 ORGANISM: Artificial Sequence <220> FEATURE:	19

<211> <212> <213> <220>	SEQ ID NO 315 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 315	
ggaaat	ggaa ccactaaga	19
<211> <212> <213> <220>	SEQ ID NO 316 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 316	
caacta	icaet ttecaatge	19
<211> <212> <213> <220>	SEQ ID NO 317 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 317	
ccacca	agat ttcatgata	19
<211> <212> <213> <220> <223>	SEQ ID NO 318 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 318	
	gaact ccaacaaga	19
<211> <212> <213> <220>	SEQ ID NO 319 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 319	
aaacgg	agct acagattat	19
<211> <212> <213> <220> <223>	SEQ ID NO 320 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 320	
	agca ttottgtaa	19
<211>	SEQ ID NO 321 LENGTH: 19 TYPE: DNA	

<213> ORGANISM: Artificial Sequence	
<pre>&lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 321	
gaagttacct tgagcaatc	19
010. GEO TD NO 000	
<210> SEQ ID NO 322 <211> LENGTH: 19	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 322	
ggacttggcc gatccagaa	19
<210> SEQ ID NO 323	
<211> LENGTH: 19 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<pre>&lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 323	
	10
gcacttggat cgagatgag	19
<210> SEQ ID NO 324	
<211> LENGTH: 19	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<pre>&lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 324	
caaagaccaa ttcgcgtta	19
-010, CEO ID NO 205	
<210> SEQ ID NO 325 <211> LENGTH: 19	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 325	
ccgaatcaat cgcatcttc	19
<210> SEQ ID NO 326 <211> LENGTH: 19	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 326	
gacatgatcc tgcagttca	19
<210> SEQ ID NO 327	
<211> LENGTH: 19 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE:	
<pre>&lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	

<400> SEQUENCE: 327	
gagogaatog toaccactt	19
<210> SEQ ID NO 328 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 328	
cctccgagct ggcgtctac	19
<210> SEQ ID NO 329 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 329	
tcacatggtt aacctctaa	19
<210> SEQ ID NO 330 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 330	
gatgagggag gggataatg	10
gatgagggac gccataatc	19
<pre>&lt;210&gt; SEQ ID NO 331 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	19
<210> SEQ ID NO 331 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 331 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 331 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 331	
<pre>&lt;210&gt; SEQ ID NO 331 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 331 cctctaacta caaatctta  &lt;210&gt; SEQ ID NO 332 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE:</pre>	
<pre>&lt;210&gt; SEQ ID NO 331 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 331 cctctaacta caaatctta  &lt;210&gt; SEQ ID NO 332 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<pre>&lt;210&gt; SEQ ID NO 331 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 331 cctctaacta caaatctta  &lt;210&gt; SEQ ID NO 332 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre> <pre>&lt;400&gt; SEQUENCE: 332</pre>	19
<pre>&lt;210&gt; SEQ ID NO 331 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 331  cctctaacta caaatctta  &lt;210&gt; SEQ ID NO 332 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 332  ggaaggtgct atccaaaat  &lt;210&gt; SEQ ID NO 333 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;210&gt; SEQ ID NO 333 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;213&gt; ORGANISM: Artificial Sequence &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE:</pre>	19

<211><212><213><223><223>	SEQ ID NO 334  LENGTH: 19  TYPE: DNA  ORGANISM: Artificial Sequence  FEATURE:  OTHER INFORMATION: Synthetic  SEQUENCE: 334	
	ggag tagacetta	19
<211> <212> <213> <220>	SEQ ID NO 335 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 335	
aggaat	cagt gttgtagta	19
<211> <212> <213> <220>	SEQ ID NO 336 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 336	
gaagag	gagt agaccttac	19
<211> <212> <213> <220>	SEQ ID NO 337 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 337	
gaaagt	caag cctggtatt	19
<211> <212> <213> <220>	SEQ ID NO 338 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 338	
aaagto	aagc ctggtatta	19
<211> <212> <213> <220> <223>	SEQ ID NO 339  LENGTH: 19  TYPE: DNA  ORGANISM: Artificial Sequence  FEATURE:  OTHER INFORMATION: Synthetic  SEQUENCE: 339	
	aacg tgaatgatc	19
<211>	SEQ ID NO 340 LENGTH: 19 TYPE: DNA	

<220> 1	ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400> 3	SEQUENCE: 340	
caagcc	tggt attacgttt	19
<211> 1 <212> 2 <213> 3 <220> 1	SEQ ID NO 341 LENGTH: 19 TYPE: DNA DRGANISM: Artificial Sequence FEATURE: DTHER INFORMATION: Synthetic	
<400> 3	SEQUENCE: 341	
ggaaca	agat ctgtcaatt	19
<211> 1 <212> 5 <213> 6 <220> 1 <223> 6	SEQ ID NO 342 LENGTH: 19 TYPE: DNA DRGANISM: Artificial Sequence FEATURE: DTHER INFORMATION: Synthetic SEQUENCE: 342	
gcaatg	aacg tgaacgaaa	19
<211> 1 <212> 5 <213> 6 <220> 1 <223> 6	SEQ ID NO 343 LENGTH: 19 TYPE: DNA DRGANISM: Artificial Sequence FEATURE: DTHER INFORMATION: Synthetic SEQUENCE: 343	
	acgt gaacgaaat	19
<211> 1 <212> 1 <213> ( <220> 1	SEQ ID NO 344 LENGTH: 19 IYPE: DNA ORGANISM: Artificial Sequence FEATURE: DTHER INFORMATION: Synthetic	
<400> 3	SEQUENCE: 344	
ggacag	gage ggtateaea	19
<211> 1 <212> 1 <213> ( <220> 1	SEQ ID NO 345 LENGTH: 19 TYPE: DNA DRGANISM: Artificial Sequence FEATURE: DTHER INFORMATION: Synthetic	
	SEQUENCE: 345	
agacag	agct tgagaataa	19
<211> 1 <212> 2 <213> 0 <220> 1	SEQ ID NO 346 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 346	
gagaagatct ttatgcaaa	19
<pre>&lt;210&gt; SEQ ID NO 347 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 347	
gaagagaaat cagcagata	19
<210> SEQ ID NO 348 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 348	
gcaagtaact caactaaca	19
<210> SEQ ID NO 349 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 349	
	19
gagctaatct gccacattg <210> SEQ ID NO 350	19
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 350	
gcagatgagt tactagaaa	19
<pre>&lt;210&gt; SEQ ID NO 351 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 351</pre>	
caacttaatt gtccagaaa	19
<pre>&lt;210&gt; SEQ ID NO 352 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 352	
caacacagga ttctgataa	19

<211> <212> <213> <220>	SEQ ID NO 353 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 353	
agatto	ytgcc taagtctct	19
<211> <212> <213> <220>	SEQ ID NO 354 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 354	
atgaaq	gatet ggaggtgaa	19
<211> <212> <213> <220>	SEQ ID NO 355 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 355	
tttgag	gactt cttgcctaa	19
<211> <212> <213> <220> <223>	SEQ ID NO 356  LENGTH: 19  TYPE: DNA  ORGANISM: Artificial Sequence FEATURE:  OTHER INFORMATION: Synthetic  SEQUENCE: 356	
agatca	accct ccttaaata	19
<211> <212> <213> <220>	SEQ ID NO 357 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 357	
caacg	gattt ggtcgtatt	19
<211> <212> <213> <220> <223>	SEQ ID NO 358 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
	SEQUENCE: 358	19
<210> <211>	SEQ ID NO 359 LENGTH: 19 TYPE: DNA	

<220>	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 359	
gaccto	caact acatggttt	19
<211>	SEQ ID NO 360 LENGTH: 19	
	TYPE: DNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 360	
tggttt	tacat gttccaata	19
<211>	SEQ ID NO 361 LENGTH: 19	
<213>	TYPE: DNA ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 361	
gaagaa	aatcg atgttgttt	19
	SEQ ID NO 362 LENGTH: 19	
<212>	TYPE: DNA	
<220>	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 362	
acacaa	aactt gaacagcta	19
	SEQ ID NO 363	
	LENGTH: 19 TYPE: DNA	
	ORGANISM: Artificial Sequence FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 363	
ggaaga	aaatc gatgttgtt	19
<210>	SEQ ID NO 364	
<211>	LENGTH: 19	
	TYPE: DNA ORGANISM: Artificial Sequence	
	FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 364	
gaaacg	gacga gaacagttg	19
<210>	SEQ ID NO 365	
<211>	LENGTH: 19	
	TYPE: DNA ORGANISM: Artificial Sequence	
<220>	FEATURE: OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 365	
gcacatggat ggaggttct	19
<210> SEQ ID NO 366 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 366	
gcagagagag cagatttga	19
<210> SEQ ID NO 367 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 367	
gaggttctct ggatcaagt	19
<210> SEQ ID NO 368 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 368	
gagcagattt gaagcaact	19
<pre>gagcagattt gaagcaact  &lt;210&gt; SEQ ID NO 369 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	19
<210> SEQ ID NO 369 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 369 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 369 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 369	
<210> SEQ ID NO 369 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 369  caaagacgat gacttcgaa  <210> SEQ ID NO 370 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
<pre>&lt;210&gt; SEQ ID NO 369 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 369  caaagacgat gacttcgaa  &lt;210&gt; SEQ ID NO 370 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<pre>&lt;210&gt; SEQ ID NO 369 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 369  caaagacgat gacttcgaa  &lt;210&gt; SEQ ID NO 370 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre> <400> SEQUENCE: 370	19
<pre>&lt;210&gt; SEQ ID NO 369 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 369  caaagacgat gacttcgaa  &lt;210&gt; SEQ ID NO 370 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 370 gatcagcatt tgcatggaa  &lt;210&gt; SEQ ID NO 371 &lt;211&gt; LENGTH: 19 &lt;222&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;221&gt; OTHER INFORMATION: Synthetic</pre>	19

<210>	SEQ ID NO 372	
<211>	LENGTH: 19	
<212>	TYPE: DNA	
<213>	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 372	
ggaag	etgat ccaccttga	19
	SEQ ID NO 373	
	LENGTH: 19	
	TYPE: DNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
-100>	CENTENCE. 272	
(400)	SEQUENCE: 373	
gcagaa	aatct aaggatata	19
geagae	acce aaggacaca	19
<210>	SEQ ID NO 374	
	LENGTH: 19	
	TYPE: DNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 374	
caacaa	aggat gaagtctat	19
	SEQ ID NO 375	
	LENGTH: 19	
	TYPE: DNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 375	
11002	bugomicu. 575	
cadcad	gaaat ctaaggata	19
5 ,	,	
<210>	SEQ ID NO 376	
	LENGTH: 19	
<212>	TYPE: DNA	
<213>	ORGANISM: Artificial Sequence	
<220>	FEATURE:	
<223>	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 376	
		10
ctagat	egget tteteagta	19
-210>	CEO ID NO 277	
	SEQ ID NO 377 LENGTH: 19	
	TYPE: DNA	
	ORGANISM: Artificial Sequence	
	FEATURE:	
	OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 377	
agacaa	aggtc ccaaagaca	19
	SEQ ID NO 378	
	LENGTH: 19	
<212>	TYPE: DNA	

	-continued
<pre>&lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 378	
ggaatggcaa gaccagcaa	19
<pre>&lt;210&gt; SEQ ID NO 379 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 379	
agaattattc cagggttta	19
<210> SEQ ID NO 380 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 380	
gcagacaagg tcccaaaga	19
<pre>&lt;210&gt; SEQ ID NO 381 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 381</pre>	
agaagcagct tcaggatga	19
<210> SEQ ID NO 382 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 382	
gagettgaet teeagaaga	19
<pre>&lt;210&gt; SEQ ID NO 383 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 383	
ccaccgaagt tcaccctaa	19
<210> SEQ ID NO 384 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 384	
gagaagagct cctccatca	19
<pre>&lt;210&gt; SEQ ID NO 385 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 385	
gaaagagcat ctacggtga	19
<pre>&lt;210&gt; SEQ ID NO 386 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 386</pre>	
gaaaggattt ggctacaaa	19
<210> SEQ ID NO 387 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 387	
	10
acagcaaatt ccatcgtgt	19
<210> SEQ ID NO 388 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 388	
ggaaagactg ttccaaaaa	19
<210> SEQ ID NO 389 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 389	
caacacgeet cateeteta	19
<210> SEQ ID NO 390 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 390	
catgaaagct tacatcaac	19

<211> <212> <213> <220> <223>	SEQ ID NO 391 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 391	
aagatg	ccat gaaagctta	19
<211> <212> <213> <220>	SEQ ID NO 392 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 392	
gcacat	accg cctgagtct	19
<211> <212> <213> <220>	SEQ ID NO 393 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 393	
gatcaa	atct gaagaagga	19
<211> <212> <213> <220>	SEQ ID NO 394 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 394	
gccaag	aagt ttcctaata	19
<211> <212> <213> <220>	SEQ ID NO 395 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic	
<400>	SEQUENCE: 395	
cagcat	atct tgaaccatt	19
<211> <212> <213> <220> <223>	SEQ ID NO 396  LENGTH: 19  TYPE: DNA  ORGANISM: Artificial Sequence  FEATURE:  OTHER INFORMATION: Synthetic  SEQUENCE: 396	
	agga aacggatga	19
<211>	SEQ ID NO 397 LENGTH: 19 TYPE: DNA	

<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 397	
CHOON DEQUENCE. 391	
cggaaacggt ccaggctat	19
<210> SEQ ID NO 398	
<211> LENGTH: 19 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 398	
wattagaga gagatgata	19
gcttcgagca gacatgata	19
<210> SEQ ID NO 399	
<211> LENGTH: 19	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 399	
Cloop begomen. 333	
cctacacggt cctcctata	19
<210> SEQ ID NO 400	
<211> LENGTH: 19	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 400	
	4.0
gccaagaacc tcatcatct	19
<210> SEQ ID NO 401	
<211> LENGTH: 19	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 401	
~	
gatatgggct gaatacaaa	19
.010. CEO TR NO 400	
<210> SEQ ID NO 402	
<211> LENGTH: 19 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 402	
acactetaat taacaaata	19
gcactctgat tgacaaata	1 <i>3</i>
<210> SEQ ID NO 403	
<211> LENGTH: 19	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 403	
tgaagtctct gattaagta	19
<210> SEQ ID NO 404 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 404	
tcagagagat cctcataaa	19
<210> SEQ ID NO 405 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 405	
gcaagaagat caccatttc	19
<210> SEQ ID NO 406 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 406	
gagagaaatt tgaggatga	19
gagagaaatt tgaggatga  <210> SEQ ID NO 407 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 407 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 407 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 407 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 407	
<210> SEQ ID NO 407 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 407  gaaaggattt ggctataag  <210> SEQ ID NO 408 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
<210> SEQ ID NO 407 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 407 gaaaggattt ggctataag  <210> SEQ ID NO 408 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<210> SEQ ID NO 407 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 407  gaaaggattt ggctataag  <210> SEQ ID NO 408 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<pre>&lt;210&gt; SEQ ID NO 407 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 407  gaaaggattt ggctataag  &lt;210&gt; SEQ ID NO 408 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 408  gaaagaaggc atgaacatt  &lt;210&gt; SEQ ID NO 409 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;210&gt; SEQ ID NO 409 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: </pre>	19

<211> <212> <213> <220>	SEQ ID NO 410 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 410		
gaagta	acatc cattataag	19	
<211> <212> <213> <220>	SEQ ID NO 411 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 411		
gtacga	acaac cgggagata	19	
<211> <212> <213> <220>	SEQ ID NO 412 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 412		
agata	gtgat gaagtacat	19	
<211> <212> <213> <220> <223>	SEQ ID NO 413 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic SEQUENCE: 413		
tgaaga	actct gctcagttt	19	
<211> <212> <213> <220>	SEQ ID NO 414 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
<400>	SEQUENCE: 414		
gcatgo	eggee tetgtttga	19	
<211><212><213><223>	SEQ ID NO 415 LENGTH: 19 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthetic		
	SEQUENCE: 415 cagcu uacuacauc	19	
<211>	SEQ ID NO 416 LENGTH: 19 TYPE: DNA		

	Concinued
<pre>&lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 416	
gaaaugcccu gguaucuca	19
<pre>&lt;210&gt; SEQ ID NO 417 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 417	
gaaggaacgu gaugugauc	19
<pre>&lt;210&gt; SEQ ID NO 418 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 418	
gcacuacucc uguguguga	19
<210> SEQ ID NO 419 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 419	
gaacccagcu ggagaacuu	19
<210> SEQ ID NO 420 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 420	
gauauacagu gugaucuua	19
<pre>&lt;210&gt; SEQ ID NO 421 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<400> SEQUENCE: 421	
guacuacgau ccugauuau	19
<210> SEQ ID NO 422 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	

<400> SEQUENCE: 422	
gugccgaccu uuacaauuu	19
<210> SEQ ID NO 423 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 423	
gaaggaaact gaattcaaa	19
<210> SEQ ID NO 424 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 424	
ggaaatatgt actacgaaa	19
<210> SEQ ID NO 425 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 425	
1100 BEGORNEE. 125	
	1.0
ccacaaagca gtgaattta	19
<pre>ccacaaagca gtgaattta  &lt;210&gt; SEQ ID NO 426 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	19
<210> SEQ ID NO 426 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	19
<210> SEQ ID NO 426 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<210> SEQ ID NO 426 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 426	
<pre>&lt;210&gt; SEQ ID NO 426 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 426 gtaacaagct cacgcagtt  &lt;210&gt; SEQ ID NO 427 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE:</pre>	
<pre>&lt;210&gt; SEQ ID NO 426 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 426 gtaacaaget caegeaget  &lt;210&gt; SEQ ID NO 427 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre>	
<pre>&lt;210&gt; SEQ ID NO 426 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 426  gtaacaagct cacgcagtt  &lt;210&gt; SEQ ID NO 427 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic</pre> <20> FEATURE: <223> OTHER INFORMATION: Synthetic	19
<pre>&lt;210&gt; SEQ ID NO 426 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 426  gtaacaagct cacgcagtt  &lt;210&gt; SEQ ID NO 427 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic &lt;400&gt; SEQUENCE: 427  gaaagaatct gtagagaaa  &lt;210&gt; SEQ ID NO 428 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;221&gt; OTHER INFORMATION: Synthetic</pre>	19

<210> SEQ ID NO 429	
<211> LENGTH: 19	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic	
•	
<400> SEQUENCE: 429	
tagaggaagat aagtaggtt	19
tgacaaaggt ggataaatt	19
<210> SEQ ID NO 430	
<211> LENGTH: 19 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 430	
ggaaatggat ctctttgaa	19
<210> SEQ ID NO 431	
<211> LENGTH: 19	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 431	
ggaaagtaat ggtccaaca	19
040 GT0 TD V0 400	
<210> SEQ ID NO 432 <211> LENGTH: 19	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 432	
	4.0
agacagttat gcagctatt	19
<210> SEQ ID NO 433	
<211> LENGTH: 19	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 433	
ccaattctcg gaagcaaga	19
<210> SEQ ID NO 434	
<211> LENGTH: 19	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic	
<400> SEQUENCE: 434	
gaaagtaatg gtccaacag	19
<210> CPO ID NO 425	
<210> SEQ ID NO 435 <211> LENGTH: 19	
<212> TYPE: DNA	

```
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<400> SEQUENCE: 435
gcgccagagt gaacaagta
                                                                        19
<210> SEQ ID NO 436
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<400> SEQUENCE: 436
gaaggtggcc cagctatgt
                                                                        19
<210> SEQ ID NO 437
<211> LENGTH: 19
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<400> SEQUENCE: 437
gagauggcac aggaggaaa
                                                                        19
```

- 1. An siRNA molecule effective at silencing Bcl-2 expression, wherein said molecule comprises a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region comprising 19-30 base pairs and said antisense region comprises a sequence that is the reverse complement of SEQ. ID NO. 309.
- 2. The siRNA of claim 1, wherein said antisense region and said sense region are each 19-25 nucleotides in length.
- 3. The siRNA of claim 1, wherein said antisense region and said sense region are each 19 nucleotides in length.
- **4**. The siRNA of claim 1, wherein said antisense region is 100% complementary to a target Bcl-2 RNA.
- **5**. The siRNA molecule of claim 1, wherein said siRNA molecule comprises at least one overhang region, wherein said overhang region comprises six or fewer nucleotides.

- **6**. The siRNA molecule of claim 1 wherein said siRNA molecule comprises no overhang regions.
- 7. The siRNA molecule of claim 2 wherein said siRNA molecule comprises at least one overhang region, wherein said overhang region comprises six or fewer nucleotides.
- **8**. The siRNA molecule of claim 2 wherein said siRNA molecule comprises no overhang regions.
- **9**. The siRNA molecule of claim 3 wherein said siRNA molecule comprises at least one overhang region, wherein said overhang region comprises six or fewer nucleotides.
- 10. The siRNA molecule of claim 3 wherein said siRNA molecule comprises no overhang regions.

* * * * *